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“We cannot solve our problems with the same level of thinking that created them.” 
(Albert Einstein, *1879 †1955) 
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1. Introduction 
Part of my work was carried out in the field of cell‐penetrating, cube‐octameric silsesquioxane 
(COSS) nanoparticles and the results of the respective investigation were summarized in my 
Diploma Thesis and the publication in Angewandte Chemie International Edition.[1] The topic is 
not further illustrated in this work. Nevertheless, the research on the modified COSS structures 
gave a good overview of the properties and effects of ionic groups on the solubility of organic 
compounds as well as the behaviour of certain functional groups in chemical reactions. 
This was a helpful preliminary work to optimize the peptide synthesis in view of a sustainable 
process. In order to give an overview of the problems of peptide synthesis and its consequences, 
especially in industrial applications, the following gives an in-depth look at peptide synthesis 
and the achievements in the field of sustainable peptide synthesis. 
1.1. Peptides 
Being elementary components in all living systems, peptides are active biomolecules comprising 
a chain of up to 100 covalently linked amino acids (aa). Their biological properties depend on 
the number of residues and their specific sequence. Natural, endogenous peptides regulate 
many biological processes such as blood sugar levels, hunger, blood coagulation, and pain. 
Peptides are currently produced on industrial scale for the treatment of cancer, diabetes, 
cardiovascular and neurodegenerative diseases.[2-4] In addition, synthetic peptides are also used 
in cosmetics[5-6], diagnostic and medical technology products, as well as in veterinary medicine, 
agrochemistry or dietary supplements.[2, 7] Thus, peptide synthesis continues to be an important 
and growing area of research. 
Peptide synthesis is the way to form an amide bond between amino acid building blocks. 
Interestingly, there is no precise definition of a peptide; it usually refers to a macromolecular 
chain of up to 100 amino acids. Chemists are able to link amino acids with peptide bonds since 
the beginning of the 20th century, but it took another 50-60 years until complex peptides like 
oxytocin and insulin have been chemically synthesized.[8] This demonstrates that peptide 
synthesis is a rather difficult chemical goal. In the last 120 years, advances in peptide chemistry 
in view of methods and instruments have developed to the point where the synthesis of peptides 
is a rank-and-file task for chemists. A very brief overview of the milestones of peptide synthesis 
is given in the following introduction, a graphical overview in Figure 1. 
The first chemical synthesis of an N-terminally masked dipeptide glycylglycine was performed 
by Theodor Curtius in 1882 by reacting the silver salt of glycine with benzoylchloride.[9] 
Nineteen years later, in 1901, Emil Fischer and Ernest Fourneau published their variant of its 
synthesis by a partial HCl hydrolysis of glycine diketopiperazine. About 100 peptides consisting 
of up to 17 amino acid residues were synthesized by Emil Fischer and his co-workers using the 
methods developed in his laboratory.[10-11] In 1932, Bergmann and Zervas introduced the first 
removable Nα-protecting group, the carboxybenzoxy (CBz, also referred to as Z) one.[12] About 
20 years later, in 1953, du Vigneaud synthesized the peptide hormone oxytocin[8] comprising 
nine amino acids and a disulfide-bridged backbone, using the actual synthetic methods. For this 
work he was awarded the Nobel Prize in Chemistry in 1955 and initiated the development of 
peptides as pharmaceuticals. 
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Figure 1: Graphical summary of the peptide synthesis milestones. 
In 1957, Anderson and McGegor introduced the tert-butyloxycarbonyl (Boc) group to protect 
an alpha-amine. This was a significant step forward. Indeed, besides the urethane protection 
against racemization, the mild acidic cleavage of the Boc protecting group provides obvious 
advantage compared to the Cbz one.[13] 
In the early 1960s, Bruce Merrifield pioneered the solid-phase peptide synthesis having 
suggested a completely novel strategy based on a polystyrene-based solid support to grow a 
peptide chain. 
In his concept, the peptides were synthesized in a stepwise manner from C- to N-terminus 
applying Nα-protected and Cα-activated amino acids; polymeric support played a role of a 
constant C-terminal protection. The tetrapeptide LAGV was synthesized using Cbz to protect an 
alpha amine, and N,N'-dicyclohexylcarbodiimide (DCC) to activate an alpha carboxylic group; 
the method was called solid-phase peptide synthesis (SPPS).[14] After the chain assembly, the 
peptide was cleaved form solid support by saponification or HBr.[14] Later, Merrifield modified 
SPPS protocol to use the Boc Nα-protecting group.[15] In 1967, Sakakibara et al. reported 
hydrogen fluoride (HF) to cleave peptides from solid support[16] and the first common SPPS 
protocol had acquired its modern shape. Now it combined the Boc protection labile in the 
presence of TFA (trifluoroacetic acid) for the N-terminus with benzyl-based groups for the side 
chains. Obviously, the side chain protecting moieties and the cleavable linker between solid 
support and the growing peptide chain needed to be stable in the presence of moderate acids 
like TFA and labile in the presence of strong acids like HF. During the period from the 1960s 
through the 1980s Merrifield fine-tuned his Boc-SPPS protocol,[17] which resulted in the 
successful synthesis of several functional polypeptides, among them a protein interleukin-3[18] 
and enzymes ribonuclease A and HIV-1 aspartyl protease.[19] 
In 1970, the 9-fluorenylmethoxycarbonyl (Fmoc) group was introduced by Carpino and Han 
for the Nα-protection.[20] A moderate base is required for its cleavage, thus providing a 
chemically milder alternative to the acid-labile Boc. Initially, this new group was applied to 
protect suitable amines in solution-based chemistry[20-21] and was proven unsuitable for this 
application. 9-Methylene-fluorene, the initial deprotection product, is reactive and able to 
reattach to the free amines.[22] However, during the screening process for the application of 
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base‐labile protecting groups in solid-phase synthesis, the Fmoc group showed its 
advantages.[23-24] Indeed, the conditions of SPPS imply the possibility for all the undesired, 
potentially harmful products to be washed away, thus avoiding possible side reactions. 
Moreover, the 9-methylene-fluorene intermediate emerging in course of deprotection turns 
yellow and allows therefore to monitor this process by UV-VIS.[25]  
The Fmoc group was adopted for solid-phase peptide synthesis in the late 1970s. The respective 
Fmoc-SPPS uses tert-butyl based side-chain protecting groups and in the majority of cases 
hydroxymethylphenoxy-based resin linkers.[23] The mild Nα-deprotection conditions as well as 
the relatively soft global cleavage are doubtlessly beneficial for peptide assembly. However, 
synthesis of Fmoc-protected amino acids using 9-fluorenylmethoxycarbonyl chloride (Fmoc-Cl) 
or 9-fluorenylmethyl N-hydroxy-succinimidyl carbonate (Fmoc-NHS) is associated with several 
side reactions. Regarding the use of Fmoc-NHS, the most frequently encountered one is a 
Lossen‐type rearrangement resulting in the formation of Fmoc‐β‐Ala‐OH and Fmoc‐β‐Ala‐aa‐
OH.[26-27] An unwanted carboxyl activation of the amino acids was observed by using Fmoc-Cl, 
resulting in the formation of the Fmoc‐aa‐aa‐OH dipeptides.[28-29] During the peptide assembly, 
these impurities can be incorporated into the growing peptide if they are not removed prior to 
the synthesis process. 
The advantages given by Fmoc-SSPS and the improvements in the related chemistry led to new 
dimensions in peptide synthesis. To date, SPPS has been continuously improved in terms of 
efficacy, reaction rate (e.g. acceleration by temperature increase, including microwave-assisted 
synthesis) and reduction of solvent consumption. The most common methods of obtaining 
peptides today are shown in Figure 2. 
 
Figure 2: Approaches to peptide production. Peptides can be assembled by chemical synthesis either in solution 
(liquid phase synthesis) (top left), solid phase synthesis (top middle) or by a hybrid approach (top right) with 
fragment condensations of smaller peptide fragments or a combination of the other methods. Alternative methods 
for peptide production are enzyme-based coupling or cleavage methods (bottom left) recombinant synthesis 
pathways by microorganisms (bottom middle) or extraction methods from natural sources (bottom right). (Modified 
figure by Uhlig et al.[3], distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike, 
Licence: CCBY-NC-SA 3.0 (https://creativecommons.org/licenses/by-nc-sa/3.0/)) 
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Methods relying on extraction from natural sources as well as recombinant synthesis of peptides 
using microorganisms are however limited in terms of using unnatural amino acids, post 
synthetic modifications on C- and/or N-Terminus or selective-side chain modifications. This 
work focuses on the chemical synthesis of peptides. 
1.2. Liquid-phase peptide synthesis (LPPS) 
Peptide synthesis in solution is called LPPS. Depending on the used technique, LPPS is divided 
into two classes: step-by-step peptide synthesis from the C- to the N-terminus by subsequent 
adding of protected amino acids[30] and convergent or semi-convergent block synthesis, with 
coupling of smaller polypeptide fragments.[31] A big disadvantage of LPPS is the necessary 
purification after each coupling step with unpredicted solubility issues. By-products from 
incomplete transformations, side reactions that may occur, or reagent impurities will 
accumulate over time and reduce the purity of the synthesized peptide. With growing length of 
the peptide chain, the purification gets more and more complicated, and each isolation step is 
accompanied by physical loss of material. Nevertheless, LPPS is still in use for industrial-scale 
production of short, up to fifteen amino acids, peptide sequences. 
1.3. Solid-phase chemistry 
The concept of solid-phase peptide synthesis was developed by Bruce Merrifield in 1963.[14] His 
idea was to find a fast, simple and 
effective way for peptide assembly. 
Merrifield showed 1964 that his new 
method of synthesis[32] had many 
advantages compared to the classical 
solution-phase approach to 
bradykinin reported by Guttman et 
al.[33-34] and Nicolaides et al.[35] In 
1972, in his article in Nature, Mutter 
et al. addressed the problems of early 
SPPS, among them accumulation of 
erroneous sequences due to 
incomplete coupling steps, lack of 
isolation/purification methods, and 
restricted repertoire of solvents and 
coupling methods.[30] In general, the 
solubility issue was recognised as 
cause of synthetic problems during 
the SPPS process.[36] 
The maturation of high performance 
liquid chromatography (HPLC) for 
peptide purification was a major 
boost for the SPPS method as it made 
possible removal of by-products 
associated with chain assembly and 
cleavage from the polymeric 
support.[37-39] Following HPLC 
 
Scheme 1: Schematic representation of the SPPS cycle.[14] 
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advancement, SPPS has become the standard method in peptide synthesis, and Bruce Merrifield 
was awarded the Nobel Prize in Chemistry (1982).[40-41] 
The SPPS strategy (Scheme 1) is as follows: The first amino acid is attached to a polymer (solid 
support) by a covalent bond via a cleavable linker. Then coupling and Fmoc deprotecting steps 
of the ongoing amino acids are repeated until the sequence is complete. The final step is the 
cleavage from solid support, very often with simultaneous liberation of the side-chain 
functionalities, the so-called global cleavage. The N-terminus of the coupled amino acid has to 
be masked by a protecting group, as otherwise the newly added amino acid could couple with 
itself which would result in by-products.[12],[13],[20] 
The enormous advantage of this method is that the purification after each reaction step is simply 
performed by washing/filtration, and the peptide intermediates remain on the solid support 
located inside the reaction vessel. This allows to add the amino acids during the coupling steps 
in a significant excess compared to the loaded resin, which leads to higher yields.[14] 
1.4. Hybrid approach (Fragment condensation) 
Hybrid approaches combining solid- and solution-phase steps to synthesize peptide sequences 
(fragments) that are coupled to make longer peptides (>50 aa), difficult sequences or 
proteins[42] are getting more popular.[43-45] Two main elaborated strategies based on fragment 
condensation approaches are available to date, the solid phase fragment condensation 
(SPFC)[46] and fragment condensation in solution. The fragment condensation itself can be 
performed applying a variety of methods, e.g. amide bond formation, native chemical 
ligation[47-50] or enzymatic reactions[51-53], a schematic overview is shown in Scheme 2. 
Depending on the used strategy, fully protected peptide fragments are required, or the 
orthogonal approach relying on fully deprotected blocks under aqueous conditions is needed. 
 
Scheme 2: Schematic representation of the two fragment condensation routes. 
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1.5. SPPS: Synthetic strategies 
There are two strategies of masking the N-terminus, the acid-labile Boc group (Boc-SPPS)[15] 
and the base-labile Fmoc one (Fmoc-SPPS).[14, 20] During chain assembly, Boc is removed with 
25% TFA, and cleavage from the solid support is performed with HF.[16] Scheme 3 shows the 
Boc-SPPS strategy. 
 
Scheme 3: Boc-SPPS strategy (Merrifield SPPS).[15-16] 
The usage of highly toxic hydrofluoric acid is quite unpopular, so the number of users of this 
method decreases; however it is still used for special applications.[54] The main disadvantage of 
the Boc SPPS has always been the lack of orthogonality regarding the temporary (Boc) and the 
constant (side chains and C-terminus) protecting groups. The repeated TFA treatment bears the 
risk of cleaving some portion of the side‐chain protecting groups as well as the resin linker 
during the peptide assembly.[54] The repetitive acidolysis was also shown to result in acid-
catalyzed side reactions, e.g. a modification of the Trp (Tryptophan) indole ring.[55] This 
particular problem during Boc-based SPPS is easily solved upon switching to Fmoc chemistry 
as demonstrated by Fields et al. for gramicidin A (containing four Trp residues).[56] 
The Fmoc method makes use of the base-labile Fmoc group to protect an amino terminus and 
an orthogonal scheme for the functional side chains. The temporary Fmoc protecting group can 
be cleaved with liquid ammonia, 20% piperidine or other moderate bases.[20] Scheme 4 shows 
the Fmoc-strategy. 
 
Scheme 4: Fmoc-SPPS strategy (Wang resin).[20] 
The coupling reaction takes place in DMF with pre-formed or in situ produced active species, 
often in form of active esters. Excess reagents are removed by washing the resin with DMF. 
Following deprotection in 20% piperidine, the next activated Fmoc-amino acid is coupled to 
the growing sequence. Global cleavage occurs in 95% TFA.[57] Fmoc-SPPS method is very 
popular because of its orthogonality, adaptability to multiple peptide synthesis, and the easy 
removal of the Fmoc protecting group under mild conditions, which makes it compatible with 
a wide variety of modified peptides, among them phosphorylated, PEGylated, glycosylated or 
biotinylated ones.[54, 58] A number of studies carried out by Angeletti et al. for the Peptide 
Synthesis Research Committee (PSRC) illustrate this trend. Over a period of six years (1991-
1996) the PSRC performed studies on the synthetic methods and analytical techniques for 
peptide synthesis.[59] At the beginning of the study in 1991, around 50% of the participating 
member labs used Fmoc-based peptide chemistry, and 50% were still using Boc-based peptide 
synthesis. By 1994, already 98% of participating laboratories switched to Fmoc-based approach. 
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One of the reasons for this development is the wide availability of Fmoc amino acids in high 
purity (>99%) and falling prices for the building blocks. 
Besides the amino group of the coupling amino acid, all side chains in the growing peptide 
sequence need to be protected to prevent side reactions. These side chains are usually masked 
with acid-labile moieties. 
1.5.1. Side-chain protecting groups 
Synthetic organic chemistry is aimed on the formation of new covalent bonds by using specific 
reagents or catalysts. If several functional groups in the molecule are reactive under the desired 
conditions, suitable protective groups are required to prevent the formation of by-products 
during the synthesis.[60-61] If the protective groups used are not selected correctly regarding the 
chosen reaction pathway, the synthesis strategy may be endangered. 
The ideal protecting group should match the following criteria: 
1) be easily introducible at the desired site;  
2) tolerate wide range of reaction conditions (even more important for multiple reaction steps); 
3) be easily removable after the synthesis.  
It is important to mention that the second and third criteria are often in an obvious conflict. 
Indeed, the repeated Boc deprotection with TFA could also result in the cleavage of small 
amounts of the side‐chain protecting groups as a side reaction. Addressing this issue, the 
concept of orthogonal protecting groups by Barany et al.[62-63] became the next synthetic 
milestone. In this concept, at least two functional groups are masked by protecting groups that 
are removable by different deprotection mechanisms. The protecting groups can be cleaved 
stepwise and in the presence of each other, and often under milder conditions, compared to 
reaction rate-based mechanisms.  
Since the introduction of the CBz protecting group by Zervas and Bergmann,[12] peptide 
chemistry has facilitated the development of new protective groups.[13, 20, 64] Generally, among 
the natural amino acids a number of functional groups need protection, among them hydroxy, 
carboxy, amino, thiol, amide, and guanidine groups as well as sometimes indole and imidazole 
rings. The following two tables give a short insight into the protecting group strategies for Boc-
(Table 1) and Fmoc-(Table 2) based peptide synthesis. The table contains the most frequently 
used protecting groups for the Boc/Fmoc strategy, their chemical structure and deprotection 
conditions. This is only a small selection from the available repertoire. Comprehensive 
description of the protecting group possibilities is given in the literature[60-61], in particular the 
application possibilities in peptide synthesis.[57, 64] 
Table 1: Side-chain protection for amino acids in Boc-based SPPS. [57, 60-61, 64] 
Amino acids 
(Abbreviations) 
Protecting group Name (Abbreviation) Cleavage conditions 
Arginine (Arg) 
 
toluolsulfonyl[65] 
(Tos) 
HF/scavengers 
 
mesitylen-2-sulfonyl[66] 
(Mts) 
CF3SO3H/TFA 
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Aspartic acid (Asp) 
Glutamic acid 
(Glu)  
benzyl[67] 
(Bzl) 
1)HF/scavenger 
2)H2 cat. 
Serine (Ser) 
Threonine (Thr) 
Tyrosine (Tyr)  
benzyl[67] 
(Bzl) 
1)HF/scavenger 
2)H2 cat. 
Asparagine (Asn) 
Glutamine (Gln) 
Asn and Gln can be used without side-chain protection. The unprotected aa show poor 
solubility in organic solvents resulting in slow coupling rates. 
 
9-xanthenyl[68] 
(Xan) 
90% TFA  and 
scavengers1,[69-70] 
Cysteine (Cys) 
 
4-methoxybenzyl[71] 
(MeOBzl)- 
HF 
 
acetamidomethyl[72] 
(Acm) 
Hg(II), Ag(I), I2, 
Tl(III), RSCL, 
Ph(SO)Ph-CH3SiCl3 
Histidine (His) 
 
benzyloxymethyl[73-74] 
(Bom) 
1)HF/scavengers 
2) TFMSA/TFA 
 
dinitrophenyl[75] 
(DNP) 
1)HF 
2)Thiolysis 
 
toluolsulfonyl[65] 
(TOS) 
HF/scavengers 
Lysine (Lys) 
 
2-chlorobenzyloxycarbonyl[76] 
(2-Cl-Z) 
HF/scavenger 
 
benzyloxycarbonyl[12] 
(CbZ)  
HF 2 
 
9-fluorenylmethoxycarbony[20-
21] 
(Fmoc) 
Piperidine 
Tryptophan (Trp)  
formyl[77] 
(For) 
1)HF/scavengers 
2)Piperidine/water 
 
cyclohexyloxycarbonyl[78] 
(Hoc) 
HF, scavengers 
The side chains are usually masked with an acid-labile protecting group during an orthogonal 
Fmoc-based SPPS scheme. This allows performing simultaneous side-chain deprotection and 
cleavage from the solid support in 95% TFA. For every amino acid orthogonal side chain 
 
1 The Xan protecting group is concurrently removed during Boc deprotection by TFA treatment; Dehydration side reaction of Asn 
or Gln residues is only possible during the coupling step, therefore Xan elimination after coupling is only a minor problem.[42-43] 
2 acid-labile, does not withstand repetitive treatments with TFA 
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protecting groups are possible, that allows to solely liberate a single side chain moiety if a 
specific post-synthetic modification is necessary.[57, 64] 
Table 2: Side-chain protection for amino acids in Fmoc-based SPPS [57, 60-61, 64] 
Amino acids 
(Abbreviations) 
Protection groups Name (Abbreviation) Cleavage conditions 
Arginine (Arg) 
 
4-methoxy-2,3,6-trimethyl-
benzenesulphonyl[79] 
(Mtr) 
1)90-95% TFA, 4-6h 
2)TFA-anisole (9:1), 
1h 
 
2,2,5,7,8-pentamethyl-
chroman-6-sulfonyl[80] 
(Pmc) 
1)50% TFA v/v in 
DCM, 3h 
2)TFA-scavanger 
 
2,2,4,6,7-pentamethyl-
dihydro-benzofuran-5-
sulfony[81] 
(Pbf) 
95% v/v TFA in DCM, 
0,5h 
Aspartic acid (Asp) 
Glutamic acid (Glu) 
 
tert-butyl[82-83] 
(tBu) 
90% v/v TFA, 0.5h 
 
allyl[84] 
(Al) 
1)Pd(Ph3P)4-AcOH-
NMM 2)Pd(Ph3P)4 
(0.02 eq.) in DCM 
 
2-phenylisopropyl[85] 
(2-PhiPr) 
4% TFA in DCM, 
15min 
Asparagine (Asn) 
Glutamine (Gln) 
 
trityl[86-88] 
(Trt) 
90% v/v TFA, 30min 
 
4-methyltrityl[89] 
(Mtt) 
95% v/v TFA, 30min 
Cysteine (Cys) 
 
trityl[86-88] 
(Trt) 
90% v/v TFA, 30min 
 
2,4,6-trimethoxybenzyl[90] 
(Tmob) 
90% v/v TFA, 1h 
 
acetamidomethyl[72] 
(Acm) 
Hg(II), Ag(I), I2, 
Tl(III), RSCL, 
Ph(SO)Ph-CH3SiCl3 
 
monomethoxytrityl[91] 
(MMT) 
2% TFA in DCM 
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tert‐butylsulfenyl[92] 
(StBu) 
RSH 
R3P 
Histidine (His) 
 
trityl[86-88] 
(Trt) 
90% v/v TFA, 30min 
 
tert-butyloxycarbonyl[13, 93] 
(Boc) 
90% v/v TFA, 30 min 
 
tert-butoxymethyl[94] 
(Bum) 
95% v/v TFA, 1-2 h 
Lysine (Lys) 
 
tert-butyloxycarbonyl[13, 93] 
(Boc) 
90% v/v TFA, 30 min 
 
allyloxycarbonyl[84] 
(Alloc) 
1)Pd(Ph3P)4 (0.1 eq.) 
2)PdSiH3 (24 eq.) in 
DCM, 10min 
 
trityl[86-88] 
(Trt) 
90% v/v TFA, 30min 
 
4-methyltrityl[89] 
(Mtt) 
95% v/v TFA, 30min 
Serine (Ser) 
Threonine (Thr) 
Tyrosine (Tyr) 
 
tert-butyl[95] 
(tBu) 
90% v/v TFA, 0,5 h 
 
trityl[86-88, 96] 
(Trt) 
90% v/v TFA, 30min 
 
tert-butyldimethylsilyl[97-98] 
(Tbdms) 
0.1M TBAF-DMF, 
15min (Tyr) 
TFA, 15min (Ser/Thr) 
Tryptophan (Trp) 
 
tert-butyloxycarbonyl[13, 93, 99] 
(Boc) 
90% v/v TFA, 30 min 
1.5.2. Solid support 
The success of a peptide synthesis by SPPS strongly depends on the solid support and its 
performance during the synthesis. These supports, referred to as resins, usually comprise a 
rather chemically inert polymeric bead decorated with a functional linker. In 1963, Merrifield 
defined the solid support as an insoluble, in all utilized solvents stable physical form which 
permits filtration and a functional group to which a linker or an amino acid are bound by a 
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covalent bond.[14] The optimal properties of the solid support have been further expanded by 
van den Nest and Albericio:[100] “1) mechanically and physically stable beads; 2) stability in 
variation of temperature; 3) mobile, well-solvated and reagent-accessible sites; 4) acceptable 
loadings; 5) good swelling in a broad range of solvents; 6) functionalized beads permitting 
covalent coupling of the first compound; 7) the resin should be chemically stable under most 
reaction conditions.”[100] But as van den Nest and Albericio stated, it is unrealistic to expect a 
solid support to have all these characteristics, therefore the resin that is best suited for the 
planned task should be chosen.[100] 
Most resins are based on polystyrenes (PS) with different functional groups, but cross-linked 
polyamides (PA), composite PS-polyethylene glycols (PEG) or totally PEG-based resins are also 
available.[100-101] The polymeric network of the resin can be modelled in two ways: 1) the rigid 
carrier model, where the resin is considered as a compact sphere and 2) the co-solvent model, 
where the effect of the resin is accounted 
in reactions. Several direct and indirect 
studies have been carried out to determine 
which is the most appropriate model to 
describe the solid support role. Regen et 
al. investigated PS-and PEG-PS based solid 
supports and concluded that both resins 
showed significant mobility and the co-
solvent model would fit best.[102-104] His 
findings were validated by Czarnik and Meldal.[100, 105-106] 
The resin Merrifield used for his SPPS was a styrene-divinylbenzene co-polymer functionalized 
by chloromethylation.[14] The first amino acid was bound to the resin via an ester linkage. The 
synthesis of a Merrifield resin is shown in Scheme 5. The cross-linkage extent affects the 
solvation and swelling properties of the resin. Standard crosslinking is performed with 1-2% 
DVB (divinylbenzene) which leads to a resin with a strong hydrophobic character. PS-DVB 
resins are widely used in the solid-phase organic chemistry.[107-108] Merrifield and others 
observed that reaction rates were slower than in solution and the incorporation of amino acids 
decreases with increasing peptide length on solid support.  
To address these intrinsic problems a PEG moiety was incorporated into the resin to enhance 
flexibility and solvation. The effect of resins with incorporated PEG units on the amide bond 
formation was investigated by Czarnik et al.[105] and others.[106, 109] Under similar reaction 
conditions, faster kinetics have been observed on PEG-PS resins. Increasing the amount of PEG 
units in the resin resulted in faster reaction kinetics.[109] It is assumed that PEG chains influence 
solvation behaviour, dielectric properties and hydrogen bond pattern. Known representatives 
of this resin group are POE-PS[110] (Tentagel®); 
PEGA[111] (glycol polyacrylamide copolymers with a 
high content of PEG); TTEGDA-PS[112] (PS resin with 
tetra(ethylene glycol) diacrylate (TTEGDA) as 
crosslinker); Clear®[113] (cross-linked ethoxylate 
acrylate resin).  
Development of fully PEG-based resins followed, 
resulting in more hydrophilic polymeric supports with 
excellent swelling properties in a wide range of solvents (water, alcohols and many organic 
solvents). This allowed using the resins for multiple applications. The amphiphilic nature of the 
 
Scheme 5: Synthesis of a Merrifield resin. Cross-linking and 
functionalization depend on ratio of the starting materials. 
 
Figure 3: Structure of ChemMatrix® resin. 
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resins was reported to increase reactivity during the coupling and deprotection steps. These 
swelling properties arise from the stretched helical superstructure of PEG in aqueous 
solutions.[114] Known representatives of PEG-based resins are SPOCC[115] 
(polyoxyethylene/polyoxy-propylene) and ChemMatrix® (CM, Figure 3).[116]  
As the ChemMatrix® resin was frequently used for the present work, the properties of this resin 
are briefly discussed. The resin is totally PEG-based, linked by primary ether bonds, and is highly 
cross-linked. The improved polarity of the CM resin allows to use polar solvents like water, 
acetonitrile, methanol and other alcohols in addition to classic hydrophobic solvents without 
the loss of swelling properties (shown in Figure 4). The high efficiency of this solid support was 
demonstrated by the synthesis of complex peptides like HIV protease (99aa)[117], Rantes 
(1-68)[118] and β-amyloid (1-42).[116] 
 
Figure 4: Comparison of the swelling properties of polystyrene and CM resins in different solvents. (Adapted with 
permission from García-Martín et al., J. Comb. Chem. 2006, 8, (2), 213-220).[116] Copyright 2006 American Chemical 
Society). 
1.5.3. Linkers 
The reversible connection between the 
peptide and the resin is provided by the linker 
molecule. This is the unit that stipulates the 
choice of chemistry used both for the assembly 
and the global cleavage. A wide variety of 
SPPS linkers has been developed to date, 
allowing to obtain acids, amides, esters, 
thioesters, hydrazides, alcohols or aldehydes 
after the cleavage from the solid support 
(examples shown in Scheme 6). 
A broad range of resins decorated with linker 
molecules of different nature is currently 
available as commercial products. Table 3 
shows some of the most common SPPS 
linkers, their specific cleavage conditions and 
the resulted C-terminal functionalisation. 
Many linkers form carboxylic acids or 
carboxylic amides upon acidic cleavage. 
Sulfonamide and hydrazide linkers allow 
 
Scheme 6: Examples of different linker types and 
cleavage reactions for SPPS. R1, R2, R3: rests depending 
on linker; X: aa side chain). 
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releasing of the peptide from solid support with different functional groups, depending on the 
conditions. 
Table 3: SPPS linkers and their cleavage conditions 
Linker  Resin-bound structure Cleavage conditions C-terminus 
Wang 
 
90–95% TFA, 1–2h Acid 
Rink acid[119] 
 
1)1–5% TFA, 5–15min 
2)10% AcOH, 2h 
Acid 
4-(4-hydroxymethyl-3-
methoxyphenoxy)butyric 
acid 
(HMPB)[120] 
 
1% TFA, 2–5min Acid 
2-chlorotrityl chloride 
(2-CTC)[121] 
 
1–5% TFA, 1min Acid 
SASRIN (super acid-
sensitive resin)[122] 
 
1% TFA, 5–10min Acid 
Rink amide[119] 
 
50% TFA, 1h Amide 
4-methylbenzhydrylamine 
(MBHA)[123] 
 
HF 0°C, 1h Amide 
Hydrazine[124] 
 
Cu(OAc)2, pyridine, 
acetic acid, 
nucleophile 
Acid, ester, 
amide 
Sulfonamide[125] 
 
1) Iodoacetonitrile/ 
DIPEA/NMP, 24h 
2) Nucleophile, 
DMAP, 24h 
Acid, ester, 
thioester, 
amide, etc. 
4-hydroxymethylbenzoic 
acid 
(HMBA)[126] 
 
NaOH 
N2H4 
NH3 
ROH 
LiBH4 
Acid 
Hydrazide 
Amide 
Ester 
Alcohol 
Backbone amide linker 
(BAL)[127] 
 
TFA/trifluoromethane-
sulfonic acid (TFMSA) 
(19 :1) 
Acid 
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1.5.4. Coupling methods 
Along with the development of novel protecting groups, the optimisation of coupling reagents 
and conditions became an important research direction. Amide (peptide) bonds are typically 
formed between carboxylic acids and amines under elimination of water. However, the amide 
bond formation does not occur spontaneously at RT (room temperature) and requires heating 
above 200°C.[128] Jursic et al. restricted this reaction to compounds matching the following 
terms: The ideal reactants should have melting points below 200°C, be non-volatile and 
thermally stable at this temperature for 30 minutes.[128] This is definitely not the case for most 
amino acids, at least the natural ones. 
Therefore, the α-carboxy group of the incoming amino acid has to be activated for an effective 
coupling. This usually means converting the OH group of the carboxylic acid into a good leaving 
group (increasing the electrophilicity of the 
carboxy group) to allow amide bond 
formation with amines under mild 
conditions. Scheme 7 shows the reactivity 
of the different carboxylic acid derivatives.  
The introduction of carbodiimides by Sheehan et al. in 1955 became a real feat in peptide 
synthesis.[129] Symmetrical carbodiimides, like N,N’-dicyclohexylcarbodiimide (DCC) and N,N’-
diisopropylcarbodiimide (DIC) activate the carboxy group by forming an O-acylurea derivative 
that serves as a leaving group upon coupling (Figure 5). 
In his SPPS, Merrifield used DCC as coupling reagent in DCM (dichloromethane) or DMF 
(N,N-dimethylformamide) although dicyclohexylurea, a byproduct formed from DCC, is nearly 
insoluble in most organic 
solvents.[14] DIC is often used 
instead of DCC in SPPS 
because the urea byproduct 
remains in solution. 
However, the carbodiimide 
activation method has been 
reported to cause 
racemization at the Cα-atom of 
certain amino acids due to the high reactivity of the O-acyl isourea. In solution-phase chemistry 
an oxazolone intermediate could be formed upon an intramolecular cyclisation, resulting in the 
potential loss of chiral integrity of the amino acid as shown in Scheme 8.[130] In SPPS reactions 
this mechanism is prevented by growing peptides from C- to N-Terminus and using urethane 
(carbamate) protecting groups for the amine. Racemization might also occur at the Cα-position 
under basic conditions resulting in the formation of a carbanion, especially with cysteine[131-132] 
and histidine.[133] Protonation of the carbanion might also lead to a racemic mixture similar to 
the oxazolone mechanism.[134] 
 
Scheme 7: Activity of the carboxy derivatives. 
 
 
Figure 5: Top: Structure of DIC and DCC. Bottom: carbodiimide-based 
activation of a carboxylic acid. 
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Scheme 8: Racemization following an oxazolone mechanism. R1, R2, R3: side chain residues, A: leaving group 
To address this issue, König and Geiger developed 1-hydroxy-1H-benzotriazole (HOBt)[135] as 
an additive when using carbodiimides to reduce the racemization level by formation of a less 
reactive HOBt ester.[136] The usage of HOBt and carbodiimides can lead to the formation of 
diazetidine, which is catalyzed by HOBt.[137] Carpino et al. reported the usage of 1-hydroxy-7-
azabenzotriazole (HOAt)[138], which was reported to be more efficient than HOBt in terms of 
yield, kinetics and racemization 
levels.[139] In recent years, a highly 
efficient leaving group has been 
introduced, called Oxyma (ethyl-2‐
cyano‐2‐(hydroxyimino)acetate). It has 
coupling efficiency and racemization 
suppression rates like HOAt but is less 
hazardous than HOBt and HOAt.[140] Structures of the compounds are shown in Figure 6. 
To date, a vast number of carbodiimides has been reported. 
Several water-soluble derivatives like 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC, Figure 7) were 
investigated by Sheehan et al.[141-142] He concluded that 
coupling was more efficient when using tertiary amine 
carbodiimides rather than quaternary derivatives. The main 
advantage of the water–soluble carbodiimides was the easy remove of urea byproducts, as the 
ureas formed when using DCC or DIC are sometimes difficult to remove. Today, water-soluble 
carbodiimides are widely used in protein chemistry.  
Carpino compared DIC, EDC and other carbodiimide analogues. The combination of DIC and 
HOAt as an active ester showed the best results upon coupling.[139] 
Over the years, new-generation coupling reagents have been developed. Modern activation 
methods prefer esters as leaving group. This can be achieved by pre-formation or by in situ 
generation.  
Most of the modern in situ 
activators are based on 
benzotriazole alcohols, 
phosphonium or uronium 
salts. The most widely used 
coupling reagents for in situ 
activation are 2-(1H-benzo-
triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)[143], benzotriazole-1-yl-
oxy-tris-pyrrolidinophosphonium hexafluorophosphat (PyBOP)[144], 1-[bis(dimethylamino)-
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid hexafluorophosphate (HATU)[138] and 
 
Figure 7: EDC. 
 
Figure 8: Phosphonium- and uronium-based in situ activators. 
 
Figure 6: Coupling additives upon ester formation. 
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O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyl-uronium hexafluorophosphate 
(HCTU)[145]; structures are shown in Figure 8. 
HATU and HCTU are similar to HBTU but react faster with less epimerization during the 
coupling step.[145-146] The reactive species of all these activators are benzotriazole esters or 
derivatives thereof. The coupling step is often performed with an excess of about 2 to 8 
equivalents in the presence of a base like N,N-diisopropyl-ethylamine (DIPEA) to effectively 
complete the desired reaction. DIPEA (Hünig base) deprotonates the α-carboxy group, see 
Scheme 9.  
 
Scheme 9: Amino acid deprotonation with DIPEA and active ester formation with HBTU. HATU and HCTU follow a 
similar mechanism. R: side-chain residue, PG: protecting group. 
The efficacy of the coupling reagents can be ordered in the following way: 
OPfp esters/HOBt < DIC/HOBt < HBTU ≈ PyBOP < HATU ≈ HCTU[146] 
In 2002, Carpino et al. showed that the common coupling reagents HBTU, HATU and HCTU 
have been identified to exist in two forms, as a uronium salt (O form) and as a guanidinium 
salt (also referred to as an aminium salt) (N 
Form) (Figure 9).[147] They have been 
originally classified as O-uronium salts and 
later the structure was revised to 
guanidinium salts by Carpino et al. The 
formation of a particular form is influenced 
by the following factors: solvent, isolation 
method, counter anion, etc. This area is of interest considering the fact that the new uronium 
coupling reagents seem to be more efficient than the corresponding guanidinium coupling 
reagents.[147] 
In addition, HBTU, HATU and HCTU can often cause a capping side reaction, which leads to 
N-terminal  guanylated peptides shown in 
Scheme 10.[148-149] Especially the aminium 
salts (guanidinium salts) are prone to cap the 
free N-terminus.[148-149] This side reaction 
leads to reduced yield or even terminates the 
chain growth. In order to prevent this side 
reaction, HBTU, HATU and HCTU need to be 
kept in a small stoichiometrically deficient amount to the coupled amino acids.[148] 
In 1995, Carpino and El-Faham introduced tetramethylfluoroformamidinium hexafluoro-
phosphate (TFFH) as coupling reagent. Generating acid fluorides in situ, TFFH was reported to 
be beneficial for the incorporation of hindered amino acids.[150]  
A series of new Oxyma-based coupling reagents such as (1-cyano-2-ethoxy-2-oxoethyliden-
aminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate (COMU)[151], Oxyma-B-
based reagents like N-((1,3-dimethyl-2,4,6-trioxotetrahydropyrimidin-5(6H)-ylidene-amino-
 
Figure 9: HBTU O- and N-form.[146] 
 
Scheme 10: Side reaction with HBTU yields an N-terminal 
guadinylated peptide. 
. 
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oxy)(dimethylamino)methylene)-N-methylmethanaminiumhexafluorophosphate (TOMBU)[152] 
or 4-((1,3-dimethyl-2,4,6-trioxotetrahydro-pyrimidin-5(6H)ylidene-aminooxy)(dimethyl-
amino)methylene)morpholin-4-ium hexafluorophosphate (COMBU)[152] have been recently 
developed (shown in Figure 10). These reagents have been reported to be advantageous over 
classic benzotriazole-based reagents in certain applications.[151-152] 
 
Figure 10: Structures of Oxyma/Oxyma-B based coupling reagents.[151-152] 
1.5.5. Automated SPPS 
The basic idea of Merrifield’s SPPS was to develop a faster, simpler and automatable approach 
to the chemical peptide synthesis.[14, 153-154] In 1965, he presented his vision of an automated 
device in Science magazine.[153] The device should have a single reaction vessel that is placed 
in a special reactor block. The device should be equipped with separate reservoirs for all 
necessary amino acids, organic solvents as well as activation and deprotection reagents. The 
device should be able to add the solutions required for each reaction step and afterwards 
remove the solvents and wash the vessel.[153] The first instrument for automated Boc-SPPS was 
built by Merrifield et al. in 1965, shown in Figure 11.[153-154] The introduction of the Fmoc-
group[20] and its reduction to SPPS practice in the late 1970s made automatization even easier 
because there was no more need to use corrosive substances like TFA during the repetitive 
deprotection cycles. Moreover, automated peptide synthesis could also be performed in a 
parallel mode to synthesize different peptides simultaneously in different reaction vessels. To 
that end, the deprotection and washing steps are performed simultaneously, and the coupling 
step is individual for each peptide sequence.  
To date automated peptide synthesizers for small-scale assembly are well established for Fmoc-
SPPS (single or parallel mode) and can be purchased in various sizes, with different acceleration 
(microwave irradiation, infrared heating, etc.) 
and monitoring mechanism (e.g. UV, 
conductivity).[155]  
Today continuous-flow peptide synthesis is 
getting more and more popular and the 
respective devices are commercially available. 
Since the introduction of a continuous-flow 
SPPS system in the early 1980s,[156-157] the 
interest in this technology has been diminished. 
However, recently it has got into the research 
focus again[54, 158-160] as it allows reducing the 
excess of reagents for the coupling und the 
solvents necessary for the SPPS synthesis.[159] 
Additionally, compared to a standard SPPS 
synthesis the washing and the reaction steps are 
inherently more rapid and efficient.[160] 
 
Figure 11: The instrument designed for automation 
of peptide synthesis by Merrifield.[153] [From R. B. 
Merrifield, Science 1965, 150, 178-185. Reprinted 
with permission from AAAS (American Association 
for the Advancement of Science)]. 
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1.5.6. Microwave-assisted SPPS 
In 1945, having noticed that a chocolate bar had melted in his pocket in close proximity to a 
magnetron, Percy Spencer discovered the ability of microwaves (MW) to heat food. Nine years 
later commercial MW devices appeared on the market, and in 1986 initial reports on the MW 
acceleration of organic synthesis were published.[161]  
To date, three main approaches to thermal activation are generally applied: Conventional 
heating like oil baths, microwave-accelerated heating, and infrared heating. Conventional 
heating activates the reactants slowly using an external 
source. Heat needs to pass the walls of the vessel to 
reach the solvents and the reactants in it. This is a rather 
slow and energy inefficient method to transfer energy 
into a reaction system. In the second way, the energy of 
the microwaves is applied directly to molecules of the 
reaction system, rising the temperature of the reaction 
fluid.  
Microwave heating has two fundamental requirements 
for energy transfer, dipole rotation or ionic conduction. 
If one of these criteria is fulfilled, it allows 
instantaneous superheating of the substance(s).[162] 
Figure 12 shows the difference between microwave 
and conventional heating. 
The effect of temperature on velocity of a chemical 
reaction is described by the Arrhenius equation (Equation 1). Arrhenius equation gives the 
dependence of the rate constant (k) of a chemical reaction on the absolute temperature, a pre-
exponential factor (A) and other constants of the reaction, where Ea is the activation energy for 
the reaction, R is the universal gas constant and T is the absolute temperature that controls the 
kinetics of the reaction. 
Equation 1:  𝑘 = 𝐴 × 𝑒−
Ea
𝑅𝑇⁄  
Numerous publications have shown that microwave assistance accelerates the reaction rate by 
a factor of 1000 compared to conventional heating.[162] Microwaves were found advantageous 
not only for conventional organic chemistry, but for SPPS as well. In 1991 Chen et al. reported 
the use of microwave irradiation to increase coupling efficiency and reduce reaction times in 
SPPS and monitored racemization of amino acids under microwave heating.[163] Several 
publications speculate that microwaves interact to a considerable extent directly with amide 
dipoles in peptides. According to these publications, microwave heating in SPPS is often not 
only faster but also offers higher purities compared to conventional SPPS at ambient 
temperature.[164-165] Thus, Bacsa et al. compared SPPS with microwave heating and 
conventional heating.[166] They synthesized three peptides with a length from 9 to 24 amino 
acids by microwave and oil-bath heating at 86 °C. The results showed similar crude purities, 
racemization levels, and identical impurity profiles of the peptides. They concluded that the 
main effect of microwave irradiation applied on SPPS appears to be a thermal one (Arrhenius 
equation; temperature increase of ~60° results in an estimated 50-fold reaction rate 
acceleration) and is not related to the electromagnetic field.[166] In 2009 Obermayer et al. 
showed that no observable athermic effects like electromagnetic field influence in microwave 
 
Figure 12: Inverse temperature gradient 
after microwave heating (left) and 
conventional heating in oil bath (right) after 
one minute. Figure by C. O. Kappe[162], 
Reproduced with kind permission of John 
Wiley & Sons. 
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chemistry exists at all.[167] In general, microwave-assisted solid-phase peptide chemistry reduces 
reaction times accompanied by an increase in the crude peptide purity. [155, 168] However the use 
of elevated temperatures is known to compromise the stereo integrity of sensitive amino 
acids.[163, 166] Racemization is discussed in detail in the following chapter. 
1.5.7. Side reactions in SPPS 
Racemization during the activation process is a problem that often occurs in SPPS. Natural 
amino acids, except glycine, have a chiral 
center with L-configuration at its α-carbon. 
In all these 19 optically active amino acids 
one of the substituents at the α-carbon is a 
potentially acidic hydrogen atom. Removal 
and subsequent reattachment of this 
hydrogen bears a risk of racemization (Scheme 11). The acidity of the hydrogen at the α-carbon 
is increased upon activation of the carboxyl group. An increased rate of racemization is also 
pronounced at elevated temperatures, e.g. upon microwave heating.[163, 166] Histidine and 
cysteine are known as extremely racemization-prone amino acids.  
Histidine  
Histidine may undergo significant racemization during base‐mediated activation methods (e.g. 
phosphonium or uronium reagents with DIPEA) or if the coupling takes a significant amount of 
time.[73-74, 94, 169] The 
imidazole π‐nitrogen 
electrons affect the 
enol formation of 
histidine active esters, 
resulting in increased 
racemization.[170] To 
avoid this side-reaction, Jones et al. established the imidazole π-nitrogen protecting group Bom, 
which is employed in Boc-chemistry.[74] Later, they introduced the TFA-labile Bum group to be 
used in Fmoc-SPPS.[94] The 4-methoxy-benzyloxymethyl (MBom) introduced by Hibino and 
Nishiuchi proved to be very effective to supress epimerisation.[171-172] Unfortunately, the 
production of Fmoc-His(MBom)-OH is expensive; moreover, in course of cleavage a number of 
unwanted side reactions was observed. A methoxybenzyl cation (electrophilic alkylating 
species) is formed during the cleavage process that was reported to induce alkylation of side 
chain residues.[171, 173] Structures of the protected histidine derivatives are shown in Figure 13. 
Therefore, Fmoc-His(Trt)-OH is still in use, even if there is a certain risk of histidine 
racemization, which becomes only minor if the coupling is performed under slightly acidic 
conditions (e.g. DIC, HOBt) at ambient temperature.[174]  
Cysteine 
Using base‐mediated activation methods (e.g. phosphonium or uronium reagents with DIPEA) 
may result in cysteine racemization.[132, 175] Preactivation and microwave heating increase 
racemization rate,[164] but this can be reduced by using base-free carbodiimide activation 
methods.[132, 174] Different protecting groups have been examined on the potential reduction of 
cysteine racemization during the synthesis process, compared to the standard trityl protection. 
MBom was shown to reduce the D-Cys formation to 0.4%.[71, 176] Unfortunately, the MBom group 
is linked to the alkylation of side chain residues during the cleavage process (similar to 
 
Scheme 11: Base-catalyzed racemization of an amino acid. 
 
Figure 13: Boc-His(Bom)-OH, Fmoc-His(Bum)-OH and Fmoc-His(MBom)-OH 
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histidine). A complete suppression however was not possible with the tested protecting 
groups.[176]  
In addition, cysteine racemization often takes place during coupling and Fmoc deprotection 
with piperidine if the cysteine residue is linked C-terminally to the resin by an ester bond.[54] 
Another enantiomerization mechanism involves the deprotonation and ring opening of an 
oxazolone intermediate. This intermediate is obtained by a nucleophilic attack on the activated 
carboxy group from the neighbouring amide bond (see chapter 1.5.4,Scheme 8).  
Aspartimide formation 
Aspartimide formation is the most harmful side reaction in Fmoc-based SPPS of peptide 
sequences containing aspartic acid. [54, 177-184] It is caused by both acids and bases,[183] being 
extremely pronounced in the case of strong bases. Therefore, it has been frequently observed 
in Fmoc-SPPS (see Scheme 12). If a peptide contains several aspartic acid residues, the 
formation of aspartimide is a serious problem resulting in a number of side products, depending 
on the reaction conditions.  
 
Scheme 12: Aspartimide formation (R1,R2,R3: residues). 
First the D/L aspartimide intermediate is formed, followed by the nucleophilic attack of water 
leading to the formation of the D/L‐β‐peptides and the D/L-α‐peptide in a ratio between 3:1 
(observed in amyloid β-protein)[185] and 2:1.[186] The attack of piperidine on the D/L aspartimide 
ring results in a mixture of D/L‐α‐piperidides and D/L‐β‐piperidides.[179-181] If the nucleophilic 
attack on the aspartimide intermediate is exercised by an amine group, the formation of 
dipeptides, cyclic peptides or piperidine adducts is observed.[187] The resulting α‐piperidides 
and β‐piperidides can be easily removed from the crude peptide by HPLC, the HPLC separation 
of the D/L‐α‐aspartyl peptides is however quite difficult.[188] Reduction of aspartimide formation 
is possible by the addition of acidic modifiers in Fmoc-SPPS.[189-190]  
Thus, Subirós‐Funosas et al. showed that the addition of 1M Oxyma[140] in 20% piperidine 
during Fmoc deprotection resulted in a significant reduction of aspartimide side products.[190] 
Backbone protection of the aspartyl α-carboxyamide bond is currently the only strategy to 
prevent aspartimide formation completely.[191-193] This is usually applied for peptides containing 
  
  Page 21 
Asp‐Gly, because the coupling of the amino acid following the 2-hydroxyl-4-methoxybenzyl 
(Hmb)[194] residue can be extremely difficult.[195]  
Another method for aspartimide reduction are Mutter’s pseudoproline (ψPro) dipeptides. 
Pseudoprolines are oxazolidine- or 
thiazolidine-based derivatives of serine, 
threonine and cysteine residues. The 
corresponding derivative is formed by a 
cyclocondensation with an aldehyde or 
ketone.[196-198] Usage of pseudoproline 
dipeptide building blocks allow for the 
incorporation of two amino acid residues at 
once; the native sequence is regenerated upon global cleavage, as shown in Scheme 13.[198-199] 
These commercially available surrogates improve cyclisation, aspartimide suppression and 
epimerization-free segment coupling during peptide synthesis.[200] However, they are limited to 
sequences containing serine, threonine or cysteine at convenient positions. 
1.6. Peptide purification  
Merrifield's breakthrough in peptide chemistry proved viable only after the introduction of 
efficient HPLC purification. An isolation/purification, which is necessary to achieve a peptide 
purity of >95%, is one of the bottlenecks of peptide production even now.  
Over the past 40 years the purification of peptides by HPLC has been significantly improved. 
Today it is the state-of-the-art process for the isolation and purification of peptides of different 
nature, structure, and complexity grade.[37-39, 201] In most cases, the purification of peptides is 
performed via reversed phase high-performance liquid chromatography (RP-HPLC). Due to the 
high resolution of modern RP-HPLC purification, peptides with nearly identical sequences can 
be separated. In reversed-phase mode, a hydrophobic molecule is captured by the stationary 
phase comprising C4, C8 or C18 alkyl ligands. The retention time depends on the hydrophobicity 
of the molecule and of the used mobile phase. RP-HPLC for peptide purification is performed 
in the presence of an organic modifier and an ion-pairing reagent, with acetonitrile and TFA 
being the compounds of choice for standard operating procedures. Purification by RP-HPLC has 
limitations regarding highly polar/unpolar peptides. The first ones bind only weakly or not at 
all to the stationary phase. The second ones do not elute from the column. The limiting factors 
for peptide purification by HPLC are usually solvent consumption and/or the time effort for the 
purification process.  
Alternative techniques mainly used for protein purification such as size-exclusion 
chromatography (SEC), ion-exchange chromatography (IEC)[202-206] or hydrophobic interaction 
chromatography (HIC)[207] can be applied to peptide purification as well.  
Ion-exchange chromatography has been used as separation method for charged biological 
molecules such as proteins, peptides, amino acids, or nucleotides for around 70 years.[202-206] 
Amino acids are amphoteric; that means they are zwitterionic compounds that contain both 
positively and negatively charged functional groups. Depending on the pH of their environment, 
amino acids (and therefore peptides and proteins as well) may carry a net charge. The 
isoelectric point is the pH value where the molecules has no net charge. The ion-exchange 
material is based on spherical particles substituted with ionic groups that are negatively or 
positively charged. The material is usually porous to increase the surface area.  
 
Scheme 13: Peptide sequence with incorporated 
pseudoproline and deprotection with TFA (ψPro) 
(R1,R2,R3: residues, R4=H, Me). 
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Ion-exchange chromatography (IEC) has large capacity, the 
material is available at moderate costs, scale-up is easy to 
perform and automation is possible. IEC process comprises the 
following steps: Equilibration of the column, adding the sample, 
gradient elution of the loaded sample, regeneration of the 
column material.[208] High-performance ion-exchange 
chromatography is also available.[209-210] In addition to the 
amphoteric character of the amino acids, functional groups may 
be introduced chemically to allow an easy ion-exchange process. In 1978, Merrifield and Bach 
introduced a monosulfonated Fmoc to allow peptide purification after SPPS cleavage on a ion-
exchange column (Figure 14).[206] This method offered the possibility of a simple purification 
of the crude peptide. However, due to the complicated handling and the special protection for 
the N-terminus, the technique has not found practical application.  
In recent years different affinity-based approaches have been reported for peptide isolation.[211-
213] Affinity chromatography, widely used for the purification of recombinantly expressed 
proteins, is based on specific binding interactions between molecules. To that end, a particular 
ligand is chemically bound to a solid support; if a crude mixture passes over the column all 
molecules with specific binding affinity to the ligand remain on the column. After all impurities 
are washed away, the bound molecule is stripped from the solid support resulting in a purified 
peptide or protein. One or more of these techniques can be used in combination to improve the 
peptide purity. 
1.7. Towards sustainable peptide synthesis 
For decades, peptides have been in the research focus in view of their pharmaceutical and 
cosmetic applications. Obviously, chemical peptide synthesis is very inefficient in terms of 
solvent and reagent consumption. Indeed, the reagents are used in high excess, solvents are 
expensive and hazardous thus posing a threat to the environment and human health. 
Additionally, the European REACH3 Regulation classifies commonly used DMF and NMP 
(N-methylpyrrolidone) as substances of very high concern due to their CMR (carcinogenic, 
mutagenic or toxic for reproduction) properties. In recent years, different approaches to 
improve peptide synthesis in terms of green chemistry or sustainable engineering have been 
reported.[214-224] In an article entitled "The ideal peptide plant", Dr. Olivier Ludemann-
Hombourger, PolyPeptide Group, discusses aspects of the synthesis process that industry 
considers to be in urgent need of improvement: „Let us dream of the future steps: A process 
with no waste of organic solvent; a fully automated process with online monitoring of the 
progress of reactions; the addition of reagents and amino acid derivatives to reduce the 
consumption of all chemicals; a reduced process time for each amino acid derivative 
incorporation; an automated purification process with quantitative yield without compromising 
productivity.“[225]  
Many organic solvents are harmful, toxic and poisonous to the environment. Their use therefore 
poses a risk to human health and surrounding milieu. As understanding solvent properties is an 
obligatory part of sustainable development, the majority of them have been classified according 
to their environmental, safety and health (ESH) issues.[226] These rankings are the core principle 
of the guidelines on solvent selection used by pharmaceutical companies (GSK, AstraZeneca, 
 
3 Regulation (EC) No. 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the 
Registration, Evaluation, Authorisation and Restriction of Chemicals (‘‘REACH”) 
 
Figure 14: 9-(2-Sulfo)fluorenyl-
methyloxycarbonyl chloride.[205] 
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Pfizer and Sanofi) and by professional groups such as the ACS Green Chemistry Institute 
Pharmaceutical Roundtable (GCI-PR).[227-230] Byrne et al. have drawn an overall conclusion from 
the Sanofi, Pfizer and GSK solvent selection guide shown in Table 4. 
Table 4: Summary of solvent selection tables by Byrne et al. (Adapted table by Byrne et al.[227] distributed under the 
terms of the Creative Commons Attribution 4.0, Licence: CC BY 4.0. (https://creativecommons.org/licenses/by/4.0/). 
Class Solvent 
Conclusion 
(Pfizer) 
Conclusion 
(GSK) 
Conclusion 
(Sanofi) 
Alcohols 
Methanol Preferred Some issues Recommended 
Ethanol Preferred Some issues Recommended 
1-propanol Preferred Some issues Recommended 
i-propanol Preferred Some issues Recommended 
1-Butanol Preferred Few issues Recommended 
2-Butanol  Few issues Substitution advisable 
t-butanol Preferred Some issues Substitution advisable 
Ethylene glycol Usable  Substitution advisable 
2-methoxyethanol  Major issues Substitution requested 
Hydro-
carbons 
n-pentane Undesirable  Banned 
Hexane(s) Undesirable Major issues Substitution requested 
Cyclohexane Usable Some issues Substitution advisable 
Methylcyclohexane Usable  Substitution advisable 
Heptane Usable Some issues Substitution advisable 
Isooctane Usable Some issues  
Benzene Undesirable Major issues  
Toluene Usable Some issues Substitution advisable 
Xylene(s) Usable Some issues Substitution advisable 
Dipolar 
aprotic 
DMSO Usable Some issues Substitution advisable 
Acetonitrile Usable Major issues Recommended 
DMF Undesirable Major issues Substitution requested 
DMAc Undesirable Major issues Substitution requested 
NMP Undesirable Major issues Substitution requested 
Esters 
Methyl acetate  Some issues Substitution advisable 
Ethyl acetate Preferred Some issues Recommended 
n-propyl acetate  Few issues Recommended 
i-propyl acetate Preferred Few issues Recommended 
Ethers 
THF Usable Major issues Substitution advisable 
2-MeTHF Usable Some issues Recommended 
TBME Usable Some issues Substitution advisable 
CPME  Some issues Substitution requested 
Diethyl ether Undesirable Major issues  
Diisopropyl ether Undesirable Major issues Substitution advisable 
1,2-DME Undesirable Major issues Substitution requested 
1,4-dioxane Undesirable Major issues Substitution requested 
Ketones 
Acetone Preferred Some issues Recommended 
Methylethyl keton Preferred Major issues Recommended 
MIBK  Some issues Recommended 
Halo- 
genated 
Dichloromethane Undesirable Major issues Substitution advisable 
1,2-dichloethane Undesirable Major issues  
Chloroform Undesirable Major issues  
CCl4 Undesirable Major issues  
Miscellan-
eous 
Water Preferred Few issues Recommended 
Acetic acid Usable  Substitution advisable 
Pyridine Undesirable  Substitution advisable 
The data collected by Pfizer, GSK and Sanofi show that the greenest solvents are water, propyl 
acetate, i-propylacetate, 1-butanol, and 2-butanol. This selection is very limited, as only alcohols 
and esters, in addition to water, are recognized as green solvents. Acetonitrile achieves a 
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different result in each of the solvent selection aids, Pfizer recommends MeCN as a substitute 
for DMF and NMP. 2-MeTHF and DMSO are also considered possible as substitutes for DMF.[228-
229]  
A recent publication of the American Chemical Society (ACS) Green Chemistry Institute 
Pharmaceutical Roundtable summarizes the current situation as follows: ”… the current state 
of the art in peptide synthesis involves primarily legacy technologies with use of large amounts 
of highly hazardous reagents and solvents and little focus on green chemistry and 
engineering.“[231] The authors call to innovation and the problems in the currently used peptide 
synthesis they identified are shown in Figure 15. 
 
Figure 15: A call to innovation to develop a sustainable peptide synthesis by ACS Green Chemistry Institute 
Pharmaceutical Roundtable (Adapted with permission from Isidro-Llobet et al., The Journal of Organic Chemistry 
2019, 84, (8), 4615-4628).[231] Copyright 2019 American Chemical Society). 
Some preliminary work has already been done in this direction, but so far, no industrial solution 
has been found. Two general trends can be observed, change to alternative solvents or reduction 
of reagent excesses. 
1.7.1. Peptide synthesis in alternative organic solvents 
McMillan et al. screened different organic solvents like tert‐butyl methyl ether, cyclopentyl-
methyl ether, dimethyl carbonate, ethyl acetate, iso‐propyl alcohol, as well as 2‐methyl 
tetrahydrofuran (2‐MeTHF) for their effect on the formation of amide bonds. Their studies 
showed that dimethyl carbonate, ethyl acetate, and 2‐MeTHF are comparable to DMF and 
DCM.[232] Jad et al. performed peptide synthesis with THF and MeCN as DMF replacement and 
achieved comparable results, even with a minor improvement in some cases.[233] Later Jad et al. 
used 2-methyltetrahydrofuran and cyclopentyl methyl ether for green SPPS.[214] They concluded 
that the use of 2-MeTHF in combination with DIC/Oxyma Pure gives the lowest degree of 
racemization in the case of short peptides, up to five amino acids in length. However, as the 
selection of building blocks was limited to only five amino acids, it could obviously indicate that 
the others suffer from insufficient solubility in the given solvent. Jad et al. showed an 
improvement of their method by introducing a protocol for the use of 2-MeTHF for Fmoc 
deprotection, however additional washing steps with EtOAc were required.[215] Even with these 
steps the Fmoc deprotection was still not optimal[217], the solvent system was further changed 
to γ-valerolactone (GVL) and N-formylmorpholine (NFM) as a “greener” alternative to DMF. 
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[218] Having determined the solubility of different Fmoc-aa-OH compounds and Oxyma Pure in 
GVL or NFM and compared the data with those for DMF, it was found that Fmoc-Leu-OH, 
Fmoc-Aib-OH, Fmoc-Tyr(tBu)-OH) were well soluble (>0.2 M) in GVL and NFM, and 
Fmoc-Phe-OH had a solubility of 0.16 M in GVL.[218]  
Lawrenson et al. have shown recently that propylene carbonate (PC) can replace DMF in 
solution‐ and solid‐phase peptide synthesis by using either the Fmoc or Boc strategy for the 
synthesis of the nonapeptide bradykinin.[219] 
Many of the recent publications indicate that a conversion to green solvents is often limited by 
the currently used Fmoc amino acid building blocks and their low solubility in alternative 
organic solvents. This represents a major obstacle that often prevents the use of greener solvents 
in peptide chemistry. 
1.7.2. Solvent-free peptide synthesis 
Different synthesis protocols for solvent-free peptide 
synthesis have been published to date. Declerck et al. 
synthesized di- and tripeptides by using the ball-milling 
(see Figure 16 for schematic drawing[234])  method with 
urethane‐protected α‐amino acid N‐carboxy-
anhydrides.[235] This method was later optimized by 
Bonnamour et al. for the synthesis of a pentapeptide Leu-
enkephalin by adding small amounts of ethyl acetate 
with an overall yield of 46%. Boc deprotection was 
performed with gaseous HCl.[236] 
Another group synthesized dipeptides by using 2,4,6‐
trichloro‐1,3,5‐triazine and triphenylphosphine upon 
ball-grinding with solvent drops.[237] Konnert et al. 
published the solvent-free synthesis of Fmoc-, Boc- and 
Z-protected amino acids by ball grinding.[238] Although the use of ball-milling is an interesting 
approach to achieve a greener peptide synthesis protocol, at the moment the method is limited 
to rather short peptides. 
1.7.3. Peptide synthesis in water 
Hojo et al. reported the preparation of different water-soluble N-protected amino acids with the 
2-[phenyl(methyl)sulfonio]ethyloxycarbonyl (Pms)[239-240] group, the ethanesulfonyl-
ethoxycarbonyl (Esc)[241] group and the 2-(4-sulfophenylsulfonyl)ethoxy-carbonyl (Sps)[242] 
group and their application to solid-phase peptide 
synthesis (structures are shown in Figure 17).[239-242] 
However, Pms-amino acids were rather unstable due to 
their onium form and Esc-amino acids (except Esc 
aromatic amino acids) were not detectable by 
measurement of optical absorption and showed only 
moderate solubility in water. In addition, the starting 
materials for the Esc group are relatively expensive. 
Usage of Sps protecting groups resulted in autooxidation 
of cysteine and methionine. Hojo et al. were able to 
 
Figure 17: Structures of Pms, Esc and Sps 
protecting groups by Hojo et al. 
 
Figure 16: Schematic representation of a 
high-energy planetary ball mill. [Reprinted 
from El-Eskandarany, Mechanical Alloying 
(Second Edition), William Andrew 
Publishing, Oxford, 2015, pp. 13-47.[233] 
With permission from Elsevier]. 
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synthesize only one short peptide in water and due to the intrinsic problems of their protecting 
groups switched to another concept. They stated: „Peptide synthesis can be carried out in water 
via chemical conversion of protected amino acids to water-soluble forms. However, additional 
conversion steps are required in total synthetic process, and it is not desirable in terms of 
preparation costs, resource saving, and energy conservation. Thus, development of simplified 
techniques other than chemical conversion is urgently needed for environmentally friendly 
peptide synthesis.”[243]  
As a solution for this, Hojo et al. described a technology using water-dispersible nanoparticulate 
Fmoc-amino acids.[243-247] This concept however was successful only in the case of amide bond 
formation. Indeed, only amino acid coupling was conducted in water; deprotection and washing 
steps had to be performed in DMF due to the intrinsic hydrophobic properties of fluorenylmethyl 
moiety, which result in water-incompatibility. Hojo et al. also showed a strategy for Boc-amino 
acid nanoparticles.[243, 248-249] However, all of these approaches required long coupling times, 
some reaction steps had to be performed in organic solvents and upscaling was quite limited. 
Microwaves were proposed as an energy source to accelerate the coupling step in water or in 
the absence of solvents,[250] although the use of elevated temperatures is known to compromise 
the stereo integrity of sensitive amino acids.[163, 166] 
Hojo et al. concluded: “In general, many organic compounds of synthetic intermediates for 
industrial use are poorly soluble in water, and therefore inadequate for reactions in water.”[243] 
This is confirmed by Cortes-Clerget et al.: “Nonetheless, in most of these reports the scope of 
the reaction is limited and large amounts of co-solvents are often needed to prevent 
aggregation.”[220] 
Cortes-Clerget et al. introduced a method using aqueous micellar medium. The reaction takes 
place within the core of nanomicelles, formed by a 2 wt% aqueous solution of TPGS-750-M to 
overcome insolubility of protected amino acids in water.[220, 223] However, the synthesis 
procedure seems to be limited to di- or tripeptides.[220, 223] 
In 2012, John Collins introduced a series of water-compatible 
N-terminal protecting groups in a patent application.[251] However, 
all of them possessed a hydrophobic character leading to low water 
solubility of the protected amino acids. The 1,1-dioxonaptho[1,2-b]-
thiophene-2-methyloxy-carbonyl group (Nsmoc), shown in Figure 
18, seemed to be the most promising structure, but the synthesis of 
the compound is sophisticated and the protected amino acids had 
only a moderate water solubility, so scale-up seemed to be quite 
limited as well. 
A recent publication by Přibylka et al. suggests using sodium hydroxide in a 2-MeTHF/MeOH 
mixture for Fmoc deprotection.[224] The authors state, that their protocol is only incompatible 
with Wang linker molecules.[224] Our own work (see results) however showed, that NaOH is 
capable of cleaving all ester molecules during the deprotection step (linker molecules and side 
chain protecting groups), so use of this method is quite limited to peptide amides without Asp 
and Glu side chain residues. 
 
 
 
Figure 18: Structure of the 
Nsmoc group. 
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2. Objective 
The present work is aimed at the development of a water-based peptide synthesis as a 
sustainable alternative to the state-of-the-art process.  
To achieve this goal, a lot of of synthetic and technical challenges should be addressed.  
To get access to water-compatible SPPS/LPPS building blocks, polar Nα-protecting groups are 
required which should ensure solubility of particular amino acids in water or aqueous solution. 
At the same time these groups must meet the requirements of peptide assembly in terms of 
stability, liability, and usability. This issue includes design and synthesis of the respective 
protecting groups and their installation in amino acids of choice with subsequent approbation 
in peptide synthesis. 
Following elaboration of an Nα protection, a reliable water-compatible convergent protecting 
group strategy for the functional side chain should be developed. The required moieties must 
demonstrate orthogonality to the aminoterminal counterpart, being at the same time easily 
removable upon global cleavage. Within the coded amino acids 12 side chains require 
protection upon peptide assembly. As my previous research on cell-penetrating COSS 
derivatives[1] has revealed that the introduction of solitair or multiple ionic pendants wielded 
major influence on the polarity/solubility of the resulting compounds, the focus was set on 
equipping commercially available protecting groups with ionic moieties.  
To allow for a real-time monitoring of peptide assembly, especially on solid support, a 
protecting group with UV/Vis or fluorescent properties is highly desirable. Therefore, the 
starting point for the design and synthesis was set at the fluorene molecular framework known 
for its fluorescent properties. 
The success of the chosen protecting group strategy should be verified by assembling several 
model peptides under aqueous conditions. 
In addition, the basic bottlenecks of peptide synthesis in the context of coupling/deprotection 
efficiency, enantiomeric purity, side reactions, and postsynthetic isolation/purification should 
be comprehensively studied.  
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3. Results and discussion 
3.1 Design of water-compatible protecting groups 
Protecting groups that can be used for peptide assembly in polar solvents like alcohols or water 
must possess hydrophilic properties. However, most of the currently used protecting groups are 
strongly hydrophobic, because they must be soluble in organic solvents. To change this 
behaviour, either modifications of the existing protective groups are necessary to increase their 
solubility in polar solvents, or the development of novel, alternative groups for polar solvents 
is required. In this thesis, the focus was set on the modification of available protecting blocks. 
Upon preliminary work with highly polar COSS compounds, basic knowledge about the 
influence of functional groups on solubility and the chemical behaviour was already obtained. 
The initial idea was to decorate existing protecting groups by additional polar moieties and to 
assess their usability in peptide synthesis.  
To that end, the following functional groups were taken into consideration: sulfo-, phospho-, 
cyano-, guanidino-, as well as quaternary ammonium bases and some other candidates. The 
sulfonated protecting groups proved to be easily accessible with no side reactions under the 
conditions of peptide synthesis. Therefore, first experiments were performed with sulfonated 
protecting groups. An overview of the modified protecting blocks is given in Figure 19. 
 
Figure 19: Overview of the sulfonated protecting-group candidates. 
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All of the shown protecting groups demonstrated high water solubility, and some of them, e.g. 
2,7-disulfo-9-fluorenylmethoxycarbonyl chloride possessed additional benefits as intrinsic 
fluorescent properties and possibility to be cleaved under milder reaction conditions. Some 
examined groups revealed increased stability, resulting in harsh cleavage conditions and were 
found therefore inapplicable (data not shown). As a result, the Smoc protecting group was 
selected as the most promising candidate for the further work. 
The jump-start for the present investigation was given accidentally. Thus, during the synthesis 
of a novel protecting group for peptide backbone an Nα-Fmoc protected amino acid was treated 
with sulfuric acid giving an unexpected water soluble, fluorescent product in preference to the 
desired compound. Thorough analysis of this molecule and the horizons that its application 
could open gave rise to the novel field of peptides synthesis. 
3.1. Synthesis of 2,7-disulfo-9-fluorenylmethoxycarbonyl chloride (Smoc-Cl) 2 
The synthesis of the Smoc protecting group 2 started from commercially available Fmoc 
chloride 1, shown in Scheme 14. 
 
Scheme 14: Synthesis of Smoc-Cl 2. 
In order to introduce two sulfo groups, different sulfonation regents were examined, among 
them sulfuric acid, oleum, chlorosulfonic acid, as well as sulphur trioxide complexes with 
pyridine, trimethylamine, DMF, and dioxane. Although application of most of the sulfonation 
reagents yielded mixtures of mono- and disulfonated products, sulfuric acid and oleum gave 
exclusively the desired 2,7-disulfo-9-fluorenylmethoxycarbonyl chloride 2.  
However, the lability of the Smoc chloride 2 in the presence of bases did not allow to remove 
the excess of acids by simple neutralization. Therefore, the surplus of oleum/sulfuric acid needs 
to be purged by other methods. The best results were achieved by using dioxane for 
complexation of SO3 excess followed by washing with 1,2-dichloroethane to obtain a pure 
product. Our work showed that the synthesis of Smoc-NHS is possible by the same reaction 
pathway, the product purification is however more complicated and therefore Smoc-Cl was 
used for the following work. 
Further optimisation resulted in an easily scalable, sustainable reaction for the synthesis of 
Smoc-Cl 2 (not part of this work) without the need to use critical solvents like dioxane and 
1,2-dichloroethane. 
3.2. Synthesis of Nα-Smoc amino acids 
Introduction of an Smoc group at the α-amine of amino acids is possible by two different 
reaction pathways, shown in Scheme 15. 
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Scheme 15: Synthesis of Nα-Smoc amino acids by direct sulfonation of an Nα-Fmoc amino acids or upon 
condensation with Smoc-Cl 2. 
A direct conversion of Fmoc-bearing amino acids lacking functional side chains to the respective 
Smoc derivatives (3, 4, 7, 12, 16, 21, 30, 31) was performed successfully applying sulfuric acid 
with subsequent neutralisation of its excess by calcium carbonate. The resulting calcium sulfate 
was removed by filtration, and the respective Smoc amino acids were isolated from aqueous 
solution by freeze-drying. 
The second route relied on the usage of Smoc-Cl 2 to synthesize the corresponding Smoc amino 
(3-32). This method was successfully applied to all canonic amino acids as well as to a number 
of non-natural building blocks, giving desired Smoc products in high yields. Moderate yield 
obtained in reaction of Smoc chloride 2 with 2-aminoisobutyric acid (AiB) 107 was attributed 
to its obvious steric hindrance. Interestingly, it was noticed that addition of minimal amounts 
of MeCN during the reaction process reduced Smoc cleavage to a minimum, thus leading to 
increased product formation. To remove excess of amino acids, HPLC purification was applied. 
All Smoc-protected amino acids used in this work were synthesized via the second route. The 
respective derivatives, their structures and the synthesis yields are summarized in Table 5. 
Amino acids with functional side chains either combined Nα-Smoc protection with the standard 
side chain protecting groups (6, 8, 9, 11, 14, 18, 23, 25, 27, 29) or possessed unprotected side 
chains (5, 7, 10, 13, 22, 24, 26, 28) to validate if a side chain protection is necessary under 
aqueous peptide synthesis conditions. Within the natural amino acid repertoire, Lys, Glu, Asp 
and Cys required side chain protection under aqueous conditions.  
Table 5: Synthesized Nα-Smoc amino acids, their structure and yields. 
Compound Structure Abbreviation Yield [%] 
3 
 
Smoc-L-Ala-OH 87.2 
4 
 
Smoc-D-Ala-OH 86.9 
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5 
 
Smoc-L-Arg-OH 85.7 
6 
 
Smoc-L-Arg(Pbf)-OH 85.1 
7 
 
Smoc-L-Asn-OH 90.4 
8 
 
Smoc-L-Asp(OtBu)-OH 86.7 
9 
 
Smoc-L-Cys(Trt)-OH 85.1 
10 
 
Smoc-L-Gln-OH 90.8 
11 
 
Smoc-L-Glu(OtBu)-OH 88.2 
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12 
 
Smoc-Gly-OH 93.7 
13 
 
Smoc-L-His-OH 92.4 
14 
 
Smoc-L-His(Trt)-OH 86.6 
15 
 
Smoc-L-Ile-OH 88.9 
16 
 
Smoc-L-Leu-OH 90.6 
17 
 
Smoc-D-Leu-OH 88.7 
18 
 
Smoc-L-Lys(Boc)-OH 87.4 
19 
 
Smoc-L-Met-OH 95.1 
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20 
 
Smoc-L-Phe-OH 93.7 
21 
 
Smoc-L-Pro-OH 85.8 
22 
 
Smoc-L-Ser-OH 90.0 
23 
 
Smoc-L-Ser(tBu)-OH 87.9 
24 
 
Smoc-L-Thr-OH 92.2 
25 
 
Smoc-L-Thr(tBu)-OH 89.2 
26 
 
Smoc-L-Trp-OH 90.7 
27 
 
Smoc-L-Trp(Boc)-OH 86.9 
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28 
 
Smoc-L-Tyr-OH 89.7 
29 
 
Smoc-L-Tyr(tBu)-OH 91.4 
30 
 
Smoc-L-Val-OH 87.2 
31 
 
Smoc-β-Ala-OH 92.5 
32 
 
Smoc-Aib-OH 57.8 
 
3.3. Nα-Smoc deprotection 
During the solid-phase peptide synthesis, the Nα-protecting group needs to be cleavable under 
mild conditions to prevent side chain deprotection, thus retaining the orthogonality. Smoc 
cleavage conditions were examined applying different aqueous bases or their solutions in polar 
solvents and the grade of deprotection after five minutes is summarized in Table 6. 
Table 6: Summary of deprotection experiments. 
Deprotection agent Concentration Solvent 
Extent of deprotection 
after 5 min 
NaOH 0.2 M water 100% 
NaOH 1 M 
water 
ethanol 
100% 
100% 
Ethanolamine 10% (v/v) 
water 
ethanol 
95% 
75% 
Ethylenediamine 10% (v/v) water 100% 
Piperazine  5% (w/v) water 100% 
Ammonia  10% (v/v) water 100% 
Piperidine  20% (v/v) water 100% 
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After 5 min, the deprotection progress was monitored by HPLC. In general, two cleavage 
products (33, 34) were observed for all used bases; in some cases, Smoc-base adducts were 
detected as well. The deprotection process is shown in Scheme 16. 
 
Scheme 16: Deprotection of the Smoc protecting group leads to the products 33, 34 as well as the possible base 
adduct. 
Deprotection was performed with different Nα-Smoc amino acids. Here, cleavage of Smoc is 
exemplarily shown for Smoc-Arg-OH 5, Smoc-Leu-OH 16 and Smoc-Tyr-OH 28. 
Deprotection of Smoc-Arg-OH 5 resulted mainly in the formation of cleavage product 33; 
cleavage product 34 was detected in higher yields after 10 minutes. Piperidine and piperazine 
led to the formation of the corresponding base adducts. Except for the deprotection experiment 
in suspension using ethanolamine in ethanol, in all base systems 95%, of the Smoc protecting 
group were cleaved within 5 minutes. Surprisingly, the suspension experiment with NaOH in 
ethanol was as efficient as the solution-based deprotection in NaOH.  
 
Figure 20 shows the relevant sections of all HPLC runs for easier comparability. The complete 
data can be seen in section 8.3.1.  
 
Figure 20: Deprotection of Smoc-Arg-OH 5 applying different bases. The shown area is reduced to the relevant 
range of the HPLC runs. Absorption values were normalized from 0 to 100%. HPLC traces were monitored at λ=220 
nm with a gradient of 0 to 40% MeCN, see section 7.2.3 for details. 
The deprotection studies of Smoc-Leu-OH 16 led to similar results. 33 was the main cleavage 
product, and 34 appeared as the major one in this experiment with piperazine and 
ethanolamine. Piperidine and piperazine also led to the formation of the corresponding base 
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adducts. In this case, the deprotection using the suspension systems (ethanolamine or NaOH in 
ethanol) led to similar results as the solution-based deprotection in water. This could be due to 
the slightly better solubility of Smoc-Leu-OH 16, compared to Smoc-Arg-OH 5, under these 
reaction conditions. In all base systems except for piperazine and ethanolamine, the Smoc 
protecting group was removed quantitatively. Figure 21 shows the relevant sections of all HPLC 
runs for easier comparability. The complete data can be seen in section 8.3.2. 
 
Figure 21: Deprotection of Smoc-Leu-OH 16 with different bases. The shown area is reduced to the relevant range of 
the HPLC runs. Absorption values were normalized from 0 to 100%. HPLC traces were monitored at λ=220 nm with 
a gradient of 0 to 40% MeCN, see section 7.2.3 for details. 
Similar results were obtained in deprotection studies of Smoc-Tyr-OH 28. 33 was the major 
cleavage product, however 34 was formed in higher amounts in comparison to the two other 
experiments. Piperidine and piperazine formed the corresponding base adducts as well. In all 
base systems, the Nα-Smoc protecting group was cleaved nearly quantitatively. Figure 22 shows 
the relevant sections of all HPLC runs for easier comparability. The complete data can be seen 
in section 8.3.3.  
In addition to the standard bases used in Fmoc-SPPS, deprotection was found possible applying 
water-soluble bases such as ammonia or sodium hydroxide. This provides an access to 
significantly cheaper and easier procedures compared to the piperidine-based deprotection. In 
general, the performed deprotection experiments showed an increased base lability of the Smoc 
group, compared to that of the Fmoc one in view of deprotection duration and chosen base.[252] 
All water-soluble bases could be applied, with aqueous sodium carbonate and ethylenediamine 
demonstrating similar behavior to the shown bases outcomes.  
However, the deprotection experiments and the application of the results to solid-phase peptide 
synthesis have revealed some limitations concerning the choice of the base. The use of sodium 
hydroxide-based systems led to the cleavage of all ester bonds during peptide synthesis. The 
quantitative cleavage of the tert-butyl esters from the side chains of Glu and Asp was observed 
as well as the cleavage of the peptide from solid support if the first amino acid was anchored 
by an ester bond. This effect however could be useful if cleavage from the support upon 
preservation of certain side chain protecting groups is required.  
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Although the usage of NaOH in methanol for Fmoc deprotection has been recently 
published[224], we also examined the ester bond cleavage in alcohol-based systems. Our results 
clearly showed that application of bases other than NaOH, both in water and alcohol, should 
be omitted in the case of ester side chain protection or ester-based solid-phase linkers. Thus, 
5% aq. piperazine has proven to be rather efficient.  
 
Figure 22: Deprotection of Smoc-Tyr-OH 28 with different bases. The shown area is reduced to the relevant range of 
the HPLC runs. Absorption values were normalized from 0 to 100%. HPLC traces were monitored at λ=220 nm with 
a gradient of 0 to 40% MeCN, see section 7.2.3 for details. 
However, if the linker molecule is stable to NaOH and no Glu/Asp are present in the peptide 
sequence, the usage of NaOH-based systems is a rapid and highly efficient method for Smoc 
deprotection on-support. 
3.4. Stability of Smoc-protected amino acids 
After the conditions for the Smoc group deprotection had been thoroughly examined, the 
stability of Nα-Smoc amino acids during aqueous peptide synthesis was studied. Only with this 
knowledge Smoc could be considered as an Nα-protecting group. To that end, Smoc-Arg-OH 5, 
Smoc-Ile-OH 15, Smoc-Phe-OH 20, Smoc-Pro-OH 21 and Smoc-Ser-OH 22 were dissolved in 
water with 3eq. NaHCO3 and the resulting solutions were subjected to HPLC analysis after 7, 
14 and 21 days; results are shown in Figure 23. 
Interestingly, some of the impurities reduced over time, but the Nα-Smoc amino acids were 
stable under reaction conditions for 21 days, which is a sufficient time window. Stability might 
even be longer, but monitoring was stopped after 21 days. 
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Figure 23: Stability studies of Smoc-Arg-OH 5 (top left), Smoc-Ile-OH 15 (top right), Smoc-Phe-OH 20 (middle left), 
Smoc-Pro-OH 21 (middle right) and Smoc-Ser-OH 22 (bottom). Reference is shown in black, 7 days in purple , 14 days 
in blue and 21 day in red. The shown area is reduced to the relevant range of the HPLC runs. Absorption values were 
normalized from 0 to 100%. HPLC traces were monitored at λ=220 nm with a gradient of 0 to 40% MeCN, see section 
7.2.3 for details. 
3.5. Synthetic concept of aqueous SPPS (ASPPS) 
After all natural and some non-canonic amino acids appeared accessible as Nα-protected Smoc 
building blocks possessing significant stability in basic aqueous solutions, but easily losing their 
aminoterminal protection upon mild treatment with particular water-soluble bases, a protocol 
for aqueous solid-phase peptide synthesis (ASPPS) was developed based on Merrifield’s solid-
phase peptide synthesis.[14]  
To that end, a water-compatible resin (e.g. Tentagel, ChemMatrix, PEGA, etc.) was required. 
The first amino acid was loaded under aqueous conditions or a commercially available 
preloaded resin was used. Loading of the first amino acid was followed by the Smoc 
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deprotection with either aqueous NaOH, NH3, piperazine or ethanolamine. Then, coupling of 
the next activated amino acid was performed followed if required by capping of unconverted 
amines with sulfoacetic acid or similar compounds. Interestingly, this ensures labelling of all 
remaining free amines with a sulfonated tag that allows for an easy purification after global 
cleavage. This cycle was repeated until the desired length of a peptide had been reached. After 
global cleavage, the target peptide, all labelled side products and the free side chain protecting 
groups appeared in solution. This mixture was loaded onto an ion-exchange column, (IE 
column) and only the target peptide was able to pass through as all impurities had been 
negatively charged upon labelling and stayed on the column. This is indeed a fast, sustainable 
and cheap purification option. Of course, if the highest purity grade is required, ion-exchange 
chromatography could serve as a prepurification step to remove most of the side products, thus 
making subsequent HPLC separation much easier. The ASSPS scheme is shown in Scheme 17. 
 
 
Scheme 17: ASPPS scheme. 
Initially, an orthogonal protecting group strategy was considered based on sulfonated Nα and 
side-chain protection. The Smoc-group was used as Nα-protecting block, side chain protection 
was performed with Sboc for amines, tBuS for alcohols, OtBuS for carboxyl groups and StBuS 
for thiols, as shown at Figure 24. 
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However, already the preliminary experiments showed that presence of an aminoterminal Smoc 
ensures sufficient water solubility of amino acids bearing classic tBu, OtBu and Boc protecting 
groups at their side chains. Therefore, elaboration of sulfonated side-chain protection was 
postponed within this work in order to generate resilient results more rapidly. Interestingly, 
certain side chains which are 
usually protected in course of 
classic SPPS, e.g. amides of Asn 
and Gln, guanidine of Arg, and 
hydroxyl of Tyr, do not require 
masking upon ASPPS. This is 
without any doubt a significant 
advantage as no time-consuming 
deprotection (especially in the 
case of Arg and Tyr) is required 
any more (see Table 7). To validate the ASPPS method, additional experiments were necessary. 
First, the coupling efficiency in water-based systems had to be assessed and optimized. 
Subsequently, peptides had to be synthesized under ASPPS conditions with subsequent 
investigation of common SPPS side reactions like racemization and aspartimide formation. 
Finally, a proof-of-concept scheme for purification and fluorescence monitoring had to be 
provided. 
Table 7: Comparison of Boc- and Fmoc-SPPS and the used ASPPS protection group schemes in this work. 
Protecting group scheme for 
Boc-SPPS Fmoc-SPPS ASPPS 
Boc-Arg(Tos)-OH Fmoc-Arg(Pbf)-OH Smoc-Arg-OH 
Boc-Asn(Trt)-OH Fmoc-Asn(Trt)-OH Smoc-Asn-OH 
Boc-Asp(OBzl)-OH Fmoc-Asp(OtBu)-OH Smoc-Asp(OtBu)-OH 
Boc-Cys(Acm)-OH Fmoc-Cys(Trt)-OH Smoc-Cys(Trt)-OH 
Boc-Gln(Trt)-OH Fmoc-Gln(Trt)-OH Smoc-Gln-OH 
Boc-Glu(OBzl)-OH Fmoc-Glu(OtBu)-OH Smoc-Glu(OtBu)-OH 
Boc-His(Dnp)-OH Fmoc-His(Trt)-OH Smoc-His(Trt)-OH/Smoc-His-OH 
Boc-Lys(2-Cl-Z)-OH Fmoc-Lys(Boc)-OH Smoc-Lys(Boc)-OH 
Boc-Ser(Bzl)-OH Fmoc-Ser(tBu)-OH Smoc-Ser(tBu)-OH 
Boc-Thr(Bzl)-OH Fmoc-Thr(tBu)-OH Smoc-Thr(tBu)-OH 
Boc-Trp(For)-OH Fmoc-Trp(Boc)-OH Smoc-Trp(Boc)-OH/Smoc-Trp-OH 
Boc-Tyr(Bzl)-OH Fmoc-Tyr(tBu)-OH Smoc-Tyr-OH 
3.6. Coupling efficiency in water-based systems 
Being one of the most fundamental chemical bonds in nature, an amide bond is the major 
constituent of protein backbone and a dominant motif in many natural products, biopolymers, 
and pharmaceuticals. To date, a vast repertoire of synthetic approaches towards amide bonds 
has been developed (see section 1.5.4 for details).  
From the early years of peptide synthesis, it has been generally accepted that the formation of 
amide/peptide bonds implies anhydrous coupling conditions. Indeed, in the presence of water, 
the condensation equilibrium is shifted towards the starting reagents and the active esters are 
hydrolysed (Scheme 18). However, the acidity of carboxylic acids in water is increased 
compared to the polar aprotic solvents commonly applied in peptide synthesis.[253] Therefore, 
the acidic proton of the carboxylic group is transferred to a water molecule, resulting in an 
increased reactivity of the carboxylate ion towards carbodiimides.[221] 
 
Figure 24: Initial ASPPS orthogonal protecting group strategy. 
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Scheme 18: EDC-HCl 37 based activation of a carboxylic acid, followed by direct amide bond formation (top), 
formation of an Oxyma 39 active ester (middle) or hydrolysis of the activated species (bottom). (R1, R2: residues). 
In order to investigate how active esters are formed under aqueous conditions and how these 
activated species participate in the amide bond formation, series of experiments with Nα-Smoc 
amino acids were performed.  
Initially, different coupling reagents or active ester-forming compounds were evaluated in the 
synthesis of a dipeptide 36 at room temperature; the synthesis scheme is shown in Scheme 19. 
 
Scheme 19: Synthesis of Smoc-L-Pro-L-Tyr-OMe 36. 
This experiment was performed using 1 eq. Smoc-Pro-OH 21, 1.2 eq. H-Tyr-OMe 35, 1 eq. 
NaHCO3 as base and 1.5 eq. of the coupling reagents 37, 42, 43 or 44 (Table 8).Coupling 
reagent 37 was used with either 38, 39, 40 or 41 as an active ester-forming reagent. After 25 
minutes, the formation of 36 was monitored by HPLC.  
Table 8: Summary of the used coupling additives and active ester-forming compounds. 
Compound Coupling reagents Structure 
37 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC-HCl)  
38 N-hydroxysuccinimide (NHS) 
 
39 Oxyma 
 
40 1-hydroxy-2-pyridone (HOPO) 
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41 
N-hydroxybicyclo[2.2.1]hept-5-ene-2,3-
dicarboximide (HONB) 
 
42 
N-ethoxycarbonyl-2-ethoxy-1,2-
dihydroquinoline(EEDQ) 
 
43 
4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-
morpholinium chloride (DMT-MM) 
 
44 
(1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)-
dimethylamino-morpholino-carbenium hexafluoro-
phosphate (COMU) 
 
The HPLC analysis of aqueous reaction mixtures with the respective coupling reagents is shown 
in Figure 25.  
 
Figure 25: Synthesis of Smoc-L-Pro-L-Tyr-OMe 36 in water. The shown area is reduced to the relevant range of the 
HPLC runs. Absorption values were normalized from 0 to 100%. A direct comparison between the HPLC runs in terms 
of product formation is not possible. HPLC traces were monitored at λ=220 nm with a gradient of 0 to 40% MeCN, 
see section 7.2.3 for details. 
The HPLC section shown is selected in such a way, that the resulting product and the starting 
reagents are visible. The graphs were normalized to 0-100%. A direct graphical comparison of 
the product peaks is not possible, since no additional normalization on the respective maxima 
was carried out. The product Smoc-L-Pro-L-Tyr-OMe 36 has a retention time of ~17.2 minutes, 
the educt Smoc-Pro-OH 21 - 13.5, and H-Tyr-OMe 35 - 14.2 minutes. The complete HPLC data 
is shown in section 8.5.3; the reference data of the educts 21 and 35, coupling reagents 37-44 
and product 36 is shown in section 8.5.1. 
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The obtained data showed that the product formation in water was most efficient using 
EDC-HCl 37 activation with active ester reagents. Usage of EEDQ 42, DMT-MM 43 and COMU 
44 resulted only in a minor product formation after 25 minutes. Product formation via 
activation with DMT-MM and EEDQ increased with longer reaction times, but these are not 
suitable for peptide synthesis with repetitive coupling steps. In addition, EEDQ has a low 
solubility in water, which further reduces its efficacy. To summarize, Oxyma 39 appeared the 
most efficient additive, followed by HOPO 
40. HONB 41 is less active, this may be 
caused by its poorer solubility compared to 
the other additives. HPLC studies showed 
the formation of Smoc-Pro-NHS 45 and 
Smoc-Pro-HONB 46. These esters are quite 
stable under the reaction conditions, both 
of them could be isolated by HPLC, 
structures are shown in Figure 26. 
NHS activation was found to be quite fast, 
but the formed NHS ester appeared rather stable and less reactive under aqueous conditions, 
which resulted in diminished product formation. Interestingly, NHS ester activation was 
associated with a number of side products, which were not formed with the other additives. 
The following Table 9 summarizes the efficiency of the used coupling reagents in water after 
25 minutes. In general, the coupling efficiency increased along with reaction time (up to 45 
minutes). 
Table 9: Summary of coupling efficiency of the different reagents in water after 25 minutes. 
Coupling reagent Coupling efficiency* Active ester side products 
EDC-HCl 37/Oxyma 39 90.7% Not observed 
EDC-HCl 37/HOPO 40 58.3% Not observed 
EDC-HCl 37/NHS 38 54% 5.7% NHS ester 
EDC-HCl 37/HONB 41 57.8% 28.9% HONB ester 
EEDQ 42 6.7% not applicable 
DMT-MM 43 17.3% not applicable 
COMU 44 3.2% Not observed 
* The coupling efficiency was calculated based on the area under the HPLC curve of the product, the starting 
materials and detected active ester derivatives. 
The same experiment was performed in 30% aq. acetonitrile, to examine if the addition of small 
amounts of an organic solvent can influence amide bond formation. The obtained HPLC data 
for different coupling reagents after 25 minutes coupling in water are shown in Figure 27. The 
complete HPLC data are shown in section 8.5.4; the reference data of the educts 21 and 35, 
coupling reagents 37-44 and product 36 - in section 8.5.1. 
 
Figure 26: Structures of the isolated Smoc-Pro-NHS 45 and 
Smoc-Pro-HONB 46 ester. 
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Figure 27: Synthesis of Smoc-L-Pro-L-Tyr-OMe 36 in 30% aq. MeCN. The shown area is reduced to the relevant range 
of the HPLC runs. Absorption values were normalized from 0 to 100%. A direct comparison between the HPLC runs 
in terms of product formation is not possible. HPLC traces were monitored at λ=220 nm with a gradient of 0 to 40% 
MeCN, see section 7.2.3 for details. 
Generally, the efficiency of all used coupling reagents significantly increased in 30% aq. MeCN. 
As expected, the general tendency was maintained, but a clear increase in the performance of 
HONB 40 and EEDQ 42 possessing low solubility in pure water was observed. The following 
Table 10 summarizes the coupling efficiency of the employed reagents in 30% aq. MeCN within 
25 minutes. It is interesting to note that combination of EDC-HCl 37/Oxyma 39 under these 
conditions allows an almost quantitative conversion. Starting Smoc-Pro-OH 21 was not 
observed in HPLC and LC-MS. 
Table 10: Summary of coupling efficiency of the different reagents in 30% aq. MeCN after 25 minutes. 
Coupling reagents Coupling efficiency* Active ester side products 
EDC-HCl 37/Oxyma 39 99.8% Not observed 
EDC-HCl 37/HOPO 40 84.2% Not observed 
EDC-HCl 37/NHS 38 48.8% 38.9% NHS ester 
EDC-HCl 37/HONB 41 47.6% 37.09% HONB ester 
EEDQ 42 40.5% not applicable 
DMT-MM 43 37.3% not applicable 
COMU 44 41.9% Not observed 
* The coupling efficiency was calculated based on the area under the HPLC curve of the product, the 
starting materials and detected active ester derivatives. 
The same experimental setup was applied to other organic solvents. Results for 30% aq. ethanol 
are shown Figure 28. The complete HPLC data shown in section 8.5.6; the reference data of 
the educts 21 and 35, coupling reagents 37-44 and product 36 - in section 8.5.1. 
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Figure 28: Synthesis of Smoc-L-Pro-L-Tyr-OMe 36 in 30% aq. ethanol. The shown area is reduced to the relevant range 
of the HPLC runs. Absorption values were normalized from 0 to 100%. A direct comparison between the HPLC runs 
in terms of product formation is not possible. HPLC traces were monitored at λ=220 nm with a gradient of 0to40 
MeCN, see section 7.2.3 for details. 
The direct comparison of ethanol and MeCN shows similar results in terms of EDC-HCl 37 and 
active ester-forming additives 38-41, but a significant reduction in efficiency for the coupling 
reagents 42-44. Compared to water, an increase in efficiency can be observed for all 
compounds. The following Table 11 summarizes the coupling efficiency of the used reagents 
in 30% aq. ethanol after 25 minutes. 
Table 11: Summary of coupling efficiency of the different reagents in 30% aq. ethanol after 25 minutes. 
Coupling reagents Coupling efficiency* Active ester side products 
EDC-HCl 37/Oxyma 39 99.0% Not observed 
EDC-HCl 37/HOPO 40 83.6% Not observed 
EDC-HCl 37/NHS 38 46.7% 28.9% NHS ester 
EDC-HCl 37/HONB 41 50.5% 37.2% HONB ester 
EEDQ 42 8% not applicable 
DMT-MM 43 36.5% not applicable 
COMU 44 24.3% Not observed 
* The coupling efficiency was calculated based on the area under the HPLC curve of the product, the 
starting materials and detected active ester derivatives. 
The formation of ethanol esters as side products was observed in LC-MS, but it was significantly 
reduced compared to pure alcohols. By extending the reaction time, the amount of ethanol ester 
increased, but was still less than 4% in our experiments and therefore in an acceptable range 
for the application in SPPS. 
Similar experiments were performed with 30% aq. isopropanol; the results are presented in 
Figure 29. The complete HPLC data are shown in section 8.5.7; the reference data of the educts 
21 and 35, coupling reagents 37-44 and product 36 shown in section 8.5.1. 
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Figure 29: Synthesis of Smoc-L-Pro-L-Tyr-OMe 36 in 30% aq. isopropanol. The shown area is reduced to the relevant 
range of the HPLC runs. Absorption values were normalized from 0 to 100%. A direct comparison between the 
HPLC runs in terms of product formation is not possible. HPLC traces were monitored at λ=220 nm with a gradient 
of 0 to 40% MeCN, see section 7.2.3 for details. 
Using 30% aq. isopropanol delivered similar results as for the ethanol-based system, with EEDQ 
coupling efficiency clearly improved due to the better solubility. The following Table 12 
summarizes the coupling efficiency of the used coupling reagents in 30% isopropanol after 25 
minutes. 
Table 12: Summary of coupling efficiency of the different reagents in 30% aq. isopropanol after 25 minutes. 
Coupling reagents Coupling efficiency* Active ester side products 
EDC-HCl 37/Oxyma 39 98.8% Not observed 
EDC-HCl 37/HOPO 40 83.6% Not observed 
EDC-HCl 37/NHS 38 47.8% 8.8% NHS ester 
EDC-HCl 37/HONB 41 62.2% 30.4% HONB ester 
EEDQ 42 53.2% not applicable 
DMT-MM 43 45.1% not applicable 
COMU 44 25.6% Not observed 
* The coupling efficiency was calculated based on the area under the HPLC curve of the product, the 
starting materials and detected active ester derivatives. 
An additional experiment was performed with 10% 2-methyltetrahydrofuran (Me-THF) as an 
additive using the same reaction setting as before. The obtained HPLC data are shown in Figure 
30. The complete HPLC data shown in section 8.5.9; the reference data of the educts 21 and 
35, coupling reagents 37-44 and product 36  -  in section 8.5.1. 
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Figure 30: Synthesis of Smoc-L-Pro-L-Tyr-OMe 36 in 10% aq. Me-THF. The shown area is reduced to the relevant range 
of the HPLC runs. Absorption values were normalized from 0 to 100%. A direct comparison between the HPLC runs 
in terms of product formation is not possible. HPLC traces were monitored at λ=220 nm with a gradient of 0 to 40% 
MeCN, see section 7.2.3 for details. 
Coupling efficiency in 10% aq. Me-THF was even lower than in pure water. Therefore, the usage 
of 10%-MeTHF was excluded from SPPS experiments. The following Table 13 summarizes the 
coupling efficiency of the used coupling reagents in 10% Me-THF after 25 minutes. 
Table 13: Summary of coupling efficiency of the different reagents in 10% aq. Me-THF after 25 minutes. 
Coupling reagents Coupling efficiency* Active ester side products 
EDC-HCl 37/Oxyma 39 88.7% Not observed 
EDC-HCl 37/HOPO 40 79.4% Not observed 
EDC-HCl 37/NHS 38 44.6% 17.4% NHS ester 
EDC-HCl 37/HONB 41 61.5% 26.2% HONB ester 
EEDQ 42 34.9% not applicable 
DMT-MM 43 39.9% not applicable 
COMU 44 11.2% Not observed 
* The coupling efficiency was calculated based on the area under the HPLC curve of the product, the 
starting materials and detected active ester derivatives. 
The same experiment was repeated with 30% aq. Me-THF. However, at this concentration phase 
separation occurred and the reaction was carried out in an emulsion. The obtained HPLC data 
are shown in Figure 31. The complete HPLC data shown in section 8.5.8; the reference data of 
the educts 21 and 35, coupling reagents 37-44 and product 36 - in section 8.5.1. 
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Figure 31: Synthesis of Smoc-L-Pro-L-Tyr-OMe 36 in 30% Me-THF in water (biphasic). The shown area is reduced to the 
relevant range of the HPLC runs. Absorption values were normalized from 0 to 100%. A direct comparison between 
the HPLC runs in terms of product formation is not possible. HPLC traces were monitored at λ=220 nm with a gradient 
of 0 to 40% MeCN, see section 7.2.3 for details. 
Interestingly, in a biphasic system higher coupling yields were observed compared to those for 
the 10% aq. Me-THF. Although most of the coupling systems demonstrated increased efficiency, 
EDC-HCl 37/HONB 41 and DMT-MM 43 showed decreased coupling yields, and EEDQ 42 did 
not lead to detectable product formation at all. Due to their hydrophobic properties, these 
reagents seem to be located exclusively in the organic layer, and a phase-transfer catalyst is 
presumably required to make this system viable. The following Table 14 summarizes the 
coupling efficiency of the used reagents in 30% aq. Me-THF after 25 minutes. 
Table 14: Summary of coupling efficiency of the different reagents in 30% Me-THF/water (biphasic) after 25 minutes. 
Coupling reagents Coupling efficiency* Active ester side products 
EDC-HCl 37/Oxyma 39 99.8% Not observed 
EDC-HCl 37/HOPO 40 81.5% Not observed 
EDC-HCl 37/NHS 38 66.6% 23.3% NHS ester 
EDC-HCl 37/HONB 41 57.4% 35.2% HONB ester 
EEDQ 42 0% not applicable 
DMT-MM 43 28.6% not applicable 
COMU 44 29.8% Not observed 
* The coupling efficiency was calculated based on the area under the HPLC curve of the product, the 
starting materials and detected active ester derivatives. 
Based on the results of the biphasic Me-THF-water system, a similar experiment was performed 
with 30% ethyl acetate in water. As before, a phase separation was observed and the reaction 
was performed in an emulsion. The obtained HPLC data are shown in Figure 32. The complete 
HPLC data shown in section 8.5.5; the reference data of the educts 21 and 35, coupling reagents 
37-44 and product 36 - in section 8.5.1. 
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Figure 32: Synthesis of Smoc-L-Pro-L-Tyr-OMe 36 in 30% EtOAc in water (biphasic). The shown area is reduced to the 
relevant range of the HPLC runs. Absorption values were normalized from 0 to 100%. A direct comparison between 
the HPLC runs in terms of product formation is not possible. HPLC traces were monitored at λ=220 nm with a gradient 
of 0 to 40% MeCN, see section 7.2.3 for details. 
The results are similar to those observed for 30% MeTHF in water, the product formation rates 
are slightly lower. Due to the difficult handling and the low efficiency of the biphasic systems 
in comparison to MeCN or alcohol-water mixtures, no SPPS reaction was carried out under 
these conditions. The following Table 15 summarizes the efficiency of the used coupling 
reagents in 30% EtOAc after 25 minutes. 
Table 15: Summary of coupling efficiency of the different reagents in 30% EtOAc/water (biphasic) after 25 minutes. 
Coupling reagents Coupling efficiency* Active ester side products 
EDC-HCl 37/Oxyma 39 87.3% Not observed 
EDC-HCl 37/HOPO 40 76.9% Not observed 
EDC-HCl 37/NHS 38 53% 21.5% NHS ester 
EDC-HCl 37/HONB 41 64.9% 24.5% HONB ester 
EEDQ 42 4.4% not applicable 
DMT-MM 43 29.9% not applicable 
COMU 44 21.1% Not observed 
* The coupling efficiency was calculated based on the area under the HPLC curve of the product, the 
starting materials and detected active ester derivatives. 
The coupling efficiency of the used coupling systems are summarized for easy comparability in 
the following Table 16. In summary, the EDC-HCl 37/Oxyma 39 and EDC-HCl 37/HOPO 40 
mixtures have proven to be the most suitable candidates for water-based peptide synthesis 
applying sodium bicarbonate as a general base. Therefore, these reagents were used for SPPS 
test reactions with a short test peptide.  
 
 
 
    
Page 50 
Table 16: Summary of coupling efficiency of the different reagents after 25 minutes. 
Coupling reagents 
Coupling efficiency* 
water 
30% 
MeCN 
30% 
EtOH 
30% 
iPrOH 
10%  
Me-THF 
30%  
Me-THF** 
30% 
EtOAc** 
EDC-HCl 37/Oxyma 39 90.7% 99.8% 99.0% 98.8% 88.7% 99.8% 87.3% 
EDC-HCl 37/HOPO 40 58.3% 84.2% 83.6% 83.6% 79.4% 81.5% 76.9% 
EDC-HCl 37/NHS 38 54% 48.8% 46.7% 47.8% 44.6% 66.6% 53% 
EDC-HCl 37/HONB 41 57.8% 47.6% 50.5% 62.2% 61.5% 57.4% 64.9% 
EEDQ 42 6.7% 40.5% 8% 53.2% 34.9% 0% 4.4% 
DMT-MM 43 17.3% 37.3% 36.5% 45.1% 39.9% 28.6% 29.9% 
COMU 44 3.2% 41.9% 24.3% 25.6% 11.2% 29.8% 21.1% 
* The coupling efficiency was calculated based on the area under the HPLC curve of the product, the 
starting materials and detected active ester derivatives. 
** Biphasic 
3.7. EDC-HCl mediated on-support coupling with Oxyma/HOPO as additives 
Following the previous experiments in solution, coupling experiments were carried out on solid 
phase. The two most promising candidates, EDC-HCl 37/Oxyma 39 and EDC-HCl 37/HOPO 
40, were used for the synthesis of the tetrapeptide Smoc-LAGV-NH2 47. The synthesis was 
performed in water and 30% aq. MeCN, respectively. 
The experimental setup and the molar excess are aligned to a standard Fmoc-SPPS approach. 
Thus, 3 eq. of the respective Nα-Smoc amino acid, 5.5 eq. EDC-HCl 37 and either 3 eq. of Oxyma 
40 or HOPO 41 with 3 eq. NaHCO3 have been used for the coupling steps. An optimization with 
regard to peptide yield was not carried out. The peptides were synthesized on solid phase (see 
section 7.8 for experimental details). After cleavage from solid support, the crude peptides 47 
were analysed by HPLC and ESI-MS. The following Table 17 summarizes the synthetic yields. 
Table 17: Summary of the SPPS yields for Oxyma 39 and HOPO 40 based peptide synthesis in water or 30% aq. MeCN. 
Coupling reagents Solvent 
Yield (calculated from average 
loading) 
EDC-HCl 37/Oxyma 39 water 19mg (51%) 
EDC-HCl 37/Oxyma 39 30% MeCN(aq) 24mg (65%) 
EDC-HCl 37/HOPO 40 water 18mg (49%) 
EDC-HCl 37/HOPO 40 30% MeCN(aq) 17mg (46%) 
 
The yields of the synthesized peptides showed that the syntheses with EDC-HCl 37/Oxyma 39 
is resulting in slightly higher yields compared to EDC-HCl 37/HOPO 40. This corresponds to 
the results obtained for solution-based peptide synthesis before. The usage of 30% organic 
solvents such as MeCN or alcohols showed a significant increase of the yield. Therefore, I 
assume that the addition of organic solvents seems to slow down the hydrolysis of the activated 
species and leads to a higher product formation. The low performance of EDC-HCl 37/HOPO 
40 in 30% MeCN seems to be caused by a mistake during the synthesis or precipitation problem. 
The synthesis for all subsequent peptides was thus performed with EDC-HCl 37/Oxyma 39 as 
standard coupling mixture. 
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3.8. Aqueous SPPS (ASPPS) of model peptides 
In order to demonstrate that water-based peptide synthesis with Nα-Smoc amino acids and the 
previously determined coupling conditions is possible, a series of prominent peptides was 
synthesized to validate the method. All peptides have been assembled manually on either a 
commercially available ChemMatrix H-Rink amide resin (loading capacity 0.4-0-6 mmol/g) or 
on a preloaded HMPB-ChemMatrix resin (loading capacity 0.3-0.65 mmol/g). Other water-
compatible resins could be used as well, some tests with TentaGel™ showed good results, too. 
The ChemMatrix H-Rink amide resin was loaded in a double coupling (2×25min) with a solution 
of Nα-Smoc amino acid (3 eq.), EDC-HCl 37 (5.5 eq.), Oxyma 39 (3 eq.) and NaHCO3 (3 eq.). 
Smoc deprotection was carried out in dependency of the used resin with either 1M NaOH, 25% 
ethanolamine(aq) or 5-10% piperazine(aq) for 5 and 10 minutes. Coupling of the amino acids was 
performed with 3 eq. Nα-Smoc amino acid, 5.5 eq. EDC-HCl 37, 3 eq. Oxyma 39 and 3 eq. 
NaHCO3. For the details of the synthetic approach see section 7.9. Peptides of different lengths 
and complexity were chosen, most of them being bioactive molecules used in cosmetic or 
pharmaceutical applications. The peptides H-CYEIS-NH2 61, H-ANKPG-NH2 62 are model 
peptides that were used to determine racemization levels of the respective amino acids during 
peptide assembly. The sequence Smoc-E(OtBu)K(Boc)R(Pbf)S(tBu)C(Trt)-OH 60 was 
synthesized as a model for a fully protected peptide that could be used in a fragment 
condensation approach.  
All peptides were synthesized as proof-of-concept; no optimization of the specific peptide 
synthesis process was performed regarding purity or yield. Therefore, there are still possibilities 
to optimize the synthesis of the specific peptides in case of a possible upscaling of the target 
peptides. The following Table 18 summarizes the synthesized peptides, the used solvents and 
the obtained yields. 
Table 18: Summary of the synthesized peptides, the used solvent and obtained yields. 
Entry Peptide sequence Solvent 
Yield (calculated 
from average 
loading) 
1 H-AGELS-NH2 (Pentapeptide-31) 48 water 13.7 mg (57.7%) 
2 H-GPQGPQ-OH (Hexapeptide-9) 49 water 9.2 mg (38.7%) 
3 H-EEMQRR-NH2 (Hexapeptide 3) 50 water 21.7 mg (51.3%) 
4 Ac-EEMQRR-NH2 (Acetyl-Hexapeptide 3) 51 water 18.7 mg (42.2%) 
5 Leu-Enkephalin amide H-YGGFM-NH2 52 water 19.6 mg (70.9%) 
6 Met-Enkephalin H-YGGFM-OH 53 30% MeCN(aq) 9 mg (63%) 
7 Leu-Enkephalin H-YGGFL-OH 54 30% MeCN(aq) 10.3 mg (71.8%) 
8 (ACP) 65-74 H-VQAAIDYING-OH 55 50% MeCN(aq) 18 mg (36%) 
9 (ACP) 65-74 H-VQAAIDYING-NH2 56 50% MeCN(aq) 23 mg (46%) 
10 H-GPRP-OH 57 water 8 mg (38%) 
11 Smoc-VVIA-NH2 58 water 26 mg (67%) 
12 Smoc-DIIW-OH 59 water 22 mg (50%) 
13 Smoc-E(OtBu)K(Boc)R(Pbf)S(tBu)C(Trt)-OH 60 50% MeCN(aq) 18 mg (44%) 
14 H-CYEIS-NH2 61 30% MeCN(aq) 15mg (49%) 
15 H-ANKPG-NH2 62 30% MeCN(aq) 13mg (53.7%) 
16 Pal-GHK-OH 63* 20% ethanol(aq) 14.1 mg (54.2%) 
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17 Pal-GQPR-OH 64* 20% ethanol(aq) 18.7 mg (59.7%) 
18 H-GPRPA-NH2 Vialox 65 30% MeCN(aq) 12 mg (48.4%) 
19 Oxytocin 66 30% MeCN(aq) 18 mg (35.8%) 
20 Vasopressin 67 30% MeCN(aq) 20 mg (39.7%) 
21 Heptaarginine 68 30% MeCN(aq) 23 mg (41.4%) 
22 Leuphasyl 69 20% MeCN(aq) 17.3 mg (57.9%) 
*Pal=Palmitic acid 
The results show that a water-based SPPS is possible. The yields of the synthesized peptides are 
within an acceptable range for a non-optimized synthesis process. It was concluded that ASPPS 
could be used as a replacement for Fmoc-based peptide synthesis in DMF.  
3.9. Racemization studies 
Two model peptides were synthesized by ASPPS to investigate potential racemization behaviour 
during the synthesis. The two peptide sequences are shown in the following Figure 33. 
 
Figure 33: Model peptides H-CYEIS-NH2 61 and H-ANKPG-NH2 62 for racemization tests. 
The synthesis of both peptides was performed on ChemMatrix H-Rink amide resins that was 
loaded in double coupling (2×25min) with a solution of Nα-Smoc amino acids (3 eq.), EDC-
HCl 37 (5.5 eq.), Oxyma 39 (3 eq.) and NaHCO3 (3 eq.). Smoc deprotection was carried out 
with 1M NaOH for 5 and 10 minutes. NaOH was used as base, as this is the strongest base used 
in the ASPPS process. If there are base catalyzed side-reactions during the synthesis process, it 
should increase the amount of side products. Coupling of the following amino acids was 
performed with 3 eq. Nα-Smoc amino acids, 5.5 eq. EDC-HCl 37, 3 eq. Oxyma 39 and 3 eq. 
NaHCO3 as base. Smoc-Asn-OH 7 and Smoc-Tyr-OH 29 were used without side-chain protecting 
groups. Peptide samples of 61 and 62 were sent to C.A.T. GmbH & Co Chromatographie und 
Analysentechnik KG (Tübingen, Germany) for the analysis of enantiomeric purity. The obtained 
results are shown in Table 19. Since the measured racemization for Asn appeared to be quite 
high, an additional sample Smoc-Asn-OH 7 was send to C.A.T. GmbH & Co Chromatographie 
und Analysentechnik KG (Tübingen, Germany) for analysis.  
Table 19: Determined racemization levels of the amino acids in both test peptides 
Amino acid Enantiomeric composition 
Isoleucine 
>99.7% L-Isoleucine 
<0.10% D-Isoleucine 
<0.10% L-allo-Isoleucine 
<0.10% D-allo-Isoleucine 
Serine <0.10% D-Enantiomer 
Cysteine <0.10% D-Enantiomer 
Glutamine/Glutamic acid <0.10% D-Enantiomer 
Tyrosine 0.25% D-Enantiomer 
Alanine 0.50% D-Enantiomer 
Proline 0.43% D-Enantiomer 
Asparagine/Aspartic acid 2.04% D-Enantiomer 
Lysine 0.11% D-Enantiomer 
Smoc-Asn-OH 7 0.30% D-Enantiomer 
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The racemization of the amino acids during the ASPPS corresponds to those expected within 
the context of a Fmoc-based SPPS in DMF. The slightly increased values for proline and alanine 
can be attributed to the synthesis process of amino acids, which was therefore easily adapted 
for future syntheses. The elevated level of racemization in the case of Asn cannot be explained 
by the used Nα-Smoc amino acid, which contains 0.30% D-enantiomer. This indicates a base-
catalyzed side reaction during the synthesis process. As the other amino acids showed no 
anomalies, and the used base concentration of NaHCO3 during the coupling process is too low 
to cause racemization it can only be a result of Smoc deprotection with NaOH. Therefore, 
additional aspartimide formation studies have been performed as this was suspected to be the 
source of racemization of Asn during the synthesis process. 
3.10. Aspartimide formation studies 
Aspartimide formation in Fmoc-SPPS is a well-documented side reaction occurring frequently 
at Asn-R or Asp-R where R is an amino acid such as Gly, Ala or Ser.[164, 177-181, 188, 191-193, 195, 254-
255]  
The treatment of the peptides containing Asp/Asn with bases such as piperidine results in the 
formation of the cyclic D/L aspartimide intermediate. Depending on the following reaction, 
multiple possible side products are formed. Hydrolysis of the D/L aspartimide intermediate 
could result in the formation of the D/L-α‐ or the D/L‐β‐peptides. Nucleophilic attack of the base 
or other amines could result in the corresponding D/L-α- or the D/L‐β‐peptide adducts (shown 
in Scheme 20).[179-181, 187] 
 
Scheme 20: Aspartimide formation under basic conditions and the possible side products. (R1, R2: residues). 
To clarify whether aspartimide formation during ASPPS is a frequent side reaction, four model 
peptides derived from peptide scorpion toxin II (H-VKDGYI-NH2 70, H-VK(D-D)GYI-NH2 71, 
H-VKNGYI-NH2 72 and H-VK(β-D)GYI-NH2 73) were synthesized. Afterwards the peptide-resins 
70-73 were split into 15 equal parts and incubated for 3h and 16h with the following bases: 
1M NaOH(aq), 1M NaOH in EtOH, 5% piperazine in DMF, 5% piperazine(aq), 20% piperidine in 
DMF and 10% ethanolamine(aq). As a reference, a non-incubated resin was subjected to global 
cleavage. After the respective incubation time, the samples were cleaved from the resin and 
analyzed by RP-HPLC and LC-MS. The results of the 3h and 16h incubation of H-VKDGYI-NH2 
70 are shown in Figure 34. As expected and described in detail in the literature, aspartimide 
formation depends on the used bases and the incubation time. Using 20% piperidine in DMF 
results in several side products after 16 hours. The main observed side products are the 
corresponding base adducts. Using 5% piperazine in DMF results in less side products after 16 
hours, as previously described by Wade et al.[182] 
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Figure 34: Summary of HPLC data of the incubation of H-VKDGYI-NH2 70 with different bases for 3h (left) and for 
16h (right) and the resulting aspartimide side product formation caused by the used bases. Retention times were 
calibrated using ascorbic acid as internal standard; absorbance was normalized between 0 and 1. HPLC traces were 
monitored at λ=220 nm with a gradient of 0 to 40% MeCN, see section 7.2.3 for details. 
The formation of the D-product and the β–product was not observed in organic solvents. 
Interestingly, using NaOH in either water or alcohol mainly resulted in the formation of the 
β-product, the D-product was not observed. Using ethanolamine in water results mainly in the 
formation of the β–product. The usage of 5% piperazine in water results in the formation of the 
β–product in a ratio of 1:3 (β–product:α-product) after 3h, after 16h incubation time the ratio 
is switched to 3:2 (β–product: α-product). In summary, in organic solvents the observed side 
products are mainly the corresponding L/D-α-base adducts or L/D-β-base adducts, the formation 
of the β–product was not observed. In water-based synthesis mainly the β–product is formed as 
side product. The ratio of the β-product formation corresponds to the D/L‐β‐peptides and the 
D/L-α‐peptide ratio described in the literature for the aspartimide formation of proteins under 
in vivo conditions (3:1 ,observed in amyloid β-protein,[185] and 2:1[186]). Using stronger bases 
like NaOH in water results in an inreased amount of β–product formation. This could depend 
on the base strength but is more likely based on the nearly instantaneous cleavage of the tert-
butyl ester side chain of Asp, resulting in a high amount of reactive species. Therefore, NaOH 
could not be used in ASPPS if esters are applied as linkers or side chain protecting groups. 
The results of the 3h and 16h incubation of H-VK(D-D)GYI-NH2 71 are shown in Figure 35. As 
expected, the incubation of H-VK(D-D)GYI-NH2 71 for 3h and 16h yielded the same results as 
the incubation of H-VKDGYI-NH2 70. Main side products in organic solvents are the 
corresponding L/D-α-base or L/D-β-base adducts, the formation of the β–product was not 
observed as well. In water-based synthesis mainly the β–product is formed as side product in 
the same ratio as observed during the H-VKDGYI-NH2 71 incubation. Interestingly, the 
incubation with 10% ethanolamine in water also results in the formation of L-product; this was 
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the only time when racemization was observed. After 16h, a ratio of 2.3:1:1 (β‐peptide: 
D-peptide:L-peptide) was observed. 
 
Figure 35: Summary of HPLC data of the incubation of H-VK(D-D)GYI-NH2 71 with different bases for 3h (left) and 
for 16h (right) and the resulting aspartimide side product formation caused by the used bases. Retention times were 
calibrated using ascorbic acid as internal standard; absorbance was normalized between 0 and 1. HPLC traces were 
monitored at λ=220 nm with a gradient of 0 to 40% MeCN, see section 7.2.3 for details. 
As Asn is prone to aspartimide formation as well, the same experiments were performed with 
H-VKNGYI-NH2 72, the results of the 3h and 16h incubation are shown in Figure 36. Using 20% 
piperidine and 5% piperazine in DMF results in a minimal amount of side products after 16h of 
incubation. 5% piperazine in water delivers results similar to those obtained for the DMF-based 
incubation after 16h, after 3h there seemed to be a side product formation that was not 
observed after 16h. The usage of 10% ethanolamine results in the formation of minor side 
products after 3h and 16h. Usage of NaOH in water or ethanol results in the formation of side 
products. With increasing time, the incubation with NaOH in ethanol seems to increase a 
possible deamination of Asn. Interestingly, this was not observed with other bases in water or 
DMF. The formation of a side product observed upon NaOH incubation is not time-dependent, 
but its isolation and LC-MS identification was not possible. In summary, using 5% piperazine 
for Smoc deprotection of aspartimide-prone sequences is advised. In comparison with 20% 
piperidine in DMF, less side product formation is observed, but compared to 5% piperazine in 
DMF there is a significant increase of side product formation. This β-peptide side product seems 
to be caused less by the base itself but by the aspartimide formation in water itself, as observed 
by proteins degradation under in vivo conditions.  
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Figure 36: Summary of HPLC data of the incubation of H-VKNGYI-NH2 72 with different bases for 3h (left) and for 
16h (right) and the resulting aspartimide side product formation caused by the used bases. Retention times were 
calibrated using ascorbic acid as internal standard; absorbance was normalized between 0 and 1. HPLC traces were 
monitored at λ=220 nm with a gradient of 0 to 40% MeCN, see section 7.2.3 for details. 
 
Figure 37: Summary of HPLC data of the incubation of the temperature dependent formation of H-VK(β-D)GYI-NH2 
73 with 5% Piperazine in water after 16 h. Retention times were calibrated using ascorbic acid as internal standard; 
absorbance was normalized between 0 and 1. HPLC traces were monitored at λ=220 nm with a gradient of 0 to 40% 
MeCN, see section 7.2.3 for details. 
Based on the literature[256], the protein degradation should increase at higher temperatures and 
decrease at the lower ones. Therefore, an additional incubation of H-VKDGYI-NH2 70 with 5% 
piperazine in water was performed at 4°C, RT and 40°C respectively. The temperature-
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dependent formation of H-VK(β-D)GYI-NH2 73 with 5% piperazine in water after 16h is shown 
in the following Figure 37. 
The obtained results show that the aspartimide formation in water is temperature dependent. 
At 4°C the (β–product:α-product) ratio is 1:3 and with increasing temperature shifted at 40°C 
to a ratio of 2.5:1. Therefore, deprotection of aspartimide-prone sequences in water should be 
performed at 4°C or below this temperature to reduce the amount of aspartimide side products. 
3.11. Fluorescent properties of the Smoc group 
Due to its particular electronic structure, the Smoc group 
absorbs in the UV/Vis spectral area and possesses fluorescent 
properties, being therefore detectable by respective analytical 
methods as shown in Figure 38. It is spectroscopically active 
and fluorescent both in Nα-Smoc amino acids and in its cleaved 
form. This is a significant advantage over the classical Fmoc 
group, which can only be observed after deprotection,[257] and 
allows to establish a real-time monitoring of the synthesis 
process. Figure 39 shows a direct 
comparison of Smoc-Gly-OH 12 with 
Fmoc-Gly-OH upon UV irradiation. 
It is necessary to determine the fluorescent properties of the Nα-Smoc 
amino acids to establish a real-time monitoring. For this purpose, the 
fluorescence spectra of a 100 nM solution of all amino acids were 
recorded between 300 nm and 400 nm. As an example, the absorption 
spectra and the fluorescence spectra of a 100 nM solution of 
Smoc-Ala-OH were recorded between 300 nm and 400 nm, results are 
shown in Figure 40. The experimental data shows excitation maxima 
of 281 nm and emission maxima of 338 nm, resulting in a Stokes shift of 57 nm. 
 
Figure 40: Emission and excitation spectra of Smoc-Ala-OH 3. Excitation and emission have been normalized. 
The determined spectral data of all synthesized Nα-Smoc amino acids are listed in Table 20. 
Excitation spectra of all Nα-Smoc amino acids were measured between 220 nm and 700 nm. All 
 
Figure 39: A sample of 
Smoc-Gly-OH 12 (right) 
and Fmoc-Gly-OH (left) as a 
reference, illuminated at 
254nm. 
 
 
Figure 38: A sample of Smoc-Cl 2 in 
water illuminated at 254nm. 
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Nα-Smoc amino acids show absorbance between 200nm and 220 nm (due to technical 
limitations of the used equipment this is not shown here) but only the range of 245-310 nm 
was identified as excitation area. 
Table 20: Excitation and emission maxima of all synthesized Nα-Smoc amino acids and their Stokes shift in water. 
Nα-Smoc amino acid Excitation maxima Emission maxima Stokes shift 
Smoc-L-Ala-OH 3 281 nm 338 nm 57 nm 
Smoc-D-Ala-OH 4 281 nm 340 nm 59 nm 
Smoc-L-Arg-OH 5 282 nm 340 nm 58 nm 
Smoc-L-Arg(Pbf)-OH 6 282 nm (Abs max. 220nm) 338 nm 56 nm 
Smoc-L-Asn-OH 7 281 nm 340 nm 59 nm 
Smoc-L-Asp(OtBu)-OH 8 282 nm 340 nm 58 nm 
Smoc-L-Cys(Trt)-OH 9 282 nm (Abs max. 220nm) 340 nm 58 nm 
Smoc-L-Gln-OH 10 281 nm 338 nm 57 nm 
Smoc-L-Glu(OtBu)-OH 11 282 nm 340 nm 58 nm 
Smoc-Gly-OH 12 281 nm 338 nm 57 nm 
Smoc-L-His-OH 13 281 nm 338 nm 57 nm 
Smoc-L-His(Trt)-OH 14 282 nm (Abs max. 220nm) 338 nm 57 nm 
Smoc-L-Ile-OH 15 282 nm 340 nm 58 nm 
Smoc-L-Leu-OH 16 281 nm 340 nm 59 nm 
Smoc-D-Leu-OH 17 282 nm 340 nm 58 nm 
Smoc-L-Lys(Boc)-OH 18 281 nm 338 nm 57 nm 
Smoc-L-Met-OH 19 281 nm 340 nm 59 nm 
Smoc-L-Phe-OH 20 281 nm 338 nm 57 nm 
Smoc-L-Pro-OH 21 281 nm 340 nm 59 nm 
Smoc-L-Ser-OH 22 281 nm 340 nm 59 nm 
Smoc-L-Ser(tBu)-OH 23 281 nm 340 nm 59 nm 
Smoc-L-Thr-OH 24 281 nm 340 nm 59 nm 
Smoc-L-Thr(tBu)-OH 25 281 nm 340 nm 59 nm 
Smoc-L-Trp-OH 26 281 nm (Abs max. 220, 225nm) 341 nm 60 nm 
Smoc-L-Trp(Boc)-OH 27 281 nm (Abs max. 220nm) 340 nm 59 nm 
Smoc-L-Tyr-OH 28 282 nm 341 nm 59 nm 
Smoc-L-Tyr(tBu)-OH 29 281 nm 340 nm 59 nm 
Smoc-L-Val-OH 30 281 nm 340 nm 59 nm 
Smoc-β-Ala-OH 31 281 nm 340 nm 59 nm 
Smoc-Aib-OH 32 281 nm 338 nm 57 nm 
Fluorescence was measured between 300 nm and 500 nm. As the results show, excitation 
maxima for Smoc was around 280 nm and the emission maxima - around 340 nm. The minor 
differences between the Nα-Smoc amino acids seem to be caused by the limited measuring 
accuracy of the used device. 
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Quantum efficiency is critical for fluorescence 
measurements, however in this work the quantum 
efficiency of all Nα-Smoc amino acids could not be 
determined due to a lack of required equipment. 
Generally, a decreased fluorescence was observed 
with aromatic amino acids tyrosine and tryptophan 
as well as with aromatic side chain protecting 
groups like trityl (Cys, His) or Pbf (Arg). This might 
be caused by an inter- or intramolecular quenching 
effect. An example for an overlap is shown in 
Figure 41.  
In case of Cys the problem of decreased 
fluorescence can be avoided by using different side 
chain protecting groups, Arg does not need side-
chain protection at all. As proof-of-concept, the 
loading of a resin and the synthesis of a model peptide were monitored by fluorescence 
measurements. 
3.12. Fluorescence monitoring of resin loading and coupling status during ASPPS 
Monitoring of the reaction progress during SPPS requires the usage of additional markers and 
detection reactions or it is only possible after the Fmoc group has been cleaved off as only the 
formed dibenzofulvene product is spectrally active.[258-262] The Smoc protecting group allows 
for detection either by UV/Vis measurements using a photometer (this generally known method 
is therefore not explicitly discussed here) or by fluorescence monitoring. The fluorescence 
properties of the Smoc group allow the detection in solution or even if bound to the solid 
support, thus enabling a real-time monitoring of the coupling and deprotection process for the 
first time in the history of solid-phase peptide synthesis.  
As a proof-of-concept study, Smoc-Gly-OH 12 in two different concentrations was loaded onto 
a water-compatible 2-CTC resin with DMSO as solvent. The choice of a solvent for this step was 
stipulated by the fact that the loading of this resin is hydrolysis-prone under aqueous conditions. 
The fluorescence was measured at the excitation maxima of 280 nm and emission maxima of 
340 nm. The obtained data (shown in Table 21) clearly show a dependence between the 
amounts of coupled amino acid and fluorescence measured.  
Table 21: Fluorescence intensity of different on-resin concentrations of Smoc-Gly-OH 12  measured on resin. 
Experiment DMSO 2-CTC resin 
Smoc-Gly-resin 
0.08mM loading 
Smoc-Gly-resin 
0.04mM loading  
1 8 255 6493 2742 
2 13 235 6363 3212 
3 6 249 6923 3540 
4 7 222 6240 3471 
mean value 8.5 240.25 6504.75 3241.25 
standard deviation 3.10 14.77 297.35 361.54 
 
To show the real-time monitoring of fluorescence is possible during the ASPPS process, a model 
peptide with the sequence H-L-V-A-I-G-NH2 74 was synthesised on a Rink amide PEGA resin in 
 
Figure 41: Donor emission and quencher 
absorption spectral overlap. Adapted figure by 
MkJohansson, distributed under the terms of 
the Attribution 3.0 Unported license (CC BY 3.0). 
https://creativecommons.org/licenses/by/3.0/ 
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water. After each synthesis step, the fluorescence of the peptide-resin was measured. The results 
are shown in Figure 42. 
 
Figure 42: Synthesis of H-LVAIG-NH2 74 in water. Fluorescence was measured on solid support after each coupling 
and deprotection step. 
The fluorescence measurement was performed by excitation at 280 nm and emission at 340 nm. 
The fluorescence allows distinguishing between the reaction steps. After Smoc deprotection, 
the fluorescence adjusts itself to a baseline value with a specific auto-fluorescence. After 
coupling of an Nα-Smoc amino acid, the fluorescence increases. The amino acids show 
intrinsically different fluorescence properties. This could be compensated by a normalisation 
that takes the quantum yield of each amino acid into account. The experiment shows that 
measuring the fluorescence on the solid phase to monitor the course of the reaction is basically 
possible. However, since it is easier to apply, fluorescence detection in solution of the coupling 
and deprotection mixture is more likely to be used. 
Although the fluorescence measurements are possible, the absorption measurements with the 
Smoc group are probably the easiest way to monitor the reaction in real time. 
3.13. Purification by affinity chromatography 
Preparative RP-HPLC is currently the industrial state-of-
the-art method for peptide purification allowing one to 
remove impurities in the crude product. Productivity, 
yield, and solvent consumption have to be considered for 
each purification process. Unfortunately, these three 
factors influence each other, as shown in Figure 43.[225] 
A general trend in peptide synthesis is to optimize the 
chemical synthesis (upstream process) and then accept 
up to 50% loss during the HPLC isolation (downstream) 
due to severe purification problems and in order to keep 
solvent consumption in acceptable ranges.[225] 
The purification system proposed by Merrifield and Bach and their 2-sulfo-Fmoc derivate[206] 
for product purification could of course be applied to the Smoc derivatives (Scheme 21).  
 
Figure 43: Productivity & solvent consumption 
of preparative HPLC depending on yield. 
(Modified picture by Ludemann-
Hombourger[225]). 
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Scheme 21: Purification method by Merrifield and Bach.[206] After global cleavage, mixture is put on an ion-exchange 
column and the protected target peptide stays on the column. This is followed by an on-column deprotection of the 
respective 2-sulfo-Fmoc derivate and the elution of the target peptide in the deprotection cocktail. 
However, this strategy is quite labor intensive as an additional deprotection step after the 
purification is necessary. As a consequence, we aimed at modifying the purification concept for 
the ASPPS strategy. In order to simplify the peptide isolation/purification process, we developed 
the capping strategy based on Sulfo-tags. This allows a large number of by-products to be 
removed using IEC. The advantages of the IEC method are high capacity, low time effort, 
application of water as solvent and easy automation. Moreover, compared to HPLC purification, 
the IEC is quite inexpensive.  
The capping method is based on Sulfo-carboxylic 
compounds, e.g. 4-sulfobenzoic acid 75 or sulfoacetic acid 
76. Structures are shown in Figure 44. After each coupling 
step, capping with 75, 76 or similar compounds is 
performed to label all free amine residues. After cleavage 
from solid support, the target peptide, all labelled side 
products and the cleaved side chain protecting groups are 
in solution. This mixture is subjected to IEC. Only the target 
peptide is able to pass, all labelled impurities stay on the column. The strategy is shown in 
Scheme 22 
  
Figure 44: Structures of 4-sulfobenzoic 
acid 75 and sulfoacetic acid 76 as 
examples for capping reagents. 
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Scheme 22: Purification of peptide by IEC using the Sulfo-tag method. 
As proof-of-concept, two peptides were synthesized applying amino acid building blocks in 
deficiency to increase side-product formation for purification tests. Hexapeptide-9 49 has been 
synthesized in water with 0.95 eq. of Nα-Smoc amino acids, compared to prior coupling, in order 
to maximize by-product formation. Capping was performed with sulfoacetic acid 76 in water. 
After cleavage from solid support, an HPLC of the crude peptide was performed. Afterwards the 
pH of the solution was adjusted to pH=2 and the solution was transferred to a DEAE Sephadex 
A-25 ion-exchange column. After washing the column with additional water, a HPLC of the 
elution was performed. The results are shown in Scheme 23. 
 
Scheme 23: Synthesis of H-GPQGPQ-OH hexapeptide 9 49 in water using 0.95 eq. of an Nα-Smoc amino acid compared 
to prior coupling in order to maximize by-product formation; capping was performed with sulfoacetic acid 76. HPLC 
chromatogram on the left shows crude peptide with labelled impurities after cleavage from solid support, HPLC 
chromatogram on the right shows purified product after IEC. HPLC traces were monitored at λ=220 nm with a 
gradient of 0 to 40% MeCN, see section 7.2.3 for details. 
The second peptide was synthesized in a similar way. Adrenorphin 77 was synthesized in DMF 
with 0.95 eq. of an Nα-Fmoc-amino acid compared to prior coupling in order to maximize by-
product formation. Capping was performed with a 4-sulfobenzoic acid 75 salt in DMF. After 
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cleavage from solid support, an HPLC of the crude peptide was performed. Afterwards the pH 
of the solution was adjusted to pH=1 and the solution was applied to a DEAE Sephadex A-25 
ion-exchange column. After washing the column with additional water, a HPLC of the eluatewas 
performed. The results are shown in Scheme 24. 
 
Scheme 24: Synthesis of H-YGGFMRRV-NH2 77 in DMF using 0.95 eq. of Fmoc-amino acid compared to prior coupling 
in order to maximize by-product formation, capping was performed with 4-sulfobenzoic acid 75. HPLC 
chromatogram on the left shows crude peptide with labelled impurities after cleavage from solid support, HPLC 
chromatogram on the right shows purified product after IEC. HPLC traces were monitored at λ=220 nm with a 
gradient of 10 to 60% MeCN, see section 7.2.3 for details. 
Both proof-of-concept experiments showed good results for the peptide purification process. 
Most of the side products were removed by IEC in around 1 minute. Interestingly, this method 
could be used for ASPPS as well as for classic DMF-based SPPS processes. 
Purification by IEC could be used as only purification step if a certain level of purity is required. 
For pharmaceutical peptides, an additional HPLC step would be necessary of course, but as 
most of the side-products are removed prior to the HPLC purification, the separation should be 
more efficient and reduced amounts of organic solvents should be assumed. This method is also 
applicable as pre-purification system or as part of multicolumn chromatography (MCC) systems. 
The same concept could be used in another way. As proof-of-concept an excess of Smoc-Gly-OH 
12 was applied to a DEAE Sephadex A-25 ion-exchange column. After the ion-exchange 
chromatography, the HPLC chromatogram showed no detectable amounts of Smoc-Gly-OH 12 
in the solution. After elution from the column, the excess of Smoc-Gly-OH 12 was detected in 
HPLC again. This could be used to remove all Sulfo-tagged impurities from the wastewater or 
for a possible regeneration of Nα-Smoc amino acids, used in excess, after coupling steps. Results 
are shown in Scheme 25. 
 
Scheme 25: Removal of Nα-Smoc amino acid excess from wastewater by IEC. 1 shows the analytical HPLC of the 
wastewater, 2 the HPLC after the IEC, 3 shows the elution from the IEC. The picture on the right shows the 
fluorescence of 1-3 upon UV-irradiation as additional analytical method. HPLC traces were monitored at λ=220 nm 
with a gradient of 0 to 40% MeCN, see section 7.2.3 for details. 
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3.14. NMR studies 
All NMR spectra were measured on a Bruker DRX 500 MHz spectrometer equipped with a room 
temperature 5 mm ATMA BBFO probe (Bruker Biospin, Karlsruhe, Germany) at 303 K. All 
samples were dissolved in deuterated DMSO purchased from Sigma Aldrich (Merck KGaA, 
Darmstadt, Germany) or deuterated CH3CN purchased from Eurisotop (Gif-Sur-Yvette, France). 
The concentrations of the samples were ~10-2mol/l. The solvent signals were used for 
referencing the 1H- and 13C-NMR spectra at 2.5 ppm and 39.5 ppm respectively. Chemical shift 
assignment was achieved with 1H-, 13C- and 13C-DEPT-135 1D spectra, 2D 1H-1H COSY 
(correlated spectroscopy), NOESY (nuclear overhauser enhancement spectroscopy), 2D 1H-13C 
HSQC (heteronuclear single quantum correlation) and 2D 1H-13C HMBC (heteronuclear 
multiple-bond correlation), using the Bruker pulse sequences zg30, zgpg30, dept135, 
cosygpmfqf, noesygptp, invietgpsi and inv4gplrl2ndqf, respectively. 1D spectra were recorded 
using an excitation pulse of 30° and a repetition time of 4.5 s (1H) and 1.5 s (13C). 32 scans 
(1H) and 2.000 scans (13C) were added and Fourier transformed with a final digital resolution 
of 0.08 Hz (1H, 0.26 Hz 13C). The hetero-nuclear long-range correlation spectrum (HMBC) was 
recorded by a matrix of 1 k data points (f2, 1H dimension) and 256 increments (data points in 
f1 13C dimension). The spectrum has been optimized for a heteronuclear coupling constant of 
9 Hz. Raw data were processed with Topspin (Bruker Biospin, Karlsruhe, Germany) and 2D 
data were analyzed using MestReNova 11.0.3 (Mestrelab Research S.L., Spain). Assessment of 
NMR results is shown in Table 22-Table 52. 
Table 22: Smoc-Cl 2 in MeCN-d3 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 8.18 2 s - 124.48 
 
2 and 7  - - - - 140.82 
3 and 6 8.0 2 d 8.1 128.13 
4 and 5 8.08 2 d 8.1 122.98 
4' and 5'  - - - - 144.97 
1' and 8'  - - - - 145.68 
9 4.55 1 t 5.7 47.8 
10 4.9 2 d 5.7 72.67 
11  - - - - 151.05 
Table 23: Smoc-L-Ala-OH 3 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.91; 7.89 2 s - 121.97; 122.01 
 
2 and 7 - - - - 147.16 
3 and 6 7.68 2 d 7.9 125.31 
4 and 5 7.83 2 d 7.9 119.47 
4' and 5' - - - - 140.52 
1' and 8' - - - - 143.99; 144.17 
9 4.23 1 t 5.5 47.02 
10a 4.38 1 dd 10.9; 5.7 
65.14 
10b 4.49 1 dd 10.9; 5.4 
11 - - - - 155.93 
NH 7.52 1 br - - 
12 3.95 1 q 7.3 49.27 
13 - - - - 174.27 
14 1.22 3 d 7.4 16.83 
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Table 24: Smoc-D-Ala-OH 4 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.89; 7.91 2 s  - 121.94 
 
2 and 7  - - - - 147.19 
3 and 6 7.68 2 d 8.2 125.28 
4 and 5 7.83 2 d 7.9 119.43 
4' and 5'  - - - - 140.49 
1' and 8'  - - - - 143.97; 144.15 
9 4.23 1 t 5.5 47.01 
10a 4.37 1 dd 11.0; 5.7 
65.11 
10b 4.38 1 dd 10.9; 5.5 
11  - - - - 155.91 
NH 7.5 1 br - - 
12 3.95 1 q 7.3 49.26 
13  - - - - 174.22 
14 1.22 3 d 7.4 16.82 
 
Table 25: Smoc-L-Arg-OH 5 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.88; 7.93 2 s - 122.01 
 
2 and 7  - - - - 146.76 
3 and 6 7.7 2 d 7.7 125.3 
4 and 5 7.85; 7.86 2 d 7.9 119.6 
4' and 5'  - - - - 140.61 
1' and 8'  - - - - 143.51; 144.50 
9 4.32 1 t 5.5 46.91 
10a 4.33 1 dd 10.0; 6.3 
64.85 
10b 4.54 1 dd 10.0; 6.3 
11  - - - - 155.93 
NH 7.52 1 d 8.5 - 
12 3.96 1 dt 9.2; 4.3 52.91 
13  - - - - 173.3 
14 1.56; 1.72 2 m - 27.87 
15 1.47 2 m - 24.93 
16a 3.02 1 dq 13.0; 6.5 
40.0 
16b 3.1 1 dq 13.0; 6.5 
NH 7.74 1 t 5.6 - 
17 - - - - 156.63 
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Table 26: Smoc-L-Arg(Pbf)-OH 6 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.88; 7.91 2 d 1.4 122.03 
 
2 and 7  - - - - 146.91 
3 and 6 7.68 2 dd 7.8; 1.4 125.28 
4 and 5 7.84 2 d 7.9 119.54 
4' and 5'  - - - - 140.55 
1' and 8'  - - - - 143.58; 144.39 
9 4.3 1 t 5.5 46.92 
10a 4.32 1 m - 
64.98 
10b 4.51 1 m - 
11  - - - - 155.96 
NH 7.52 1 br - - 
12 3.9 1 dt 9.1; 4.7 53.17 
13  - - - - 173.35 
14 1.50; 1.63 2 m - 27.8 
15 1.37 2 m - 25.1 
16 3.07 2 q 7.3 39.71 
NH 7.74 1 t 5.6 - 
17  - - - - 166.74 
18  - - - - 133.9 
19  - - - - 131.42 
20  - - - - 124.33 
21  - - - - 157.57 
22  - - - - 116.34 
23  - - - - 137.32 
24 2.97 2 s - 42.35 
25  - - - - 86.32 
26 1.41 6 s - 28.25 
27 2.43 3 s - 18.91 
28 2.48 3 s - 17.51 
29 2.01 3 s - 12.22 
 
Table 27: Smoc-L-Asn-OH 7 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.90; 7.91 2 s - 122.11 
 
2 and 7  - - - - 146.99 
3 and 6 7.69 2 d 7.5 125.37 
4 and 5 7.84 2 d 7.9 119.57 
4' and 5'  - - - - 140.59 
1' and 8'  - - - - 144.03; 144.14 
9 4.26 1 t - 46.06 
10 4.42 2 m - 65.25 
11  - - - - 155.83 
NH 7.4 1 d 8.2 - 
12 4.27 1 m - 50.71 
13  - - - - 172.83 
14 2.43 1 dd 15.2; 7.5 
36.78 
14b 2.54 1 dd 15.2; 5.8 
15 - - - - 171.56 
NH2 5.6 2 br - - 
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Table 28: Smoc-L-Asp(OtBu)-OH 8 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.89; 7.94 2 s - 122.31; 122.45 
 
2 and 7  - - - - 147.26 
3 and 6 7.69 2 d 7.7 125.25 
4 and 5 7.83 2 d 7.9 119.35 
4' and 5'  - - - - 140.31 
1' and 8'  - - - - 143.78; 144.15 
9 4.23 1 m - 46.62 
10 4.22 2 m - 65.47 
11  - - - - 155.36 
NH 6.8 1 d 7.5 - 
12 3.97 1 dt 7.5; 5.3 52.92 
13  - - - - 170.72 
14 2.4 1 dd 14.7; 7.8 
39.54 
14b 2.59 1 dd 14.7; 5.4 
15 - - - - 172.58 
16 - - - - 79.1 
17 1.38 9 s - 27.78 
 
Table 29: Smoc-L-Cys(Trt)-OH 9 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.90; 7.91 2 s - 122.0 
 
2 and 7  - - - - 147.4 
3 and 6 7.68 2 d 7.9 125.3 
4 and 5 7.82 2 d 7.8 119.35 
4' and 5'  - - - - 140.36 
1' and 8'  - - - - 143.97 
9 4.2 1 t 5.6 47.0 
10a 4.37 1 dd 11.1; 5.8 
65.57 
10b 4.41 1 dd 11.5; 6.5 
11  - - - - 155.94 
NH 6.6 1 d 8.4  
12 3.77 1 m - 53.58 
13  - - - - 171.63 
14 2.38 1 dd 12.4; 5.0 
32.52 
14b 2.56 1 dd 12.6; 9.4 
15 - - - - 66.28 
16 - - - - 144.21 
17 7.3 6 m - 129.0 
18 7.3 6 m - 128.0 
19 7.24 3 t 6.9 126.67 
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Table 30: Smoc-L-Gln-OH 10 in DMSO-d6 (1H NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.90; 7.93 2 s - 122.15 
 
2 and 7  - - - - 147.12 
3 and 6 7.69 2 d 7.8 125.32 
4 and 5 7.84 2 d 7.8 119.48 
4' and 5'  - - - - 140.45; 140.50 
1' and 8'  - - - - 143.67; 144.32 
9 4.27 1 t 6 46.86 
10a 4.32 1 dd 10.7; 5.7 
65.18 
10b 4.45 1 dd 10.7; 6.8 
11  - - - - 156.12 
NH 7.54 1 d 7.7 - 
12 3.88 1 dt 10.4; 5.0 53.47 
13  - - - - 173.68 
14a 1.68 1 m - 
26.16 
14b 1.99 1 m - 
15 2.16 2 ddd 9.5; 6.8; 3.2 31.23 
16 - - - - 173.58 
 
Table 31: Smoc-L-Glu(OtBu)-OH 11 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.89; 7.94 2 s - 122.3 
 
2 and 7  - - - - 147.2 
3 and 6 7.69 2 d 8.0 125.0 
4 and 5 7.83 2 d 8.0 119.3 
4' and 5'  - - - - 140.31 
1' and 8'  - - - - 143.95 
9 4.23 1 m - 46.2 
10 4.23 2 m - 65.2 
11  - - - - 155.5 
NH 6.63 1 d 6.7 - 
12 3.65 1 q 6.0 54.8 
13  - - - - 172.4 
14 1.78 1 tt 12.1; 5.6 
27.96 
14b 1.9 1 tt 10.7; 5.2 
15a 2.12 1 ddd 16.0; 10.8; 5.3 
30.73 
15b 2.23 1 ddd 16.1; 10.9; 5.5 
16 - - - - 173.5 
17 - - - - 79.13 
18 1.38 9 s - 27.73 
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Table 32: Smoc-Gly-OH 12 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.91 2 s - 122.05 
 
2 and 7  - - - - 147.04 
3 and 6 7.69 2 d 7.9 125.36 
4 and 5 7.85 2 d 7.9 119.56 
4' and 5'  - - - - 140.59 
1' and 8'  - - - - 144.11 
9 4.25 1 t 5.7 46.97 
10 4.43 2 d 5.8 65.37 
11  - - - - 156.52 
NH 7.49 1 br - - 
12 3.61 2 s - 42.15 
13  - - - - 171.39 
 
Table 33: Smoc-L-His-OH 13 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.84; 7.92 2 s - 121.9; 122.0 
 
2 and 7  - - - - 146.86 
3 and 6 7.71 2 d 7.9 125.36 
4 and 5 7.85 2 d 7.9 119.65 
4' and 5'  - - - - 140.57; 140.66 
1' and 8'  - - - - 143.60; 144.34 
9 4.23 1 m - 46.69 
10a 4.33 1 dd 10.8; 5.3 
65.12 
10b 4.41 1 dd 10.8; 6.8 
11  - - - - 155.78 
NH 7.66 1 d 8.8 - 
12 4.23 1 m - 52.73 
13  - - - - 171.97 
14 2.94 1 dd 15.0; 7.9 
26.03 
14b 3.13 1 dd 15.0; 4.4 
15 - - - - 129.28 
16 7.27 1 s - 117.38 
17 8.92 1 s - 133.71 
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Table 34: Smoc-L-His(Trt)-OH 14 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.89; 7.99 2 s - 122.3 
 
2 and 7  - - - - 147.65 
3 and 6 7.69 2 d 7.7 125.6 
4 and 5 7.84 2 d 7.7 119.1 
4' and 5'  - - - - 140.8 
1' and 8'  - - - - 143.76; 144.0 
9 4.19 1 t 6.3 46.9 
10a 3.94 1 m - 
65.23 
10b 4.13 1 m - 
11  - - - - 156.0 
NH 6.97 1 br - - 
12 3.96 1 m - 55.81 
13  - - - - 171.29 
14 2.65 1 dd 14.9; 8.6 
31.95 
14b 2.99 1 dd 14.8; 4.6 
15 - - - - 138.3 
16 ?* - - - 118.8 
17 7.22 - br - 137.5 
18 - - - - 74.38 
19 - - - - 142.4 
20 7.06 6 m - 128.9 
21 7.37 6 m - 128.5 
22 7.06 3 m - 127.5 
*: Signals have not been detected under the used conditions 
 
Table 35: Smoc-L-Ile-OH 15 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.92 2 s  - 122.09 
 
2 and 7  - - - - 147.15; 147.17 
3 and 6 7.68 2 dd 7.9; 1.2 125.31 
4 and 5 7.83 2 d 7.9 119.44 
4' and 5'  - - - - 140.48 
1' and 8'  - - - - 144.03; 144.16 
9 4.23 1 t 5.8 47.11 
10a 4.37 1 dd 10.9; 5.7 
65.46 
10b 4.86 1 dd 10.9; 5.9 
11  - - - - 156.44 
NH 7.46 1 d 8.1 - 
12 3.87 1 t 6.5 58.68 
13  - - - - 173.06 
14 1.75 1 m - 35.72 
15a 1.17 1 ddq 13.6; 8.9; 7.3 
24.88 
15b 1.39 1 ddq 13.6; 7.4; 4.5 
16 0.81 3 t 7.4 11.22 
17 0.84 3 d 6.9 15.48 
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Table 36: Smoc-L-Leu-OH 16 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.90; 7.91 2 s - 122.0 
 
2 and 7 - - - - 147.29 
3 and 6 7.68 2 d 8 125.27 
4 and 5 7.83 2 d 8 119.37 
4' and 5' - - - - 140.42 
1' and 8' - - - - 144.01; 144.09 
9 4.22 1 t 5.6 47.06 
10a 4.38 1 dd 11.0; 5.6 
65.35 
10b 4.46 1 dd 11.0; 5.6 
11 - - - - 156.29 
NH 7.51 1 d 7.9 - 
12 3.93 1 dt 10.7; 5.4 52.28 
13 - - - - 174.17 
14a 1.53 1 ddd 
13.4; 
10.2; 5.1 
39.5 
14b 1.41 1 ddd 
13.5; 9.0; 
4.9 
15 1.61 1 m - 24.17 
16 0.83 3 d 6.5 21.28 
17 0.85 3 d 6.6 22.78 
 
Table 37: Smoc-D-Leu-OH 17 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.92; 7.93 2 s - 122.07 
 
2 and 7 - - - - 146.96; 146.99 
3 and 6 7.69 2 dd 8; 1.5 125.36 
4 and 5 7.85 2 d 8.0 119.56 
4' and 5' - - - - 140.61 
1' and 8' - - - - 144.14; 144.23 
9 4.23 1 t 5.6 47.12 
10a 4.39 1 dd 11.0; 5.6 
65.35 
10b 4.47 1 dd 11.0; 5.7 
11 - - - - 156.33 
NH 7.51 1 br - - 
12 3.92 1 dd 9.7; 4.8 52.32 
13 - - - - 174.23 
14a 1.52 1 ddd 
13.7; 
10.1; 5.1 
39.56 
14b 1.41 1 ddd 
13.7; 9.0; 
4.9 
15 1.61 1 m - 24.23 
16 0.82 3 d 6.6 21.33 
17 0.85 3 d 6.6 22.83 
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Table 38: Smoc-L-Lys(Boc)-OH 18 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.88; 7.93 2 s - 122.26; 122.38 
 
2 and 7 - - - - 147.24; 147.31 
3 and 6 7.68 2 dd 7.9; 1.4 125.22 
4 and 5 7.82 2 d 7.9 119.33 
4' and 5' - - - - 140.3 
1' and 8' - - - - 143.92; 144.08 
9 4.24 1 t - 46.75 
10 4.23 2 m - 65.3 
11 -  - - 155.45 
NH 6.56 1 br - - 
12 3.61 1 q 6.1 55.58 
13 - - - - 173.58 
14a 1.54 1 m - 
32.44 
14b 1.64 1 dq 10.3; 5.4 
15 1.22 2 m - 22.53 
16 1.33 2 m - 29.6 
17 2.86 2 dt 7.4; 6.9 40.03 
NH 6.69 1 br - - 
18 - - - - 155.24 
19 - - - - 77.14 
20 1.33 9 s - 28.24 
 
Table 39: Smoc-L-Met-OH 19 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.91; 7.92 2 s  - 122.1 
 
2 and 7  - - - - 147.08 
3 and 6 7.69 2 dd 7.9; 1.2 125.36 
4 and 5 7.84 2 d 7.9 119.53 
4' and 5'  - - - - 140.56 
1' and 8'  - - - - 144.02; 144.18 
9 4.24 1 t 5.7 47.06 
10a 4.38 1 dd 10.9; 5.6 
65.33 
10b 4.47 1 dd 10.9; 5.9 
11  - - - - 156.33 
NH 7.6 1 d 7.6 - 
12 4.03 1 dt 7.7; 5.6 52.93 
13  - - - - 173.5 
14 1.87 2 m - 30.31 
15 2.47 2 m - 29.83 
16 2.01 3 s - 14.53 
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Table 40: Smoc-L-Phe-OH 20 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.9 2 s  - 122.02; 122.08 
 
2 and 7  - - - - 147.2 
3 and 6 7.69 2 dd 7.9; 1.2 125.31 
4 and 5 7.83 2 d 7.9 119.43 
4' and 5'  - - - - 140.44 
1' and 8'  - - - - 143.99; 144.05 
9 4.16 1 t 5.5 47.05 
10a 4.33 1 dd 11.0; 5.8 
65.37 
10b 4.38 1 dd 11.0; 5.7 
11  - - - - 156.05 
NH 7.61 1 d 8.1 - 
12 4.12 1 m - 55.65 
13  - - - - 173.02 
14a 2.88 1 dd 13.8; 9.5 
36.43 
14b 2.99 1 dd 13.8; 5.3 
15 - - - - 137.81 
16 7.22 2 d 7.4 129.06 
17 7.26 2 t 7.5 128.19 
18 7.15 1 t 7.2 126.22 
 
Table 41: Smoc-L-Pro-OH 21 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.91; 7.92 2 d 1.4 122.42 
 
2 and 7  - - - - 147.17 
3 and 6 7.68 2 dd 7.9; 1.4 125.3 
4 and 5 7.84 2 d 7.9 119.49 
4' and 5'  - - - - 140.43 
1' and 8'  - - - - 143.66; 143.90 
9 4.29 1 t 5.6 46.47 
10 4.2-4.3 2 m - 66.28 
11  - - - - 153.84 
12 4.17 1 dd 8.6; 3.2 58.85 
13  - - - - 173.5 
14a 1.85 1 m - 
29.34 
14b 2.21 1 m - 
15 1.85 2 m - 23.9 
16 3.41 2 m - 46.01 
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Table 42: Smoc-L-Ser-OH 22 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.90; 7.92 2 s - 122.0; 122.07 
 
2 and 7 - - - - 147.1 
3 and 6 7.69 2 dd 7.9; 1.5 125.32 
4 and 5 7.84 2 d 7.9 119.53 
4' and 5' - - - - 140.54 
1' and 8' - - - - 143.92; 144.20 
9 4.25 1 t 5.7 46.96 
10a 4.41 1 dd 11.0; 5.6 
65.29 
10b 4.47 1 dd 11.0; 6.0 
11 - - - - 156.01 
NH 7.14 1 br - - 
12 4.0 1 t 5.2 56.72 
13 - - - - 171.94 
14a 3.62 1 dd 11.3; 5.3 
61.27 
14b 3.65 1 dd 11.3; 4.2 
OH 4.01 1 br - - 
 
Table 43: Smoc-L-Ser(tBu)-OH 23 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.92 2 s - 122.08 
 
2 and 7 - - - - 147.43 
3 and 6 7.69 2 d 7.9 125.29 
4 and 5 7.82 2 d 7.9 119.32 
4' and 5' - - - - 140.33 
1' and 8' - - - - 143.87; 144.94 
9 4.23 1 t 5.9 46.94 
10a 4.37 1 dd 10.9; 5.9 
65.6 
10b 4.42 1 dd 10.9; 6.0 
11 - - - - 156.01 
NH 7.17 1 d 8.1 - 
12 4.08 1 dt 8.0; 5.2 54.9 
13 - - - - 171.79 
14a 3.54 1 dd 9.5; 4.9 
61.23 
14b 3.57 1 dd 9.5; 5.5 
15 - - - - 72.78 
16 1.1 9 s - 27.14 
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Table 44: Smoc-L-Thr-OH 24 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.91; 7.92 2 s  - 122.07 
 
2 and 7  - - - - 147.22 
3 and 6 7.69 2 d 7.9 125.3 
4 and 5 7.83 2 d 7.9 119.43 
4' and 5'  - - - - 140.44 
1' and 8'  - - - - 143.86; 144.07 
9 4.25 1 t 6.0 46.95 
10a 4.39 1 dd 10.9; 5.7 
65.52 
10b 4.46 1 dd 10.9; 6.1 
11  - - - - 156.38 
NH 6.83 1 d 8.7 - 
12 3.92 1 dd 8.1. 3;8 60.18 
13  - - - - 172.09 
14 4.02 1 dq 6.5; 3.7 66.44 
15 1.07 3 d 6.5 20.32 
 
Table 45: Smoc-L-Thr(tBu)-OH 25 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.90. 7.96 2 s  - 122.6. 122.7 
 
2 and 7  - - - - 147.19 
3 and 6 7.69 2 dd 7.9; 15 125.55 
4 and 5 7.83 2 d 7.9 119.56 
4' and 5'  - - - - 140.28 
1' and 8'  - - - - 143.95 
9 4.23 1 m - 46.54 
10 4.23 2 m - 65.58 
11  - - - - 156.1 
NH 6.18 1 d 8.7 - 
12 3.59 1 dd 8.7; 3.3 61.82 
13  - - - - 173 
14 3.96 1 dq 6.2; 3.4 68.37 
15 1.05 3 d 6.2 21.08 
16 - - - - 72.43 
17 1.1 9 s - 28.56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
Page 76 
Table 46: Smoc-L-Trp-OH 26 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.90; 7.93 2 s -  122.02 
 
2 and 7  - - - - 147.00; 147.07 
3 and 6 7.69; 7.70 2 dd 7.9. 1.5 125.32; 125.35 
4 and 5 7.82; 7.83 2 d 7.9 119.54 
4' and 5'  - - - - 140.54; 140.57 
1' and 8'  - - - - 143.96; 144.25 
9 4.21 1 t 5.8 46.9 
10a 4.29 1 dd 10.8; 5.5 
65.28 
10b 4.4 1 dd 10.8; 6.1 
11  - - - - 155.96 
NH 7.53 1 d 8.2 - 
12 4.12 1 dt 9; 4.5 45.18 
13  - - - - 173.47 
14a 2.95 1 dd 14.6; 9.9 
26.53 
14b 3.16 1 dd 14.6; 4.5 
15 - - - - 109.67 
16 7.14 1 s - 124.31 
NH 10.87 1 s - - 
17 - - - - 135.84 
18 7.29 1 d 7.5 111.33 
19 7.03 1 t 7.5 120.64 
20 6.96 1 t 7.4 118.18 
21 7.48 1 d 7.8 117.81 
22 - - - - 127.04 
 
Table 47: Smoc-L-Trp(Boc)-OH 27 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.87; 7.94 2 s  - 122.3; 122.5 
 
2 and 7  - - - - 147.77 
3 and 6 7.69 2 d 7.9 125.2 
4 and 5 7.82 2 d 7.9 119.3 
4' and 5'  - - - - ?* 
1' and 8'  - - - - ?* 
9 4.18 1 m - 46.27 
10 4.18 2 m - 65.18 
11  - - - - ?* 
NH 6.72 1 d 6.8 - 
12 3.93 1 q 6.1 55.19 
13  - - - - 173.45 
14a 2.97 1 dd 14.6; 6.3 
27.4 
14b 3.16 1 dd 14.6; 5.4 
15 - - - - ?* 
16 7.43 1 s - ?* 
17 - - - - ?* 
18 8.0 1 d 8.2 114.3 
19 7.26 1 t 7.7 123.9 
20 7.21 1 t 7.4 122.2 
21 7.64 1 d 7.7 119.3 
22 - - - - ?* 
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23 - - - - ?* 
24 - - - - 83.24 
25 1.61 9 s - 27.69 
*: Signals have not been detected under the used conditions or assignment was not possible. 
 
Table 48: Smoc-L-Tyr-OH 28 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.9 2 s  - 122.05 
 
2 and 7  - - - - 147.06; 147.13 
3 and 6 7.69 2 d 8.0 125.34 
4 and 5 7.84 2 d 8.0 119.5 
4' and 5'  - - - - 140.52 
1' and 8'  - - - - 144.1 
9 4.18 1 t 5.7 47.06 
10a 4.33 1 dd 11.0; 5.8 
65.33 
10b 4.39 1 dd 11.0; 5.7 
11  - - - - 156.05 
NH 7.5 1 d 8.0 - 
12 4.03 1 q 7.1 56.0 
13  - - - - 173.19 
14a 2.74 1 dd 13.9; 9.3 
35.74 
14b 2.86 1 dd 13.9; 5.4 
15 - - - - 127.8 
16 6.98 2 d 8.1 129.97 
17 6.64 2 d 8.1 115.05 
18 - - - -  155.77 
OH 8.15 1 s  - - 
 
Table 49: Smoc-L-Tyr(tBu)-OH 29 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.86; 7.92 2 s  - 122.71 
 
2 and 7  - - - - 147.78 
3 and 6 7.67; 7.68 2 d 8.0 125.5 
4 and 5 7.81 2 d 8.0 119.48 
4' and 5'  - - - - 140.24 
1' and 8'  - - - - 143.89 
9 4.14 1 m - 46.53 
10 4.15 2 m - 65.34 
11  - - - - 155.31 
NH 6.51 1 d 7.2 - 
12 3.83 1 q 6.6 57.47 
13  - - - - 173.08 
14a 2.79 1 dd 13.6; 7.1 
37.56 
14b 3.0 1 dd 13.6; 4.9 
15 - - - - 134.06 
16 7.07 2 d 8.1 129.71 
17 6.78 2 d 8.1 123.09 
18 - - -  - 152.97 
19 - - -  - 77.37 
20 1.21 9 s  - 28.54 
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Table 50: Smoc-L-Val-OH 30 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.92; 7.93 2 s  - 122.1 
 
2 and 7  - - - - 147.13 
3 and 6 7.68 2 dd 8.0; 1.3 125.31 
4 and 5 7.83 2 d 8.0 119.45 
4' and 5'  - - - - 140.48 
1' and 8'  - - - - 144.02; 144.18 
9 4.23 1 t 5.7 47.13 
10a 4.38 1 dd 11.0; 5.7 
65.45 
10b 4.46 1 dd 11.0; 5.9 
11  - - - - 156.53 
NH 7.46 1 d 8.3 - 
12 3.81 1 t 6.7 59.82 
13  - - - - 173.07 
14a 2 1 oct 6.7 
29.41 
14b 2.86 1 dd 13.9; 5.4 
15 0.87 3 d 6.8 18.4 
16 0.87 3 d 6.8 19.08 
 
Table 51: Smoc-β-Ala-OH 31 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H #H 
Multi-
plicity 
Coupling 
constant 
13C 
 
1 and 8 7.87 2 s  - 121.92 
 
2 and 7  - - - - 147.28 
3 and 6 7.67 2 d 8 125.21 
4 and 5 7.81 2 d 7.9 119.34 
4' and 5'  - - - - 140.39 
1' and 8'  - - - - 144.01 
9 4.22 1 t 5.7 47.0 
10 4.42 2 d 5.7 64.86 
11  - - - - 155.99 
NH 7.19 1 br - - 
12 3.14 2 t 7.4 36.84 
13 2.36 2 t 7.3 34.01 
14 - - - - 173.58 
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Table 52: Smoc-Aib-OH 32 in DMSO-d6 (1H-NMR at 500 MHz, 13C-NMR at 126 MHz). 
Position 1H 
#
H 
Multi-plicity 
Coupling 
constant 
13C 
 
1 and 8 7.89 2 s - 121.97 
 
2 and 7 - - - - 147.23 
3 and 6 7.67 2 d 7.8 125.23 
4 and 5 7.82 2 d 7.8 119.35 
4' and 5' - - - - 140.43 
1' and 8' - - - - 144.04 
9 4.21 1 t 5.5 47.05 
10 4.41 2 d 5.3 64.8 
11 - - - - 155.06 
NH 7.44 1 br - - 
12 - - - - 55.2 
13 - - -  175.6 
14 1.29 6 s - 24.97 
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4. Graphical summary of the present work 
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5. Summary & Outlook 
During the time elapsed since the first oligopeptide has been assembled by chemical means, 
scientists constantly improve the methods of peptide synthesis in view of optimized reaction 
conditions, protecting schemes, tailor-made coupling agents, and solvent systems. The 
introduction of Merrifield’s solid-phase approach in early 1960s became a major breakthrough 
that has designated the vector of peptide synthesis for the following decades. To date, 
production of peptides has gained almost optimal efficiency in terms of coupling yield and 
reaction times. However, solvent consumption, that has been recognized as an economic and 
environmental issue since a decade, makes solid-phase peptide synthesis one of the most 
inefficient synthetic approaches known. Indeed, DMF and NMP which are currently the solvents 
of choice in SPPS, are classified by the European REACH Regulation as substances of very high 
concern due to their carcinogenic, mutagenic or toxic for reproduction (CMR) properties. 
Therefore, sustainable, green peptide synthesis that does not require or minimizes application 
of highly hazardous solvents is currently in research focus. 
In the frame of the present work, a water-based solid-phase peptide synthesis (ASPPS) was 
developed, which relies on an original water-compatible protecting group strategy. The 
cornerstone of this concept, an Smoc protecting group, combines the fluorenyl system with 
charged sulfonic pendants and therefore possesses high water solubility and intrinsic 
fluorescent properties. This moiety was efficiently introduced at the aminoterminus in all the 
natural amino acids using the corresponding Smoc-Cl 2. Reliable synthesis routes were 
developed that provided synthetic access to the respective Nα-Smoc amino acids in good to 
excellent yields (derivatives 3-31, Table 53). Non-natural Smoc-Aib-OH 32 was obtained in 
moderate yield due to the obvious steric hindrance. 
Table 53: Summary of the Nα-Smoc amino acid yields. 
Compound 3 4 5 6 7 8 9 10 11 12 
Yield [%] 87.2 86.9 85.7 85.1 90.4 86.7 85.1 90.8 88.2 93.7 
Compound 13 14 15 16 17 18 19 20 21 22 
Yield [%] 92.4 86.6 88.9 90.6 88.7 87.4 95.1 93.7 85.8 90.0 
Compound 23 24 25 26 27 28 29 30 31 32 
Yield [%] 87.9 92.2 89.2 90.7 86.9 89.7 91.4 87.2 92.5 57.8 
Stability of Nα-Smoc amino acids under reaction conditions and liability of Smoc in the presence 
of deprotection bases was thoroughly investigated. It was found that all Nα-Smoc amino were 
stable within days in aqueous solutions of sodium bicarbonate. The Smoc protection was easily 
cleaved with aqueous sodium hydroxide or ammonia as well as under milder conditions by 
ethanolamine or piperazine. Our studies showed the slightly higher base-lability of an Smoc- 
compared to the Fmoc-protecting group.  
Generation of a peptide bond in aqueous environment is a synthetic challenge per se. 
Throughout the whole story of peptide synthesis water was assigned as the major handicap for 
successful amide coupling, and water-free peptide synthesis grade chemicals were obligatory. 
To provide access to aqueous peptide synthesis, coupling efficacy was assessed in water-based 
systems applying respective Nα-Smoc amino acids and using different activation approaches. In 
our hands, several water-compatible activating additives were found appropriate, with EDC-
HCl 37, Oxima 39 and HOPO 40 being the most efficient.  
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The experiments showed that although coupling of amino acids in pure water gave reasonable 
yields and purity of peptides, the addition of organic co-solvents enhanced coupling 
performance significantly (Table 54). 
Table 54: Summary of coupling efficiency of EDC-HCl 37, Oxima 39 and HOPO 40 after 25 minutes. 
Coupling reagents 
Coupling efficiency 
water 30% MeCN 30% EtOH 30% iPrOH 10% Me-THF 
EDC-HCl 37/Oxyma 39 90.7% 99.8% 99.0% 98.8% 88.7% 
EDC-HCl 37/HOPO 40 58.3% 84.2% 83.6% 83.6% 79.4% 
Indeed, in 20-30% aqueous acetonitrile or alcohols amide coupling was as efficient as in water-
free organic solvents, presumably due to stabilization of intermediate active esters. 
The concept of aqueous SPPS (ASPPS) was further validated by assembling certain prominent 
peptides in water or water-based systems. Thus, we established a reliable synthesis of peptides 
47-69 in good yields and purity (Table 55). To the best of our knowledge, to date our ASPPS 
approach is the most efficient water-based peptide synthesis process known. 
Table 55: Summary of the peptide yields. 
Compound 48 49 50 51 52 53 54 55 56 57 58 
Yield [%] 57.7 38.7 51.3 42.2 70.9 63 71.8 36 46 38 67 
Compound 59 60 61 62 63 64 65 66 67 68 69 
Yield [%] 50 44 49 53.7 54.2 59.7 48.4 35.8 39.7 41.4 57.9 
Additional studies on enantiomeric composition showed no increased racemization levels 
during the ASPPS process. Studies on the aspartimide formation showed that usage of 5% 
piperazine at 4°C is advised for Smoc deprotection of aspartimide-prone sequences resulting in 
the formation of around 15-25% of the corresponding β-peptide while the deprotection in 20% 
piperidine in DMF resulted in 83% aspartimide by-products. 
Special attention was given to spectral properties of Smoc-bearing molecular constructs. 
Additional studies aimed at investigating the absorbance and fluorescent characteristics of the 
Nα-Smoc amino acids showed that both in resin-bound and in-solution state this moiety could 
be used for the real-time monitoring of the reaction progress upon both the coupling and the 
deprotection steps as well as to determine the concentration of loaded on-support Nα-Smoc 
amino acids. 
An elegant approach towards a reliable purification of synthetic peptides has been proposed 
based on the ionic properties of the Smoc protecting group. Already Merrifield showed that 
mono-sulfonated Fmoc derivative could be applied to peptide isolation with ion-exchange 
chromatography.[206] This method was further optimized and integrated as capping strategy 
into the ASPPS-based peptide assembly. To that end, all the by-products originating from 
incomplete couplings are labelled with charged Sulfo-tags and can be easily removed upon 
successive IEC after cleavage from solid support. Our studies showed that this method could 
also be applied to Fmoc-based peptide synthesis. This method allows tailoring of purification 
strategy depending on required peptide purity grade. It can be applied solely or serve as a pre-
purification system to simplify and optimize the following HPLC separation. In addition, the 
same method could be used to refine the wastewater.  
It is important to mention that development of specific, water-optimized resins and respective 
linker systems still remains the challenge that must be addressed. However, this issue was 
beyond the scope of the present work. The next goal in the frame of this study would be to 
synthesize longer, more complex peptides and develop automated protocols for ASPPS.  
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6. Zusammenfassung und Ausblick 
Seit der ersten chemischen Herstellung eines Oligopeptids verbesserten Wissenschaftler die 
Methoden der Peptidsynthese im Hinblick auf optimierte Reaktionsbedingungen, 
Schutzgruppenstrategien, maßgeschneiderte Kupplungsreagenzien und Lösungsmittelsysteme 
ständig weiter. Die Einführung des Festphasenansatzes von Merrifield Anfang der 1960er Jahre 
hat die Peptidsynthese revolutioniert und die Peptidsynthese für Jahrzehnte geprägt. 
Mittlerweile hat die Synthese von Peptiden eine nahezu optimale Effizienz in Bezug auf 
Kupplungsausbeute und Reaktionszeiten erreicht. Der Verbrauch an organischen 
Lösungsmitteln, der seit einem Jahrzehnt als ökonomisches und ökologisches Problem erkannt 
ist, macht die Festphasen-Peptidsynthese jedoch zu einem der ineffizientesten bekannten 
synthetischen Ansätze. Tatsächlich werden DMF und NMP, derzeit die Lösungsmittel der Wahl 
in der SPPS, nach der europäischen Reach-Verordnung aufgrund ihrer krebserzeugenden, 
erbgutverändernden oder fortpflanzungsgefährdenden (CMR) Eigenschaften als besonders 
besorgniserregend eingestuft. Daher steht derzeit die nachhaltige, grüne Peptidsynthese im 
Fokus, die den Einsatz hochgefährlicher Lösungsmittel nicht erfordert oder minimiert. 
Im Rahmen der vorliegenden Arbeit wurde eine wasserbasierte Festphasen-Peptidsynthese 
(ASPPS) entwickelt, die auf einer originären wasserverträglichen Schutzgruppenstrategie 
basiert. Die in dieser Arbeit entwickelte Smoc-Schutzgruppe, kombiniert das Fluorenylsystem 
mit geladenen Sulfonsäuregruppen und verfügt somit über eine hohe Wasserlöslichkeit und 
intrinsische Fluoreszenzeigenschaften. Diese Gruppe wurde mit dem entsprechenden Smoc-Cl 
2 effizient am Aminoterminus von allen natürlichen Aminosäuren angebracht. Es wurden 
zuverlässige Synthesewege entwickelt, die einen synthetischen Zugang zu den entsprechenden 
Nα-Smoc-Aminosäuren in guten bis sehr guten Ausbeuten ermöglichten (Derivate 3-31, Tabelle 
53). Nicht-natürliches Smoc-Aib-OH 32 wurde aufgrund der offensichtlichen sterischen 
Hinderung nur in moderater Ausbeute hergestellt. 
Tabelle 53: Zusammenfassung der Nα-Smoc Aminosäure Ausbeuten. 
Verbindung 3 4 5 6 7 8 9 10 11 12 
Ausbeute [%] 87.2 86.9 85.7 85.1 90.4 86.7 85.1 90.8 88.2 93.7 
Verbindung 13 14 15 16 17 18 19 20 21 22 
Ausbeute [%] 92.4 86.6 88.9 90.6 88.7 87.4 95.1 93.7 85.8 90.0 
Verbindung 23 24 25 26 27 28 29 30 31 32 
Ausbeute [%] 87.9 92.2 89.2 90.7 86.9 89.7 91.4 87.2 92.5 57.8 
Die Stabilität von Nα-Smoc-Aminosäuren unter Reaktionsbedingungen und die Abspaltbarkeit 
von Smoc in Gegenwart von Entschützungsbasen wurde untersucht. Es wurde festgestellt, dass 
alle Nα-Smoc Aminosäuren stabil für mehrere Tage in wässrigen Natriumhydrogencarbot 
Lösungen waren. Die Smoc-Schutzgruppe konnte leicht mit wässrigem Natriumhydroxid oder 
Ammoniak sowie unter milderen Bedingungen mit Ethanolamin oder Piperazin abgespalten 
werden. Unsere Studien zeigten eine etwas erhöhte Basen-Labilität der Smoc-Gruppe im 
Vergleich zur Fmoc-Schutzgruppe.  
Die Erzeugung einer Peptidbindung in wässriger Umgebung ist per se eine synthetische 
Herausforderung. Während der gesamten Geschichte der Peptidsynthese wurde Wasser als 
Haupthindernis für eine erfolgreiche Amidkopplung genannt, und wasserfreie Chemikalien 
waren obligatorisch. Um Zugang zur wässrigen Peptidsynthese zu erhalten, wurde die 
Kopplungseffizienz in wässrigen Systemen mit entsprechenden Nα-Smoc-Aminosäuren und mit 
verschiedenen Aktivierungsreagenzien untersucht. Es wurden mehrere wasserverträgliche 
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Aktivierungsreagenzien identifiziert, wobei EDC-HCl 37, Oxima 39 und HOPO 40 die 
effizientesten waren.  
Die Experimente zeigten, dass, obwohl die Kopplung von Aminosäuren in reinem Wasser eine 
angemessene Ausbeute und Reinheit der Peptide ergab, die Zugabe von organischen 
Co-Lösungsmitteln die Kopplungseffizienz signifikant verbesserte. (Tabelle 54). 
Tabelle 54: Zusammenfassung der Kopplungseffizienz von EDC-HCl 37, Oxima 39 und HOPO 40 nach 25 Minuten. 
Kopplungsreagenzien 
Kopplungseffizienz 
Wasser 30% MeCN 30% EtOH 30% iPrOH 10% Me-THF 
EDC-HCl 37/Oxyma 39 90.7% 99.8% 99.0% 98.8% 88.7% 
EDC-HCl 37/HOPO 40 58.3% 84.2% 83.6% 83.6% 79.4% 
Tatsächlich war die Kopplung in 20-30% wässrigem Acetonitril oder Alkoholen genauso 
effizient wie in wasserfreien organischen Lösungsmitteln, vermutlich aufgrund der 
Stabilisierung der intermediären Aktivester. 
Das Konzept des wässrigen SPPS (ASPPS) wurde weiter validiert, indem ausgewählte bekannte 
Peptide in wässrigen oder wasserbasierten Systemen synthetisiert wurden. So haben wir eine 
zuverlässige Synthese der Peptide 47-69 in guter Ausbeute und Reinheit etabliert (Tabelle 55). 
Nach bestem Wissen ist der hier beschriebene ASPPS-Ansatz der effizienteste bisher bekannte 
wasserbasierte Peptidsyntheseprozess. 
Tabelle 55: Zusammenfassung der Peptid-Ausbeuten. 
Verbindung 48 49 50 51 52 53 54 55 56 57 58 
Ausbeute [%] 57.7 38.7 51.3 42.2 70.9 63 71.8 36 46 38 67 
Verbindung 59 60 61 62 63 64 65 66 67 68 69 
Ausbeute [%] 50 44 49 53.7 54.2 59.7 48.4 35.8 39.7 41.4 57.9 
Zusätzliche Studien zur enantiomere Zusammensetzung zeigten keine erhöhte Racemisierung 
während des ASPPS-Prozesses. Studien zur Aspartimidbildung zeigten, dass die Verwendung 
von 5% Piperazin bei 4°C für die Smoc-Entschützung von Aspartimid-gefährdeten Sequenzen 
vorteilhaft ist. Dies führt zur Bildung von etwa 15-25% des entsprechenden β-Peptids, die 
Entschützung in 20% Piperidin in DMF führte dagegen zu 83% Aspartimid Nebenprodukten. 
Besonderes Augenmerk wurde auf die spektralen Eigenschaften von Smoc-tragenden 
Verbindungen gelegt. Studien zur Absorption und Fluoreszenz der Nα-Smoc-Aminosäuren 
zeigten, dass dieser Teil sowohl im harzgebundenen als auch in Lösung zur 
Echtzeitüberwachung des Reaktionsfortschritts sowohl beim Kupplungs- als auch beim 
Entschützungsschritt sowie zur Bestimmung der Nα-Smoc-Aminosäurebeladung auf der festen 
Phase verwendet werden kann. 
Ein eleganter Ansatz für eine einfache und kostengünstige Reinigung synthetischer Peptide 
wurde auf der Grundlage der ionischen Eigenschaften der Smoc-Schutzgruppe in dieser Arbeit 
etabliert. Merrifield zeigte bereits, dass monosulfoniertes Fmoc-Derivat zur Peptidisolierung mit 
IEC eingesetzt werden kann.[206] Diese Methode wurde weiter optimiert und als Capping-
Strategie in die ASPPS-basierte Peptidsynthese integriert. Zu diesem Zweck sind alle 
Nebenprodukte, die bei unvollständigen Kupplungen entstehen, mit geladenen Sulfotags 
markiert und können durch IEC nach der Abspaltung von der festen Phase leicht entfernt 
werden. Unsere Studien zeigten, dass diese Methode auch auf die Fmoc-basierte Peptidsynthese 
angewendet werden kann. Diese Methode ermöglicht die Anpassung der Aufreinigungsstrategie 
an den gewünschten Peptidreinheitsgrad. Sie kann allein angewendet werden oder als 
Vorreinigungsstrategie zur Vereinfachung und Optimierung der anschließenden HPLC-
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Trennung dienen. Darüber hinaus kann das gleiche Verfahren zur Reinigung des bei der ASPPS 
anfallenden wässrigen Lösungsmittels eingesetzt werden. 
Die Entwicklung spezifischer, für den Einsatz in wässrigen Lösungsmitteln optimierte Harze 
und entsprechender Linkersysteme bleibt nach wie vor die Herausforderung und wird 
Gegenstand von künftigen Arbeiten zur Verbesserung der hier vorgeschlagenen 
Synthesestrategie sein. Auch steht noch an, längere und komplexere Peptide zu synthetisieren 
und automatisierte Protokolle für die ASPPS zu entwickeln.  
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7. Experimental 
7.1. General 
 
7.1.1. Solvents 
Solvents were obtained from Carl Roth GmbH + Co. KG (Karlsruhe, Germany), Fisher Scientific 
GmbH (Schwerte, Germany) or Merck KGaA (Darmstadt, Germany) and used without further 
purification except when mentioned specifically. 
7.1.2. Reagents 
All reagents, amino acids and reagents were used as supplied by Carl Roth GmbH + Co. KG 
(Karlsruhe, Germany), Fisher Scientific GmbH (Schwerte, Germany), Merck KGaA (Darmstadt, 
Germany), Iris Biotech GmbH (Marktredwitz, Germany) or Carbolution Chemicals GmbH (St. 
Ingbert, Germany). 
7.1.3. Freeze-drying 
Removal of the solvents was performed with a Beta 2-8 LDplus freeze-dryer (Martin Christ 
Gefriertrocknungsanlagen GmbH, Osterode, Germany) equipped with a high vacuum pump, 
Vacuubrand chemistry hybrid pump RC6 (Vacuubrand GmbH+Co. KG, Wertheim, Germany). 
7.1.4. Centrifugation 
The phase separation and the washing of peptides were done in a Multifuge 3 L-R centrifuge 
(Thermo Fisher Scientific, Schwerte, Germany). 
7.1.5. Storage 
All Fmoc-protected amino acids and activation reagents were stored at 4°C. All other substances 
were stored as recommended by the supplier. 
7.1.6. Removal of organic solvents 
Organic solvents were evaporated under reduced pressure using a rotary evaporator. 
7.2. Analytics 
 
7.2.1. Mass spectrometry 
Electrospray ionization mass spectroscopy (ESI-MS) spectra were obtained by using a Shimadzu 
LCMS-2020 mass spectrometer equipped with a Phenomenex Synergi™ Hydro-RP LC Column 
(4 u, 80 Å, 100 x 3 mm). Eluent system consisted of 0.1% aq. formic acid, LC-MS grade (eluent 
A) and 100% acetonitrile containing 0.1% formic acid, LC-MS grade (eluent B). 
7.2.2. HR-MS 
HR-MS electron ionization were obtained by using a Bruker Impact II using electrospray 
ionization mass spectroscopy (ESI-MS). 
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7.2.3. Liquid chromatography 
Analytical reversed-phase high performance liquid chromatography (RP-HPLC) was performed 
on a Agilent 1100 series HPLC equipped with a Interchim US5C18HQ-250/046 (5u, 
250×4.6mm) at a flow rate of 1 mL/min. Eluent A: 0.1% aq. trifluoroacetic acid (TFA), eluent 
B: MeCN with 0.1% TFA. 4 min of isocratic flow (starting concentration of eluent B) was 
followed by 20 min of gradient flow. Absorption was measured by UV/VIS detector at 220 nm 
and 280 nm. 
For isolation of peptides or Nα-Smoc amino acids on a semi-preparative Interchim PuriFlash 
4250 equipped with a preparative C18 column (Interchim US5C18HQ-250/212 (5u, 
250×21.2mm) was used at a flow rate of 18 mL/min. Eluent A: 0.1% aq. trifluoroacetic acid 
(TFA), eluent B: MeCN with 0.1% TFA. 5 min of isocratic flow (starting concentration of eluent 
B) was followed by 20 min of gradient flow. Absorption was measured by UV/VIS detector at 
220 nm and 280 nm. 
7.2.4. NMR 
1H, 13C, 13C DEPT and the 2D NMR spectra 1H-13C HMBC, 1H-1H NOESY, 1H-1H COSY were 
recorded with a 500 MHz NMR Spectrometer DRX 500 (Bruker BioSpin GmbH, Karlsruhe) 
equipped with a 5mm ATMA BBFO probe . All Samples were dissolved in deuterated DMSO d6 
purchased from Sigma Aldrich (Merck KGaA, Darmstadt, Germany) or deuterated MeCN 
purchased from Euriso Top (Gif-Sur-Yvette, France). 
7.3. Synthesis of Smoc-Cl 2 
 
Scheme 26: Synthesis of Smoc-Cl 2. 
60g Fmoc chloride 1 were dissolved in 250 ml dichloromethane (DCM). 62 ml of 20% oleum 
were slowly dropped into the solution under stirring. After precipitation of a white-grey solid, 
the solution was drained and 20 ml of 1,4-dioxane were added under ice-cooling and stirring 
until the SO3-dioxane complex was formed (approx. 10-15 min). To dissolve this rubber-like 
compound, 150 ml of 1,2-dichloroethane were added and stirred. SO3-dioxane complex 
remained in solution, Smoc-Cl 2 precipitated as solid. The crude product was filtered, washed 
twice with DCM, and dried in vacuo and the used 1,2-dichlorethane was regenerated. Smoc-Cl 
2 was obtained as a slightly yellow powder (yield ~75%). 
HR-MS calc. for C15H11ClO8S2 m/z: 416.95111, meas. 416.95146 [M-H]-. 
1H NMR (500 MHz, CD3CN) δ: 4.55 (t, J = 5.7 Hz, 1H), 4.90 (d, J = 5.7 Hz, 2H), 8.00 (d, 
J = 8.1 Hz, 2H), 8.08 (d, J = 8.1 Hz, 2H), 8.18 (s, 2H). 
13C NMR (126 MHz, CD3CN): δ 47.80, 72.67, 122.98, 124.48, 128.13, 140.82, 144.97, 145.68, 
151.05. 
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7.4. Synthesis of Nα-Smoc amino acids 
 
7.4.1. General procedure 
Typically, 1 eq. of the corresponding amino acid was dissolved in water and 1 eq. Smoc-Cl 2 
was added to the solution. The pH of the solution was adjusted to 8.5 to allow the formation of 
the Nα-Smoc amino acid. After 30 minutes, the reaction mixture was frozen and lyophilized, 
with subsequent isolation by preparative HPLC, giving the respective Smoc-protected amino 
acid as a white or slightly white powder after freeze-drying (yields > 85%). 
7.4.2. Synthesis of Smoc-L-Ala-OH 3 
 
Scheme 27: Synthesis of Smoc-L-Ala-OH 3. 
According to the general procedure, 2.00g (22.45 mmol, 1 eq.) L-alanine 78 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 10.72g (87.2%) of Smoc-L-alanine 3 were obtained as 
a white powder.  
RP-HPLC (gradient normalized B): tR = 12.54 min. 
ESI-MS calc. for C18H17NO10S2 m/z: 471.45, meas. 470.17 [M+H]-; calc. 235.73, meas. 234.84 
[M+H]2-. 
HR-MS calc. for C18H17NO10S2 m/z: 472.03666, meas. 472.03698 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.22 (d, J = 7.4 Hz, 3H), 3.95 (q, J = 7.3 Hz, 1H), 4.23 (t, 
J = 5.5 Hz, 1H), 4.38 (dd, J = 10.9, 5.7 Hz, 1H), 4.49 (dd, J = 10.9, 5.4 Hz, 1H), 7.52 (br, 
NH), 7.68 (d, J = 7.9 Hz, 2H), 7.83 (d, J = 7.9 Hz, 2H), 7.89 (s, 1H), 7.91 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 16.83, 47.02, 49.27, 65.14, 119.47, 121.97, 122.01, 125.31, 
140.52, 143.99, 144.17, 147.16, 155.93, 174.24. 
7.4.3. Synthesis of Smoc-D-Ala-OH 4 
 
Scheme 28: Synthesis of Smoc-D-Ala-OH 4. 
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According to the general procedure, 2.00g (22.45 mmol, 1 eq.) D-alanine 79 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 10.58g (86.9%) of Smoc-D-alanine 4 were obtained as 
a white powder.  
RP-HPLC (normalized B): tR = 12.29 min. 
ESI-MS calc. for C18H17NO10S2 m/z: 471.45, meas. 470.05 [M+H]-; calc. 235.73, meas. 234.92 
[M+H]2-. 
HR-MS calc. for C15H11ClO8S2 m/z: 470.0221, meas. 470.02370 [M-H]-. 
1H NMR (500 MHz, DMSO-d6) δ: 1.22 (d, J = 7.3 Hz, 3H), 3.95 (q, J = 7.3 Hz, 1H), 4.23 (t, 
J = 5.5 Hz, 1H), 4.37 (dd, J = 11.0, 5.7 Hz, 1H), 4.38 (dd, J = 10.9, 5.5 Hz, 1H), 7.5 (br, NH), 
7.68 (d, J = 8.2 Hz, 2H), 7.83 (d, J = 7.9 Hz, 2H), 7.89 (s, 1H), 7.91 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 16.82, 47.01, 49.26, 65.11, 119.43, 121.94, 125.28, 140.49, 
143.97, 144.15, 147.19, 155.91, 174.22. 
7.4.4. Synthesis of Smoc-L-Arg-OH 5 
 
Scheme 29: Synthesis of Smoc-L-Arg-OH 5. 
According to the general procedure, 3.91g (22.45 mmol, 1 eq.) L-arginine 80 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 11.55g (85.7%) of Smoc-L-arginine-OH 5 were 
obtained as a white powder.  
RP-HPLC (normalized B): tR = 12.88 min. 
ESI-MS calc. for C21H24N4O10S2 m/z: 556.56, meas. 555.4 [M-H]-; calc. 278.28, meas. 277.3 
[M-H]2-. 
HR-MS calc. for C21H24N4O10S2 m/z: 557.10066, meas. 557.10069 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.47 (m, 2H), 1.56, 1.72 (m, 2H), 3.02 (dq, J = 13.0, 6.5 Hz, 
1H), 3.10 (dq, J = 13.0, 6.5 Hz, 1H), 3.96 (dt, J = 9.2, 4.3 Hz, 1H), 4.32 (t, J = 5.5, 21), 4.33 
(dd, J = 10.0, 6.3 Hz, 1H), 4.54 (dd, J = 10.0, 6.3 Hz, 1H), 7.52 (d, J = 8.5 Hz, NH), 7.70 (d, 
J = 7.7, 2H), 7.74 (t, J = 5.6 Hz, NH), 7.85, 7.86 (d, J = 7.9, 2H), 7.88 (s, 1H), 7.93 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 24.93, 27.87, 40.00, 46.91, 52.91, 64.85, 119.60, 125.30, 
140.61, 143.51, 144.50, 146.76, 155.93, 156.63, 173.30. 
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7.4.5. Synthesis of Smoc-L-Arg(Pbf)-OH 6 
 
Scheme 30: Synthesis of Smoc-L-Arg(Pbf)-OH 6. 
According to the general procedure, 3.00g (7.27 mmol, 1 eq.) L-Arg(Pbf)-OH 81 and 3.03g 
(7.27 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water acetonitrile mixture (2:1) and 
sodium hydrogen carbonate was added to adjust the pH to 8.5. The reaction mixture was stirred 
at ambient temperature and the solvent was removed by lyophilization. The product was 
isolated by preparative RP-HPLC (gradient 10 to 100% B). After work up, 5.19g (85.1%) of 
Smoc-L-Arg(Pbf)-OH 6 were obtained as a slightly yellow powder.  
RP-HPLC (10 to 100% B): tR = 14.70 min. 
ESI-MS calc. for C33H38N4O13S3 m/z: 808.89, meas. 807.19 [M-H]-; calc. 404.45, meas. 403.46 
[M-2H]2-. 
HR-MS calc. for C33H38N4O13S3 m/z: 809.18268, meas. 809.18227 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1,41 (s, 6H), 1.47 (m, 2H), 1.56 – 1.64 (m, 2H), 2.01 (s, 6H), 
2.43 (s, 6H), 2.48 (s, 6H), 3.07 (q, J = 7.3 Hz, 2H), 2.97 (s, 2H), 3.96 (td, J = 9.1, 4.7 Hz, 
1H), 4.3 (t, J = 5.5 Hz, 1H), 4.32 (m, 1H), 4.51 (m, 1H), 7.68 (d,d J = 7.8, 1.4 Hz, 2H), 7.52 
(br, NH), 7.74 (t, J = 5.6 Hz, NH), 7.84 (d, J = 7.9, 2H), 7.88 (s, 1H), 7.91 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 12.22, 17.51, 18.91, 25.10, 27.80, 28.25, 39.71, 42.35; 46.92, 
53.17, 64.98, 86.32, 116.34, 119.54, 122.03, 124.33, 125.28, 131.42, 133.90, 137.32, 140.55, 
143.58, 144.39, 146.91, 155.96, 157.57, 166.74, 173.35. 
7.4.6. Synthesis of Smoc-L-Asn-OH 7 
 
Scheme 31: Synthesis of Smoc-L-Asn-OH 7. 
According to the general procedure, 3.37g (22.45 mmol, 1 eq.) L-asparagine 82 (mono hydrate) 
and 9.36g (22.45 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen 
carbonate was added to adjust the pH to 8.5. The reaction mixture was stirred at ambient 
temperature and the solvent was removed by lyophilization. The product was isolated by 
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preparative RP-HPLC (gradient normalized B). After work up, 12.03g (90.4%) of 
Smoc-L-asparagine-OH 7 were obtained as a white powder.  
RP-HPLC (normalized B): tR = 10.76 min. 
ESI-MS calc. for C19H18N2O11S2 m/z: 514.48, meas. 513.20 [M-H]-; calc. 257.24, meas. 256.30 
[M-2H]2-. 
HR-MS calc. for C19H18N2O11S2 m/z: 515.04248, meas. 515.04298 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 2.43 (dd, J = 15.2, 7.5 Hz, 1H), 2.54 (dd, J = 15.2, 5.8 Hz, 
1H), 4.26 (t, 1H), 4.27 (m, 1H), 4.42 (m, 2H), 5.6 (br, NH), 7.40 (d, J = 8.2 Hz, 1H), 7.69 (d, 
J = 7.5 Hz, 2H), 7.84 (d, J = 7.9 Hz, 1H), 7.90 (s, 1H), 7.91 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 36.78, 46.06, 50.71, 65.25, 119.57, 122.11, 125.37, 140.59, 
144.03, 144.14, 146.99, 155.83, 171.56, 172.83.  
7.4.7. Synthesis of Smoc-L-Asp(OtBu)-OH 8 
 
Scheme 32: Synthesis of Smoc-L-Asp(OtBu)-OH 8. 
According to the general procedure, 4.00g (21.14 mmol, 1 eq.) L-Asp(OtBu)-OH 83 and 8.81g 
(21.14 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 40ml water and sodium hydrogen carbonate 
was added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature 
and the solvent was removed by lyophilization. The product was isolated by preparative RP-
HPLC (gradient 0 to 60% B). After work up, 11.32g (86.7%) of Smoc- L-Asp(OtBu)-OH 8 were 
obtained as a white powder.  
RP-HPLC (0 to 60% B): tR = 15.14 min. 
ESI-MS calc. for C23H25NO12S2 m/z: 571.57, meas. 570.08 [M-H]-; calc. 285.79, meas. 284.84 
[M-2H]2-. 
HR-MS calc. for C23H25NO12S2 m/z: 610.04498, meas. 610.04568 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.38 (s, 9H), 2.40 (dd, J = 14.7, 7.8 Hz, 1H), 2.59 (dd, 
J = 14.7, 5.4 Hz, 1H), 3.97 (dt, J = 7.5, 5.3 Hz, 1H), 4.22 (m, 2H), 4.23 (m, 1H), 6.80 (d, 
J = 7.5 Hz, NH), 7.69 (d, J = 7.7 Hz, 2H), 7.83 (d, J = 7.9 Hz, 2H),7.89 (s, 1H), 7.94 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 27.78, 39.54, 46.62, 52.92, 65.47, 79.10, 119.35, 122.31, 
122.45, 125.25, 140.31, 143.78, 144.15, 147.26, 155.36, 170.72, 172.58.  
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7.4.8. Synthesis of Smoc-L-Cys(Trt)-OH 9 
 
Scheme 33: Synthesis of Smoc- L-Cys(Trt)-OH 9. 
According to the general procedure, 4.00g (11.00 mmol, 1 eq.) L-Cys(Trt)-OH 84 and 4.59g 
(11.00 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 40ml water acetonitrile mixture (1:1) and 
sodium hydrogen carbonate was added to adjust the pH to 8.5. The reaction mixture was stirred 
at ambient temperature and the solvent was removed by lyophilization. The product was 
isolated by preparative RP-HPLC (30 to 100% B). After work up, 7.40g (85.1%) of 
Smoc-L-Cys(Trt)-OH 9 were obtained as a white powder.  
RP-HPLC (10 to 100% B): tR = 16.94 min. 
ESI-MS calc. for C37H31NO10S3 m/z: 745.83, meas. 744.18 [M-H]-; calc. 372.92, meas. 371.96 
[M-2H]2-. 
HR-MS calc. for C37H31NO10S m/z: 744.10373, meas. 744.10393 [M-H]-. 
1H NMR (500 MHz, DMSO-d6) δ: 2.38 (dd, J = 12.4, 5.0 Hz, 1H), 2.56 (dd, J = 12.6, 9.6 Hz, 
1H), 3.77 (m, 1H), 4.37 (dd, J = 11.1; 5.8 Hz, 1H), 4.20 (t, J = 5.6 Hz, 1H ), 4.41 (dd, J = 11.5, 
6.5 Hz, 1H), 6.6 (d, J = 8.4 Hz, NH), 7.24 (t, J = 6.9 Hz, 3H), 7.3 (m, 12H), 7.68 (d, J = 7.9 
Hz, 2H), 7.82 (d, J = 7.8 Hz, 2H), 7.90 (s, 1H), 7.91 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 32.52, 47.0, 53.58, 65.57, 66.28, 119.35, 122.0, 125.30, 126.67, 
128.0, 129.0, 140.36, 143.97, 144.21, 147.4, 155.94, 171.63.  
7.4.9. Synthesis of Smoc-L-Gln-OH 10 
 
Scheme 34: Synthesis of Smoc-L-Gln-OH 10. 
According to the general procedure, 3.28g (22.45 mmol, 1 eq.) L-glutamine 85 and 9.36g 
(22.45 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate 
was added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature 
and the solvent was removed by lyophilization. The product was isolated by preparative RP-
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HPLC (gradient normalized B). After work up, 12.24g (90.8%) of Smoc-L-Gln-OH 10 were 
obtained as a white powder.  
RP-HPLC (normalized B): tR = 11.38 min. 
ESI-MS calc. for C20H20N2O11S2 m/z: 528.50, meas. 527.20 [M-H]-; calc. 264.25, meas. 263.30 
[M-2H]2-. 
HR-MS calc. for C20H20N2O11S2 m/z: 529.05813, meas. 529.05847 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.68 (m, 1H), 1.99 (m, 1H), 2.16 (ddd, J = 9.5, 6.8, 3.2 Hz, 
2H), 3.88 (dt, J = 10.4, 5.0 Hz, 1H), 4.27 (t, J = 6.0 Hz, 1H), 4.32 (dd, J = 10.7, 5.7 Hz, 1H), 
4.45 (dd, J = 10.7, 6.8 Hz, 1H), 7.54 (d, J = 7.7 Hz, NH), 7.69 (d, J = 7.8 Hz, 2H), 7.84 (d, 
J = 7.9 Hz, 2H), 7.90 (s, 1H), 7.93 (s, 1H).  
13C NMR (126 MHz, DMSO) δ: 26.16, 31.23, 46.86, 53.47, 65.18, 119.48, 122.15, 125.32, 
140.45, 140.50, 143.67, 144.32, 147.12, 156.12, 173.58, 173.68. 
7.4.10. Synthesis of Smoc-L-Glu(OtBu)-OH 11 
 
Scheme 35: Synthesis of Smoc-L-Glu(OtBu)-OH 11. 
According to the general procedure, 4.50g (22.14 mmol, 1 eq.) L-Glu(OtBu)-OH 86 and 9.23g 
(22.14 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate 
was added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature 
and the solvent was removed by lyophilization. The product was isolated by preparative RP-
HPLC (gradient 0 to 60% B). After work up, 12.29g (88.2%) of Smoc-L-Glu(OtBu)-OH 11 were 
obtained as a white powder.  
RP-HPLC (0 to 60% B): tR = 16.31 min. 
ESI-MS calc. for C24H27NO12S2 m/z: 585.60, meas. 584.08 [M-H]-; calc. 292.80, meas. 291.85 
[M-2H]2-. 
HR-MS calc. for C24H27NO12S2 m/z: 608.08669, meas. 608.08709 [M+H]+; calc. 624.06063 
meas. 624.06093 [M+K]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.38 (s, 9H), 1.78 (tt, J = 12.1, 5.6, 1H), 1.90 (tt, J = 10.7, 
5.2, 1H), 2.12 (ddd, J = 16.0, 10.8, 5.3 Hz, 1H), 2.23 (ddd, J = 16.1, 10.9, 5.5 Hz, 1H), 3.65 
(q, J = 6.0 Hz, 1H), 4.23 (m, 3H), 6.63 (d, J = 6.7 Hz, NH), 7.69 (d, J = 8.0 Hz, 2H), 7.83 (d, 
J = 8.0 Hz, 2H), 7.89 (s, 1H), 7.94 (s, 1H).  
13C NMR (126 MHz, DMSO) δ: 27.73, 27.96, 30.73, 46.20, 54.80, 65.20, 79.13; 119.30, 122.30, 
125.00, 140.31, 143.95, 147.20, 155.50, 172.40, 173.50.  
    
Page 94 
7.4.11. Synthesis of Smoc-Gly-OH 12 
 
Scheme 36: Synthesis of Smoc-Gly-OH 12. 
According to the general procedure, 1.69g (22.45 mmol, 1 eq.) glycine 87 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 10.55g (93.7%) of Smoc-Gly-OH 12 were obtained as 
a white powder.  
RP-HPLC (normalized B): tR = 11.48 min. 
ESI-MS calc. for C17H15NO10S2 m/z: 457.42, meas. 456.17 [M-H]-; calc. 228.71, meas. 227.84 
[M-2H]2-. 
HR-MS calc. for C17H15NO10S2 m/z: 458.02101, meas. 458.02086 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 3.61 (s, 2H), 4.25 (t, J = 5.7 Hz, 1H), 4.43 (d, J = 5.8 Hz, 
2H), 7.49 (br, NH), 7.69 (d, J = 7.9, 2H), 7.85 (d, J = 7.9 Hz, 2H), 7.91 (s, 2H). 
13C NMR (126 MHz, DMSO) δ: 42.15, 46.97, 65.37, 119.56, 122.05, 125.36, 140.59, 144.11, 
147.04, 156.52, 171.39. 
7.4.12. Synthesis of Smoc-L-His-OH 13 
 
Scheme 37: Synthesis of Smoc-L-His-OH 13. 
According to the general procedure, 3.48g (22.45 mmol, 1 eq.) L-histidine 88 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 12.06g (92.4%) of Smoc-L-His-OH 13 were obtained 
as a white powder.  
RP-HPLC (normalized B): tR = 11.90 min. 
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ESI-MS calc. for C21H19N3O10S2 m/z: 537.51, meas. 536.40 [M-H]-; calc. 268.76, meas. 267.80 
[M-2H]2-. 
HR-MS calc. for C21H19N3O10S2 m/z: 538.05846, meas. 538.05888 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 2.94 (dd, J = 15.0, 7.9 Hz, 1H), 3.13 (dd, J = 15.0, 4.4 Hz, 
1H), 4.23 (m, 1H), 4.33 (dd, J = 10.8, 5.3 Hz, 1H), 4.41 (dd, J = 10.8, 6.8 Hz, 1H), 7.27 (s, 
1H), 7.66 (d, J = 8.8 Hz, NH), 7.71 (d, J = 7.9 Hz, 2H), 7.84 (s, 1H), 7.85 (d, J = 7.9 Hz, 2H), 
7.92 (s, 1H), 8.92 (s, 1H). 
13C NMR (126 MHz, DMSO) δ 26.03, 46.69, 52.73, 65.12, 117.38, 119.65, 121.90, 122.00, 
125.36, 129.28, 133.71, 140.57, 140.66, 143.60, 144.34, 146.86, 155.78, 171.97. 
7.4.13. Synthesis of Smoc-L-His(Trt)-OH 14 
 
Scheme 38: Synthesis of Smoc-L-His(Trt)-OH 14. 
According to the general procedure, 2.89g (7.27 mmol, 1 eq.) L-His(Trt)-OH 89 and 3.03g (7.27 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 50ml water acetonitrile mixture (1:1) and sodium 
hydrogen carbonate was added to adjust the pH to 8.5. The reaction mixture was stirred at 
ambient temperature and the solvent was removed by lyophilization. The product was isolated 
by preparative RP-HPLC (30 to 100% B). After work up, 5.19g (86.6%) of Smoc-L-His(Trt)-OH 
14 were obtained as a white powder.  
RP-HPLC (10 to 100% B): tR = 15.28 min. 
ESI-MS calc. for C40H33N3O10S2 m/z: 779.84, meas. 778.19 [M-H]-; calc. 389.92, meas. 388.86 
[M-2H]2-. 
HR-MS calc. for C40H33N3O10S2 m/z: 780.16801, meas. 780.16788 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 2.65 (dd, J = 14.9, 8.6 Hz, 1H), 2.99 (dd, J = 14.8, 4.6 Hz, 
1H), 3.94 (m, 1H), 3.96 (m, 1H), 4.13 (m, 1H), 4.19 (t, J = 6.3 Hz, 1H), 6.97 (br, NH), 7.06 
(m, 9H), 7.22 (br, 1H), 7.37 (m, 6H), 7.69 (d, J = 7.7 Hz, 2H), 7.84 (d, J = 7.7 Hz, 2H), 7.89 
(s, 1H), 7.99 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 31.95, 46.9, 55.81, 65.23, 74.38, 118.80, 119.10, 122.30, 
125.60, 127.50, 128.5, 128.9, 137.50, 138.30, 140.80, 142.40, 143.76, 144.00, 147.65, 156.0, 
171.29.  
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7.4.14. Synthesis of Smoc-L-Ile-OH 15 
 
Scheme 39: Synthesis of Smoc-L-Ile-OH 15. 
According to the general procedure, 2.94g (22.45 mmol, 1 eq.) L-isoleucine 90 and 9.36g 
(22.45 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water acetonitrile mixture (3:1) and 
sodium hydrogen carbonate was added to adjust the pH to 8.5. The reaction mixture was stirred 
at ambient temperature and the solvent was removed by lyophilization. The product was 
isolated by preparative RP-HPLC (gradient normalized B). After work up, 11.13g (88.9%) of 
Smoc-L-isoleucine 15 were obtained as a white powder.  
RP-HPLC (normalized B): tR = 17.12 min. 
ESI-MS calc. for C21H23NO10S2 m/z: 513.53, meas. 512.17 [M-H]-; calc. 256.77, meas. 255.84 
[M-2H]2-. 
HR-MS calc. for C21H23NO10S2 m/z: 514.08361, meas. 514.08407 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 0.81 (d, J = 7.4 Hz, 3H), 0.84 (d, J = 6.9 Hz, 3H), 1.17 (ddq, 
J = 13.6, 8.9, 7.3 Hz, 1H), 1.39 (ddq, J = 13.6, 7.4, 4.5 Hz, 1H), 1.75 (m, 1H), 3.87 (t, J = 6.5 
Hz, 1H), 4.23 (t, J = 5.8 Hz, 1H), 4.37 (dd, J = 10.9, 5.7 Hz, 1H), 4.86 (dd, J = 10.9, 5.9 Hz, 
1H), 7.46 (d, J = 8.1 Hz, NH), 7.68 (dd, J = 7.9, 1.2 Hz, 2H), 7.83 (d, J = 7.9 Hz, 2H), 7.92 
(s, 2H). 
13C NMR (126 MHz, DMSO) δ: 11.22, 15.48, 24.88, 35.72, 47.11, 58.68, 65.46, 119.44, 122.09, 
125.31, 140.48, 144.03, 144.16, 147.15, 147.17, 156.44, 173.06. 
7.4.15. Synthesis of Smoc-L-Leu-OH 16 
 
Scheme 40: Synthesis of Smoc-L-Leu-OH 16. 
According to the general procedure, 2.94g (22.45 mmol, 1 eq.) L-leucine 91 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water acetonitrile mixture (3:1) and sodium 
hydrogen carbonate was added to adjust the pH to 8.5. The reaction mixture was stirred at 
ambient temperature and the solvent was removed by lyophilization. The product was isolated 
by preparative RP-HPLC (gradient normalized B). After work up, 11.33g (90.6%) of 
Smoc-L-leucine 16 were obtained as a white powder.  
RP-HPLC (normalized B): tR = 17.52 min. 
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ESI-MS calc. for C21H23NO10S2 m/z: 513.53, meas. 512.17 [M-H]-; calc. 256.77, meas. 255.84 
[M-2H]2-. 
HR-MS calc. for C21H23NO10S22 m/z: 514.08361, meas. 514.08410 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 0.83 (d, J = 6.5 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H), 1.41 (ddd, 
J = 13.5, 9.0, 4.9 Hz, 1H), 1.53 (ddd, J = 13.5, 10.2, 5.1 Hz, 1H), 1.61 (m, 1H), 3.93 (dt, 
J = 10.7, 5.4 Hz, 1H), 4.22 (t, J = 5.6 Hz, 1H), 4.38 (dd, J = 11.0, 5.6 Hz, 1H), 4.46 (dd, 
J = 11.0, 5.6 Hz, 1H), 7.51 (d, J = 7.9 Hz, NH), 7.68 (d, J = 8.0, 2H), 7.83 (d, J = 8.0 Hz, 
2H), 7.90 (s, 1H), 7.91 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 21.28, 22.78, 24.17, 39.5, 47.06, 52.28, 65.35, 119.37, 122.00, 
125.27, 140.42, 144.01, 144.09, 147.29, 156.29, 174.17.  
7.4.16. Synthesis of Smoc-D-Leu-OH 17 
 
Scheme 41: Synthesis of Smoc-D-Leu-OH 17. 
According to the general procedure, 2.94g (22.45 mmol, 1 eq.) D-leucine 92 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water acetonitrile mixture (3:1) and sodium 
hydrogen carbonate was added to adjust the pH to 8.5. The reaction mixture was stirred at 
ambient temperature and the solvent was removed by lyophilization. The product was isolated 
by preparative RP-HPLC (gradient normalized B). After work up, 11.10g (88.7%) of 
Smoc-D-leucine 17 were obtained as a white powder.  
RP-HPLC (normalized B): tR = 17.70 min. 
ESI-MS calc. for C21H23NO10S2 m/z: 513.53, meas. 512.07 [M-H]-; calc. 256.77, meas. 255.84 
[M-2H]2-. 
HR-MS calc. for C15H11ClO8S2 m/z: 512.0691, meas. 512.0739 [M-H]-. 
1H NMR (500 MHz, DMSO-d6) δ: 0.82 (d, J = 6.6 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H), 1.41 (ddd, 
J = 13.7, 9.0, 4.9 Hz, 1H), 1.52 (ddd, J = 13.7, 10.1, 5.1 Hz, 1H), 1.61 (m, 1H), 3.92 (dd, 
J = 9.7, 4.8 Hz, 1H), 4.23 (t, J = 5.6 Hz, 1H), 4.39 (dd, J = 11.0, 5.6 Hz, 1H), 4.47 (dd, 
J = 11.0, 5.7 Hz, 1H), 7.51 (br, NH), 7.69 (d, J = 8.0, 2H), 7.85 (dd, J = 8.0, 1.5 Hz, 2H), 
7.92 (s, 1H), 7.93 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 21.33, 22.83, 24.23, 39.56, 47.12, 52.32, 65.35, 119.56, 122.07, 
125.36, 140.61, 144.14, 144.23, 146.96, 146.99, 156.33, 174.23.   
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7.4.17. Synthesis of Smoc-L-Lys(Boc)-OH 18 
 
Scheme 42: Synthesis of Smoc-L-Lys(Boc)-OH 18. 
According to the general procedure, 5.53g (22.45 mmol, 1 eq.) L-Lys(Boc)-OH 93 and 9.36g 
(22.45 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate 
was added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature 
and the solvent was removed by lyophilization. The product was isolated by preparative RP-
HPLC (0 to 60% B). After work up, 13.20g (87.4%) of Smoc-L-Lys(Boc)-OH 18 were obtained 
as a white powder. 
RP-HPLC (0 to 60% B): tR = 16.96 min. 
ESI-MS calc. for C26H32N2O12S2 m/z: 628.66, meas. 627.09 [M-H]-; calc. 314.33, meas. 313.35 
[M-2H]2-. 
HR-MS calc. for C26H32N2O12S2 m/z: 629.14694, meas. 629.14704 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.22 (m, 2H), 1.33 (m, 11H), 1.54 (m, 1H), 1.64 (dq, 
J = 10.3, 5.4 Hz, 1H), 2.86 (dt, J = 7.4, 6.9 Hz, 2H), 3.61 (q, J = 6.1 Hz, 1H), 4.23 (m, 2H), 
4.24 (t, 1H), 6.56 (br, NH), 6.69 (br, NH), 7.68 (dd, J = 7.9, 1.4 Hz, 2H), 7.82 (d, J = 7.9 Hz, 
2H), 7.88 (s, 1H), 7.93 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 22.53, 28.24, 29.60, 32.44, 40.03, 46.75, 55.58, 65.30, 77.14, 
119.33, 122.26, 122.38, 125.22, 140.30, 143.92, 144.08, 147.24, 147.31, 155.24, 155.45, 
173.58.  
7.4.18. Synthesis of Smoc-L-Met-OH 19 
 
Scheme 43: Synthesis of Smoc-L-Met-OH 19. 
According to the general procedure, 3.35g (22.45 mmol, 1 eq.) L-methionine 94 and 9.36g 
(22.45 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate 
was added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature 
and the solvent was removed by lyophilization. The product was isolated by preparative RP-
HPLC (gradient normalized B). After work up, 12.29g (95.1%) of Smoc-L-Met-OH 19 were 
obtained as a white powder.  
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RP-HPLC (normalized B): tR = 15.27 min. 
ESI-MS calc. for C20H21NO10S3 m/z: 531.57, meas. 530.10 [M-H]-; calc. 265.79, meas. 264.80 
[M-2H]2-. 
HR-MS calc. for C20H21NO10S3 m/z: 432.04004, meas. 432.04046 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.87 (m, 2H), 2.01 (s, 3H), 2.47 (m, 2H), 4.03 (dt, J = 7.7, 
5.6 Hz, 1H), 4.24 (t, J = 5.7 Hz, 1H), 4.38 (dd, J = 10.9, 5.6 Hz, 1H), 4.47 (dd, J = 10.9, 5.9 
Hz, 1H), 7.60 (d, J = 7.6 Hz, NH), 7.69 (dd, J = 7.9, 1.2 Hz, 2H), 7.84 (d, J = 7.9 Hz, 2H), 
7.91 (s, 1H), 7.92 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 14.53, 29.83, 30.31, 47.06, 52.93, 65.33, 119.53, 122.10, 
125.36, 140.56, 144.02, 144.18, 156.33, 173.50.  
7.4.19. Synthesis of Smoc-L-Phe-OH 20 
 
Scheme 44: Synthesis of Smoc-L-Phe-OH 20. 
According to the general procedure, 3.71g (22.45 mmol, 1 eq.) L-Phe 95 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 12.44g (93.7%) of Smoc-L-Phe-OH 20 were obtained 
as a white powder.  
RP-HPLC (normalized B): tR = 18.32 min. 
ESI-MS calc. for C24H21NO10S2 m/z: 547.55, meas. 546.20 [M-H]-; calc. 273.76, meas. 272.80 
[M-2H]2-. 
HR-MS calc. for C24H21NO10S2 m/z: 548.06796, meas. 548.06857 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 2.88 (dd, J = 13.8, 9.5 Hz, 1H), 2.99 (dd, J = 13.8, 5.3 Hz, 
1H), 4.12 (m, 1H), 4.16 (t, J = 5.5 Hz, 1H), 4.33 (dd, J = 11.0, 5.8 Hz, 1H), 4.38 (dd, J = 11.0, 
5.7 Hz, 1H), 7.15 (t, J = 7.2 Hz, 1H), 7.22 (d, J = 7.4 Hz, 2H), 7.26 (t, J = 7.5 Hz, 2H), 7.61 
(d, J = 8.1 Hz, NH), 7.69 (dd, J = 7.9, 1.2 Hz, 2H), 7.83 (d, J = 7.9 Hz, 2H), 7.90 (s, 2H). 
13C NMR (126 MHz, DMSO) δ: 36.43, 47.05, 55.65, 65.37, 119.43, 122.02, 122.08, 125.31, 
126.22, 128.19, 129.06, 137.81, 140.44, 143.99, 144.05, 147.20, 156.05, 173.02.  
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7.4.20. Synthesis of Smoc-L-Pro-OH 21 
 
Scheme 45: Synthesis of Smoc-L-Pro-OH 21. 
According to the general procedure, 2.58g (22.45 mmol, 1 eq.) L-Pro 96 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 10.43g (85.8%) of Smoc-L-Pro-OH 21 were obtained 
as a white powder.  
RP-HPLC (normalized B): tR = 13.50 min. 
ESI-MS calc. for C20H19NO10S2 m/z: 497.49, meas. 496.17 [M-H]-; calc. 248.75, meas. 247.84 
[M-2H]2-. 
HR-MS calc. for C20H19NO10S2 m/z: 498.05231, meas. 498.05248 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.85 (m, 3H),  2.21 (m, 1H), 3.41 (m, 2H), 4.17 (dd, J = 8.6, 
3.2 Hz, 1H), 4.20 – 4.30 (m, 2H), 4.29 (t, J = 5.6 Hz, 1H), 7.68 (dd, J = 7.9, 1.4 Hz, 2H), 7.84 
(d, J = 7.9 Hz, 2H), 7.91 (d, J = 1.4 Hz, 1H), 7.92 (d, J = 1.4 Hz, 1H).  
13C NMR (126 MHz, DMSO) δ: 23.90, 29.34, 46.47, 58.85, 119.49, 122.42, 125.30, 140.43, 
143.66, 143.90, 147.17, 153.84, 173.50. 
7.4.21. Synthesis of Smoc-L-Ser-OH 22 
 
Scheme 46: Synthesis of Smoc-L-Ser-OH 22. 
According to the general procedure, 2.36g (22.45 mmol, 1 eq.) L-Ser-OH 97 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 10.74g (90.0%) of Smoc-L-Ser-OH 22 were obtained 
as a white powder.  
RP-HPLC (normalized B): tR = 11.30 min. 
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ESI-MS calc. for C18H17NO11S2 m/z: 487.45, meas. 486.20 [M-H]-; calc. 243.73, meas. 242.80 
[M-2H]2-. 
HR-MS calc. for C18H17NO11S2 m/z: 488.03158, meas. 488.03176 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 3.62 (dd, J = 11.3, 5.3 Hz, 1H), 3.65 (dd, J = 11.3, 4.2 Hz, 
1H), 4.00 (t, J = 5.2 Hz, 1H), 4.01 (br, OH), 4.25 (t, J = 5.7 Hz, 1H), 4.41 (dd, J = 11.0, 5.6 
Hz, 1H), 4.47 (dd, J = 11.0, 6.0 Hz, 1H), 7.14 (br, NH), 7.69 (dd, J = 7.9, 1.5 Hz, 2H), 7.84 
(d, J = 7.9 Hz, 2H), 7.90 (s, 1H), 7.92 (s, 1H).  
13C NMR (126 MHz, DMSO) δ: 46.96, 56.72, 61.27, 65.29, 119.53, 122.00, 122.07, 125.32, 
140.54, 143.92, 144.20, 147.10, 156.01, 171.94. 
7.4.22. Synthesis of Smoc-L-Ser(tBu)-OH 23 
 
Scheme 47: Synthesis of Smoc-L-Ser(tBu)-OH 23. 
According to the general procedure, 3.62g (22.45 mmol, 1 eq.) L-Ser(tBu)-OH 98 and 9.36g 
(22.45 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate 
was added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature 
and the solvent was removed by lyophilization. The product was isolated by preparative RP-
HPLC (gradient 0 to 60% B). After work up, 11.59g (87.9%) of Smoc-L-Ser(tBu)-OH 23 were 
obtained as a white powder.  
RP-HPLC (0 to 60% B): tR = 14.36 min. 
ESI-MS calc. for C22H25NO11S2 m/z: 543.56, meas. 542.08 [M-H]-; calc. 271.78, meas. 270.84 
[M-2H]2-. 
HR-MS calc. for C22H25NO11S m/z: 544.09418, meas. 544.09431 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.10 (s, 9H), 3.54 (dd, J = 9.5, 4.9 Hz, 1H), 3.57 (dd, J = 9.5, 
5.5 Hz, 1H),  4.08 (dt, J = 8.0, 5.2 Hz, 1H), 4.23 (t, J = 5.9 Hz, 1H), 4.37 (dd, J = 10.9, 5.9 
Hz, 1H), 4.42 (dd, J = 10.9, 6.0 Hz, 1H), 7.17 (d, J = 8.1 Hz, NH), 7.69 (d, J = 7.9 Hz, 2H), 
7.82 (d, J = 7.9 Hz, 2H), 7.92 (s, 2H).  
13C NMR (126 MHz, DMSO) δ: 27.14, 46.94, 54.90, 61.23, 65.60, 72.78, 119.32, 122.08, 
125.29, 140.33, 143.87, 143.94, 147.43, 156.01, 171.79.  
    
Page 102 
7.4.23. Synthesis of Smoc-L-Thr-OH 24 
 
Scheme 48: Synthesis of Smoc-L-Thr-OH 24. 
According to the general procedure, 2.67g (22.45 mmol, 1 eq.) L-Thr-OH 99 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(normalized B). After work up, 11.30 (92.2%) of Smoc-L-Thr-OH 24 were obtained as a white 
powder.  
RP-HPLC (gradient normalized B): tR = 12.07 min. 
ESI-MS calc. for C19H19NO11S2 m/z: 501.48, meas. 500.07 [M-H]-; calc. 250.74, meas. 249.84 
[M-2H]2-. 
HR-MS calc. for C19H19NO11S2 m/z: 502.04723, meas. 502.04749 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.07 (d, J = 6.5 Hz, 3H), 3.92 (dd, J = 8.1, 3.8 Hz, 1H), 4.02 
(qd, J = 6.5, 3.7 Hz, 1H), 4.25 (t, J = 6.0 Hz, 1H), 4.39 (dd, J = 10.9, 5.7 Hz, 1H), 4.46 (dd, 
J = 10.9, 6.1 Hz, 1H), 6.83 (d, J = 8.7 Hz, NH), 7.69 (d, J = 7.9 Hz, 2H), 7.83 (d, J = 7.9 Hz, 
2H), 7.91 (s, 1H), 7.92 (s, 1H).  
13C NMR (126 MHz, DMSO) δ: 20.32, 46.95, 60.18, 65.52, 66.44, 119.43, 122.07, 125.30, 
140.44, 143.86, 144.07, 147.22, 156.38, 172.09.  
7.4.24. Synthesis of Smoc-L-Thr(tBu)-OH 25 
 
Scheme 49: Synthesis of Smoc-L-Thr(tBu)-OH 25. 
According to the general procedure, 3.93g (22.45 mmol, 1 eq.) L-Thr(tBu)-OH 100 and 9.36g 
(22.45 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate 
was added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature 
and the solvent was removed by lyophilization. The product was isolated by preparative RP-
HPLC (0 to 60% B). After work up, 12.05 (89.2%) of Smoc-L-Thr(tBu)-OH 25 were obtained as 
a white powder.  
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RP-HPLC (0 to 60% B): tR = 15.14 min. 
ESI-MS calc. for C23H27NO11S2 m/z: 557.59, meas. 556.08 [M-H]-; calc. 278.80, meas. 277.74 
[M-2H]2-. 
HR-MS calc. for C23H27NO11S2 m/z: 580.09177 meas. 580.09193 [M+Na]+; m/z: calc. 
596.06571 meas. 596.06589 [M+K]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.05 (d, J = 6.2 Hz, 3H), 1.10 (s, 9H), 3.59 (dd, J = 8.7, 3.3 
Hz, 1H), 3.96 (dq, J = 6.2, 3.4 Hz, 1H), 4.23 (m, 3H), 6.18 (d, J = 8.7 Hz, NH), 7.69 (dd, 
J = 7.9, 1.5 Hz, 2H), 7.83 (d, J = 7.9 Hz, 2H), 7.90 (s, 1H), 7.96 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 21.08, 28.56, 46.54, 61.82, 65.58, 68.37, 72.43, 119.56, 122.60, 
122.70, 125.55, 140.28, 143.95, 147.19, 156.10, 173.00.  
7.4.25. Synthesis of Smoc-L-Trp-OH 26 
 
Scheme 50: Synthesis of Smoc-L-Trp-OH 26. 
According to the general procedure, 4.48g (22.45 mmol, 1 eq.) L-Trp-OH 101 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 12.84g (90.7%) of Smoc-Trp-OH 26 were obtained as 
a white powder.  
RP-HPLC (normalized B): tR = 19.55 min. 
ESI-MS calc. for C26H22N2O10S2 m/z: 586.59, meas. 585.20 [M-H]-; calc. 293.30, meas. 292.30 
[M-2H]2-. 
HR-MS calc. for C26H22N2O10S2 m/z: 587.07886, meas. 587.07914 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 2.95 (dd, J = 14.6, 9.9 Hz, 1H), 3.16 (dd, J = 14.6, 4.5 Hz, 
1H), 4.12 (dt, J = 9.0, 4.5 Hz, 1H), 4.21 (t, J = 5.8 Hz, 1H), 4.29 (dd, J = 10.8, 5.5 Hz, 1H), 
4.40 (dd, J = 10.8, 6.1 Hz, 1H), 6.96 (t, J = 7.4 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 7.14 (s, 
1H), 7.29 (d, J = 7.5 Hz, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.69, 7.70 
(dd, J = 7.9, 2.5 Hz, 2H), 7.82, 7.83 (dd, J = 7.9, 2.5 Hz, 2H), 7.90 (s, 1H), 7.93 (s, 1H), 10.87 
(s, NH). 
13C NMR (126 MHz, DMSO) δ: 26.53, 45.18, 46.90, 65.28, 109.67, 111.33, 117.81, 118.18, 
119.54, 120.64, 122.02, 124.31, 125.32, 125.35, 127.04, 135.84, 140.54, 140.57, 143.96, 
144.25, 147.00, 147.07, 155.96, 173.47. 
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7.4.26. Synthesis of Smoc-L-Trp(Boc)-OH 27 
 
Scheme 51: Synthesis of Smoc-L-Trp(Boc)-OH 27. 
According to the general procedure, 3.00g (9.86 mmol, 1 eq.) L-Trp(Boc)-OH 102 and 4.11g 
(9.86 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate 
was added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature 
and the solvent was removed by lyophilization. The product was isolated by preparative RP-
HPLC (gradient 0 to 80% B). After work up, 6.26g (86.9%) of Smoc-Trp(Boc)-OH 27 were 
obtained as a white powder.  
RP-HPLC (0 to 100% B): tR = 15.14 min. 
ESI-MS calc. for C31H30N2O12S2 m/z: 686.70, meas. 685.08 [M-H]-; calc. 343.35, meas. 342.36 
[M-2H]2-. 
HR-MS calc. for C31H30N2O12S2 m/z: 685.11679, meas. 685.11674 [M-H]-. 
1H NMR (500 MHz, DMSO-d6) δ: 1.61 (s, 9H), 2.97 (dd, J = 14.6, 6.3 Hz, 1H), 3.16 (dd, 
J = 14.6, 5.4 Hz, 1H), 3.93 (q, J = 6.1 Hz, 1H), 4.18 (s, 3H), 6.72 (d, J = 6.8 Hz, 1H), 7.21 (t, 
J = 7.4 Hz, 2H), 7.26 (t, J = 7.7 Hz, 1H), 7.43 (s, 1H), 7.64 (d, J = 7.7 Hz, 1H), 7.69 (d, 
J = 7.9 Hz, 4H), 7.82 (d, J = 7.9 Hz, 3H), 7.87 (s, 1H), 7.94 (s, 1H), 8.00 (d, J = 8.2 Hz, 1H).  
13C NMR (126 MHz, DMSO) δ: 27.4, 27.69, 55.99, 65.18, 83.24, 110.23, 114.30, 118.13, 
118.55, 119.29, 119.37, 122.21, 122.30, 122.5, 123.48, 123.91, 125.2, 130.90, 134.56, 137.32, 
138.88, 142.08, 147.77, 149.10, 173.45. 
7.4.27. Synthesis of Smoc-L-Tyr-OH 28 
 
Scheme 52: Synthesis of Smoc-L-Tyr-OH 28. 
According to the general procedure, 4.07g (22.45 mmol, 1 eq.) L-Tyr-OH 103 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
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solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 12.24g (89.7%) of Smoc-L-Tyr-OH 28 were obtained 
as a white powder.  
RP-HPLC (normalized B): tR = 15.65 min. 
ESI-MS calc. for C24H21NO11S2 m/z: 563.55, meas. 562.20 [M-H]-; calc. 281.77, meas. 280.80 
[M-2H]2-. 
HR-MS calc. for C24H21NO11S2 m/z: 564.06288, meas. 564.06314 [M+H]+; m/z: calc. 
586.04482 meas. 586.04494 [M+Na]+. 
1H NMR (500 MHz, DMSO-d6) δ: 2.74 (dd, J = 13.9, 9.3 Hz, 1H), 2.86 (dd, J = 13.9, 5.4 Hz, 
1H), 4.03 (q, J = 7.1 Hz, 1H), 4.18 (t, J = 5.7 Hz, 1H), 4.33 (dd, J = 11.0, 5.8 Hz, 1H), 4.39 
(dd, J = 11.0, 5.7 Hz, 1H), 6.64 (d, J = 8.1 Hz, 2H), 6.98 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 8.0 
Hz, NH), 7.69 (d, J = 8.0 Hz, 2H), 7.84 (d, J = 7.9 Hz, 2H), 7.90 (s, 2H), 8.15 (s, OH).  
13C NMR (126 MHz, DMSO) δ: 35.74, 47.06, 56.00, 65.33, 115.05, 119.50, 122.05, 125.34, 
127.80, 129.97, 140.52, 144.10, 147.06, 147.13, 155.77, 156.05, 173.19. 
7.4.28. Synthesis of Smoc-L-Tyr(tBu)-OH 29 
 
Scheme 53: Synthesis of Smoc-L-Tyr(tBu)-OH 29. 
According to the general procedure, 5.33g (22.45 mmol, 1 eq.) L-Tyr(tBu)-OH 104 and 9.36g 
(22.45 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate 
was added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature 
and the solvent was removed by lyophilization. The product was isolated by preparative RP-
HPLC (gradient 0 to 60% B). After work up, 13.61g (91.4%) of Smoc-L-Tyr(tBu)-OH 29 were 
obtained as a white powder.  
RP-HPLC (0 to 60% B): tR = 17.95 min. 
ESI-MS calc. for C28H29NO11S2 m/z: 619.66, meas. 618.09 [M-H]-; calc. 309.83, meas. 308.85 
[M-2H]2-. 
HR-MS calc. for C28H29NO11S2 m/z: 620.12548, meas. 620.12539 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 1.21 (s, 9H), 2.79 (dd, J = 13.6, 7.1 Hz, 1H), 3.00 (dd, 
J = 13.6, 4.9 Hz, 1H), 3.83 (q, J = 6.6 Hz, 1H), 4.14 (m, 3H), 6.51 (d, J = 7.2 Hz, NH), 6.78 
(d, J = 8.0 Hz, 2H), 7.07 (d, J = 8.1 Hz, 2H), 7.68 (d, J = 8.0 Hz, 2H), 7.81 (d, J = 8.0 Hz, 
2H), 7.86 (s, 1H), 7.92 (s, 1H).  
13C NMR (126 MHz, DMSO) δ: 28.54, 37.56, 46.53, 57.47, 65.34, 77.37, 119.48, 122.71, 
123.09, 125.50, 129.71, 134.06, 140.24, 143.89, 147.78, 152.97, 155.31, 173.08. 
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7.4.29. Synthesis of Smoc-L-Val-OH 30 
 
Scheme 54: Synthesis of Smoc-L-Val-OH 30. 
According to the general procedure, 2.63g (22.45 mmol, 1 eq.) L-Val-OH 105 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 10.64g (87.2%) of Smoc-L-Val-OH 30 were obtained 
as a white powder.  
RP-HPLC (normalized B): tR = 15.04 min. 
ESI-MS calc. for C20H21NO10S2 m/z: 499.51, meas. 498.20 [M-H]-; calc. 249.76, meas. 248.80 
[M-2H]2-. 
HR-MS calc. for C20H21NO10S2 m/z: 500.06796 meas. 500.06823 [M+H]+. 
1H NMR (500 MHz, DMSO-d6) δ: 0.87 (d, J = 6.8 Hz, 6H), 2.00 (oct, J = 13.9 Hz, 1H), 2.86 
(dd, J = 13.9, 5.4 Hz, 1H),  3.81 (t, J = 6.7 Hz, 1H), 4.23 (t, J = 5.7 Hz, 1H), 4.38 (dd, 
J = 11.0, 5.7 Hz, 1H), 4.46 (dd, J = 11.0, 5.9 Hz, 1H), 7.46 (d, J = 8.3 Hz, NH), 7.68 (dd, 
J = 8.0, 1.3 Hz, 2H), 7.83 (d, J = 8.0 Hz, 2H), 7.92 (s, 1H), 7.93 (s, 1H).  
13C NMR (126 MHz, DMSO) δ: 18.40, 19.08, 29.41, 47.13, 59.82, 65.45, 119.45, 122.10, 
125.31, 140.48, 144.02, 144.18, 147.13, 156.53, 173.07.  
7.4.30. Synthesis of Smoc-β-Ala-OH 31 
 
Scheme 55: Synthesis of Smoc-β-Ala-OH 31. 
According to the general procedure, 2.03g (22.45 mmol, 1 eq.) β-Ala-OH 106 and 9.36g (22.45 
mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water and sodium hydrogen carbonate was 
added to adjust the pH to 8.5. The reaction mixture was stirred at ambient temperature and the 
solvent was removed by lyophilization. The product was isolated by preparative RP-HPLC 
(gradient normalized B). After work up, 10.71g (92.5%) of Smoc-β-Ala-OH 31 were obtained 
as a white powder.  
RP-HPLC (normalized B): tR = 12.12 min. 
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ESI-MS calc. for C18H17NO10S2 m/z: 471.45, meas. 470.20 [M-H]-; calc. 235.73, meas. 234.80 
[M-2H]2-. 
HR-MS calc. for C18H17NO10S2 m/z: 470.02211, meas. 470.02236 [M-H]-. 
1H NMR (500 MHz, DMSO-d6) δ: 2.36 (t, J = 7.3 Hz, 2H), 3.14 (t, J = 7.4 Hz, 2H), 4.22 (t, 
J = 5.7 Hz, 1H), 4.42 (d, J = 5.7 Hz, 2H), 7.19 (br, NH), 7.67 (d, J = 8.0 Hz, 2H), 7.81 (d, 
J = 7.9 Hz, 2H), 7.87 (s, 2H). 
13C NMR (126 MHz, DMSO) δ: 34.01, 36.48, 47.00, 64.86, 119.34, 121.92, 125.21, 140.39, 
144.01, 147.28, 155.99, 173.58.  
7.4.31. Synthesis of Smoc-Aib-OH 32 
 
Scheme 56: Synthesis of Smoc-Aib-OH 32. 
According to the general procedure, 1.00g (9.55 mmol, 1 eq.) 2-aminoisobutyric acid 107 and 
3.98g (9.55 mmol, 1 eq.) Smoc-Cl 2 were dissolved in 30ml water acetonitrile mixture (1:1) 
and sodium hydrogen carbonate was added to adjust the pH to 8.5. The reaction mixture was 
stirred at ambient temperature and the solvent was removed by lyophilization. The product was 
isolated by preparative RP-HPLC (50 to 100% B). After work up, 2.93g (57.8%) of Smoc-Aib-
OH 32 were obtained as a white powder.  
RP-HPLC (normalized B): tR = 13.49 min. 
ESI-MS calc. for C19H19NO10S2 m/z: 485.48, meas. 484.20 [M-H]-; calc. 242.74, meas. 241.80 
[M-2H]2-. 
HR-MS calc. for C19H19NO10S2 m/z: 484.03776, meas. 484.03817 [M-H]-. 
1H NMR (500 MHz, DMSO-d6) δ: 1.29 (s, 6H), 4.21 (t, J = 5.5 Hz, 1H), 4.41 (d, J = 5.3 Hz, 
2H), 7.44 (br, NH), 7.67 (d, J = 7.8 Hz, 2H), 7.82 (d, J = 7.8 Hz, 2H), 7.89 (s, 2H).  
13C NMR (126 MHz, DMSO) δ: 24.97, 47.05, 55.20, 64.80, 119.35, 121.97, 125.23, 140.43, 
144.04, 147.23, 155.06, 175.60. 
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7.5. Deprotection studies 
 
Scheme 57: Deprotection of the Nα-Smoc protecting group. 
Deprotection studies were performed with 15mg of Smoc-Arg-OH 5, Smoc-Leu-OH 16 and 
Smoc-Tyr-OH 28 upon the addition of 1 ml of the respective base (20% piperidine in water; 
10% ethanolamine in water and ethanol; 1M NaOH in water and ethanol; 0.2M NaOH in water; 
5% piperazine in water and 10% ammonia in water) to 15 mg of the respective amino acid. The 
resulting mixture was incubated under shaking for 5 min at ambient temperature. Mixtures of 
ethanol and Nα-Smoc amino acids gave a suspension due to a low solubility in pure ethanol. 
After 5min the deprotection progress was monitored by HPLC. 
7.6. Stability of Smoc-protected amino acids 
To determine the stability of Nα-Smoc protected amino acids under reaction conditions, 3mg of 
Smoc-Arg-OH 5, Smoc-Ile-OH 15, Smoc-Phe-OH 20, Smoc-Pro-OH 21 or Smoc-Ser-OH 22 were 
dissolved in 0.1 ml water and 3eq. NaHCO3 were added to each sample. The solutions were 
stored at ambient temperature and monitored by analytical RP-HPLC after 7, 14 and 21 days. 
7.7. Coupling efficiency in solution and solvent influence 
 
Scheme 58: Synthesis of Smoc-L-Pro-L-Tyr-OMe 36. 
For all coupling tests 1 eq. Smoc-Pro-OH 21, 1.2 eq. H-Tyr-OMe 35, 1 eq. NaHCO3 and either 
1.5 eq. EDCI-HCl 37 with 1 eq. of the following ester-forming reagents NHS 38, Oxyma 39, 
HOPO 40, HONB 41 or 1.5 eq. of EEDQ 42, DMT-MM 43 or COMU 44 were dissolved in 3 mL 
of the following solvent systems: water, 30% aq. MeCN, 30% aq. ethanol, 30% aq. isopropanol, 
10% aq. Me-THF, 30% Me-THF/water (biphasic) and 30% ethyl acetate/water (biphasic). After 
that time, the reaction progress was monitored by RP-HPLC. 
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7.8. SPPS coupling efficiency: Test with Oxyma 39 and HOPO 40 
 
Figure 46: Smoc-LAGV-NH2 47 synthesis with EDC-HCl 37 and Oxyma 39/HOPO 40. 
Peptide synthesis was carried out in a plastic syringe attached to a vacuum manifold to remove 
excess of reagents and solvents rapidly. The synthesis was carried out on 100 mg ChemMatrix 
H-Rink amide resin (loading capacity 0.4-0-6 mmol/g, 0.05 mmol; calculated on average 
loading). The resin was swollen for 2h in either water or 30% MeCN(aq) and loaded in double 
coupling (2×25min) using a solution of Nα-Smoc amino acid (3 eq.), EDC-HCl 37 (5.5 eq.), 
Oxyma 39 (3 eq.) or HOPO 40 (3 eq.) and NaHCO3 (3 eq.) as base in 6 mL water or 30% 
MeCN(aq). Then the resin was washed with water twice followed by Smoc deprotection in 1M 
NaOH for 5 and 10 minutes with subsequent wash with water (2 times 5 mL). The coupling 
step of the next Nα-Smoc amino acid followed. After the chain assembly, the peptide was cleaved 
from the resin (without drying step) with TFA:H2O (98:2) at ambient temperature for 2 h. The 
crude peptides 47 were precipitated in ice-cold diethyl ether, dried, dissolved in water and 
isolated by lyophilization. Analysis was performed by LC-MS and reverse-phase HPLC. 
47 using EDC-HCl 37/Oxyma 39 activation: 
Yield in water: 19 mg (51% calculated on average loading) 
Yield in 30% MeCN(aq): 24 mg (65% calculated on average loading) 
47 using EDC-HCl 37/HOPO 40 activation: 
Yield in water: 18 mg (49% calculated on average loading) 
Yield in 30% MeCN(aq): 17 mg (46% calculated on average loading) 
RP-HPLC (normalized B): tR = 15.3 min. 
ESI-MS calc. for C31H40N4O13S2 m/z: 740.80 meas. 738.18 [M-2H]-, calc. 370.40 meas. 368.86 
[M-2H]2-. 
7.9. Peptide synthesis 
 
7.9.1. General procedure for peptide synthesis 
Peptide synthesis was carried out in a plastic syringe attached to a vacuum manifold to remove 
excess of reagents and solvents rapidly. The synthesis was conducted either on ChemMatrix 
H-Rink amide resin (loading capacity 0.4-0-6 mmol/g), HMPB-ChemMatrix resin (loading 
capacity 0.3-0.65 mmol/g) or on a commercially available preloaded HMPB resin; all resins 
were swollen for 2h in water. The first amino acid was attached by double coupling (2×25min) 
using a solution of Nα-Smoc amino acid (3 eq.), EDC-HCl 37 (5.5 eq.), Oxyma 39 (3 eq.) and 
NaHCO3 (3 eq.) as base in 6 mL water or its mixture with organic solvent. The resin was washed 
with water twice followed by Smoc deprotection with either 1M NaOH, 25% aq. ethanolamine 
or 5-10% aq. piperazine for 5 and 10 minutes (depending on the used resin). Afterwards the 
resin was washed twice with water followed by coupling of the next amino acid until the desired 
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peptide was completed. If not otherwise mentioned, the peptide was cleaved from the resin 
upon treatment with TFA:H2O:TES (96:2:2) at RT for 1 h. The crude peptide was precipitated 
in ice-cold diethyl ether, dried, dissolved in water or aqueous acetonitrile and isolated by 
lyophilization. Analysis was performed by LC MS and reverse-phase HPLC. 
7.9.2. Synthesis of H-AGELS-NH2 (Pentapeptide-31) 48 
 
Figure 47: H-AGELS-NH2 (Pentapeptide-31) 48. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 500 mg H-Rink amide-ChemMatrix (0.40-0.60 mmol/g, 0.25 mmol; calculated on average 
loading) in water. Preloading and coupling were performed according to the general procedure 
for 45 min at ambient temperature, deprotection of the Smoc protecting group was performed 
with 1M NaOH(aq). The crude peptide 48 was precipitated in ice-cold diethyl ether, dried, 
dissolved in water and isolated by lyophilization. Analysis was performed by LC MS and reverse-
phase HPLC. 
Yield: 13.72 mg (57.71% calculated on average loading) 
RP-HPLC (0 to 60% B): tR = 11.18 min. 
ESI-MS calc. for C19H34N6O8 m/z: 474.52 meas. 475.37 [M+H]+. 
7.9.3. Synthesis of H-GPQGPQ-OH (Hexapeptide-9) 49 
 
Figure 48: H-GPQGPQ-OH (Hexapeptide-9) 49. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 200 mg preloaded H-Gln-HMPB-ChemMatrix resin (0.30-0.70 mmol/g, 0.09 mmol; 
calculated on average loading) in water. Coupling was performed according to the general 
procedure for 45 min at ambient temperature, deprotection of the Smoc protecting group was 
performed with 25% ethanolamine(aq). Smoc-glutamine 10 was used without side-chain 
protecting group. The crude peptide 49 was precipitated in ice-cold diethyl ether, dried, 
dissolved in water and isolated by lyophilization. Analysis was performed by LC MS and reverse-
phase HPLC. 
Yield: 9.22 mg (38.7% calculated on average loading) 
RP-HPLC (0 to 60% B): tR = 11.09 min. 
ESI-MS calc. for C24H38N8O9 m/z: 582.62 meas. 581.37 [M-H]-. 
7.9.4. Synthesis of H-EEMQRR-NH2 (Hexapeptide 3) 50 
 
Figure 49: H-EEMQRR-NH2 (Hexapeptide 3) 50. 
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Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg H-Rink amide-ChemMatrix (0.40-0.60 mmol/g, 0.05 mmol; calculated on average 
loading) in water. Preloading and coupling were performed according to the general procedure 
for 45 min at ambient temperature, deprotection of the Smoc protecting group was performed 
with 1M NaOH(aq). Smoc-glutamine 10 and Smoc-arginine 5 were used without side-chain 
protecting groups. The crude peptide 50 was precipitated in ice-cold diethyl ether, dried, 
dissolved in water and isolated by lyophilization. Analysis was performed by LC MS and reverse-
phase HPLC. 
Yield: 21.73 mg (51.31% calculated on average loading). 
RP-HPLC (normalized B): tR = 9.24 min. 
ESI-MS calc. for C32H58N14O11S m/z: 846.96 meas. 847.60 [M+H]+. 
7.9.5. Synthesis of Ac-EEMQRR-NH2 (Acetyl-Hexapeptide 3) 51 
 
Figure 50: Ac-EEMQRR-NH2 (Acetyl-Hexapeptide 3) 51. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg H-Rink amide-ChemMatrix (0.40-0.60 mmol/g, 0.05 mmol; calculated on average 
loading) in water. Preloading and coupling were performed according to the general procedure 
for 45 min at ambient temperature, deprotection of the Smoc protecting group was performed 
with 1M NaOH(aq). Smoc-glutamine 10 and Smoc-arginine 5 were used without side-chain 
protecting groups. The crude peptide 51 was precipitated in ice-cold diethyl ether, dried, 
dissolved in water and isolated by lyophilization. Analysis was performed by LC MS and reverse-
phase HPLC. 
Yield: 18.74 mg (42.16% calculated on average loading). 
RP-HPLC (0 to 60% B): tR = 9.28 min. 
ESI-MS calc. for C34H60N14O12S m/z: 889.00 meas. 889.70 [M+H]+; calc. 444.50 meas. 445.60 
[M+2H]2+. 
7.9.6. Synthesis of Leu-Enkephalin amide 52 
 
Figure 51: Leu-Enkephalin amide 52. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg H-Rink amide-ChemMatrix (0.40-0.60 mmol/g, 0.05 mmol; calculated on average 
loading) in water. Preloading and coupling were performed according to the general procedure 
for 45 min at ambient temperature, deprotection of the Smoc protecting group was performed 
with 1M NaOH(aq). Smoc-tyrosine 28 was used without side-chain protecting group. The crude 
peptide 52 was precipitated in ice-cold diethyl ether, dried, dissolved in water and isolated by 
lyophilization. Analysis was performed by LC MS and reverse-phase HPLC. 
Yield: 19.65mg (70.86% calculated on average loading). 
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RP-HPLC (normalized B): tR = 17.98 min. 
ESI-MS calc. for C28H38N6O6 m/z: 554.65 meas. 555.47 [M+H]+. 
7.9.7. Synthesis of Met-Enkephalin: H-YGGFM-OH 53 
 
Figure 52: Met-Enkephalin 53. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 50 mg preloaded H-Met-HMPB-ChemMatrix resin (0.30-0.70 mmol/g, 0.025 mmol; 
calculated on average loading) in a water MeCN mixture (70:30). Coupling was performed 
according to the general procedure for 45 min at ambient temperature, deprotection of the 
Smoc protecting group was performed with 25% ethanolamine(aq). Peptide 53 was cleaved from 
solid support using 20% HFIP (in DCM)[263] to prevent oxidation of the Met-residue for 120 
min, solvent was removed by rotary evaporator, dissolved in water and isolated by 
lyophilization. Analysis was performed by LC MS and reverse-phase HPLC. 
Yield: 9 mg (63% calculated on average loading) 
RP-HPLC (0 to 60% B): tR = 17.77 min. 
ESI-MS calc. for C27H35N5O7S m/z: 573.67 meas. 574.18 [M+H]+. 
7.9.8. Synthesis of Leu-Enkephalin: H-YGGFL-OH 54 
 
Figure 53: Leu-Enkephalin 54. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 50 mg preloaded H-Leu-HMPB-ChemMatrix resin (0.30-0.70 mmol/g, 0.025 mmol; 
calculated on average loading) in a water MeCN mixture (70:30). Coupling was performed 
according to the general procedure for 45 min at ambient temperature, deprotection of the 
Smoc protecting group was performed with 25% ethanolamine(aq). Smoc-tyrosine 28 was used 
without side-chain protecting group. Peptide 54 was cleaved from solid support using HFIP 
(0.1% HCl)[264] for 120 min, solvent was removed by rotary evaporator, dissolved in water and 
isolated by lyophilization. Analysis was performed by LC MS and reverse-phase HPLC. 
Yield: 10.3 mg (71.82% calculated on average loading) 
RP-HPLC (0 to 60% B): tR = 19.46 min. 
ESI-MS calc. for C28H37N5O7 m/z: 555.63 meas. 556.37 [M+H]+. 
7.9.9. Synthesis of Acyl-Carrier-Protein (ACP) 65-74 peptide: H-VQAAIDYING-OH 55 
 
Figure 54: Acyl-Carrier-Protein (ACP) 65-74: H-VQAAIDYING-OH 55. 
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Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg preloaded H-Gly-HMPB-ChemMatrix resin (0.30-0.65 mmol/g, 0.045 mmol; 
calculated on average loading) in a water MeCN mixture (50:50). Coupling was performed 
according to the general procedure for 25 min at ambient temperature as double coupling step, 
deprotection of the Smoc protecting group was performed with 5% piperazine(aq). Smoc-
tyrosine 28, Smoc-asparagine 7 and Smoc-glutamine 10 were used without side-chain 
protecting groups. Peptide 55 was cleaved from solid support using HFIP with 0.1% HCl[264] for 
120 min. The crude peptide 55 was precipitated in ice-cold diethyl ether, dried, dissolved in 
water and isolated by lyophilization. Analysis was performed by LC MS and reverse-phase 
HPLC. 
Yield: 18 mg (36% calculated on average loading) 
RP-HPLC (10 to 100% B): tR = 11.66 min. 
ESI-MS calc. for C47H75N13O15 m/z: 1062.19 meas. 1063.67 [M+H]+, calc. 531.5 meas. 532.55 
[M+2H]2+. 
7.9.10. Synthesis of Acyl-Carrier-Protein (ACP) 65-74: H-VQAAIDYING-NH2 56 
 
Figure 55: Acyl-Carrier-Protein (ACP) 65-74: H-VQAAIDYING-NH2 56. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg H-Rink amide-ChemMatrix (0.40-0.60 mmol/g, 0.05 mmol; calculated on average 
loading) in a water MeCN mixture (50:50). Preloading and coupling were performed according 
to the general procedure for 25 min at ambient temperature as double coupling step, 
deprotection of the Smoc protecting group was performed with 5% piperazine(aq). Smoc-
-tyrosine 28, Smoc-asparagine 7 and Smoc-glutamine 10 were used without side-chain 
protecting groups. Peptide 56 was cleaved from solid support using TFA:H2O:TES (95:2.5:2.5) 
for 60 min. The crude peptide 56 was precipitated in ice-cold diethyl ether, dried, dissolved in 
water and isolated by lyophilization. Analysis was performed by LC MS and reverse-phase 
HPLC. 
Yield: 23 mg (46% calculated on average loading) 
RP-HPLC (10 to 100% B): tR = 11.57 min. 
ESI-MS calc. for C47H74N12O16 m/z: 1063.18 meas. 1062.67 [M+H]+, calc. 531.59 meas. 532.05 
[M+2H]2+. 
7.9.11. Synthesis of H-GPRP-OH 57 
 
Figure 56: H-GPRP-OH 57. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg preloaded H-Gly-HMPB-ChemMatrix resin (0.30-0.65 mmol/g, 0.045 mmol; 
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calculated on average loading) in water. Coupling was performed according to the general 
procedure for 45 min at ambient temperature, deprotection of the Smoc protecting group was 
performed with 25% ethanolamine(aq). Peptide 57 was cleaved from solid support using HFIP 
with 0.1% HCl[264] for 120 min. The crude peptide 57 was precipitated in ice-cold diethyl ether, 
dried, dissolved in water or aqueous acetonitrile and isolated by lyophilization. Analysis was 
performed by LC MS and reverse-phase HPLC. 
Yield: 8 mg (38% calculated on average loading) 
RP-HPLC (normalized B): tR = 13.29 min. 
ESI-MS calc. for C18H31N7O8 m/z: 425.49 meas. 426.40 [M+H]+, calc. 212.75 meas. 214.00 
[M+2H]2+. 
7.9.12. Synthesis of Smoc-VVIA-NH2 58 
 
Figure 57: Smoc-VVIA amide 58. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg H-Rink amide-ChemMatrix (0.40-0.60 mmol/g, 0.05 mmol; calculated on average 
loading) in water. Coupling was performed according to the general procedure for 45 min at 
ambient temperature, deprotection of the Smoc protecting group was performed with 1M 
NaOH(aq). The final Nα-Smoc protecting group was left on the peptide for an easier HPLC 
detection, Smoc-peptide 58 was cleaved from solid support using TFA:H2O (95:5). The crude 
Smoc-peptide 58 was precipitated in ice-cold diethyl ether, dried, dissolved in water and 
isolated by lyophilization. Analysis was performed by LC MS and reverse-phase HPLC. 
Yield: 26 mg (67% calculated on average loading) 
RP-HPLC (normalized B): tR = 16.45 min. 
ESI-MS calc. for C34H47N5O12S2 m/z: 781.89 meas. 780.40 [M-H]-, calc. 390.20 meas. 390.00 
[M-2H]2-. 
7.9.13. Synthesis of Smoc-DIIW-OH 59 
 
Figure 58: Smoc-DIIW-OH 59. 
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Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg preloaded H-Trp-HMPB-ChemMatrix resin (0.30-0.65 mmol/g, 0.045 mmol; 
calculated on average loading) in water. Coupling was performed according to the general 
procedure for 45 min at ambient temperature, deprotection of the Smoc protecting group was 
performed with 1M NaOH(aq). The final Nα-Smoc protecting group was left on the peptide for 
an easier HPLC detection, Smoc-peptide 59 was cleaved from solid support using HFIP with 
0.1% HCl[264] for 120 min. The crude Smoc-peptide 59 was precipitated in ice-cold diethyl ether, 
dried, dissolved in water and isolated by lyophilization. Analysis was performed by LC MS and 
reverse-phase HPLC. 
Yield: 22 mg (50% calculated on average loading) 
RP-HPLC (normalized B): tR = 16.32 min. 
ESI-MS calc. for C42H49N5O15S2 m/z: 927.99 meas. 928.40 [M-H]-, calc. 464.20 meas. 463.97 
[M-2H]2-. 
7.9.14. Synthesis of Smoc-E(OtBu)K(Boc)R(Pbf)S(tBu)C(Trt)-OH 60 as model for a fully 
protected peptide. 
 
Figure 59: Structure of Smoc-E(OtBu)K(Boc)R(Pbf)S(tBu)C(Trt)-OH 60. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 50 mg preloaded H-Cys(Trt)-HMPB-ChemMatrix resin (0.30-0.65 mmol/g, 0.045 mmol; 
calculated on average loading) in a water MeCN mixture (50:50). Preloading and coupling were 
performed according to the general procedure for 25 min at ambient temperature as double 
coupling step, deprotection of the Smoc protecting group was performed with 5% piperazine(aq). 
The fully protected Peptide 60 was cleaved from solid support using 20% HFIP (in DCM) for 
120 min and solvent removed by rotary evaporator. The crude peptide 60 was dried, dissolved 
in aqueous acetonitrile and isolated by lyophilization. Analysis was performed by LC MS and 
reverse-phase HPLC. 
Yield: 18 mg (44% calculated on average loading) 
RP-HPLC (50 to 100% B): tR = 18.83 min. 
ESI-MS calc. for C19H19NO10S2 m/z: 855.53 meas. 854.30 [M-2H]2-. 
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7.9.15. Synthesis of model peptides 61,62 for racemization tests 
 
Figure 60: Model peptides H-CYEIS-NH2 61 and H-ANKPG-NH2 62 for racemization tests. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg H-Rink amide-ChemMatrix (0.40-0.60 mmol/g, 0.05 mmol; calculated on average 
loading) in a water MeCN mixture (70:30). Preloading and Coupling was performed according 
to the general procedure for 25 min at ambient temperature as double coupling step, 
deprotection of the Smoc protecting group was performed with 1M NaOH(aq). Smoc-asparagine 
7 and Smoc-tyrosine 28 were used without side-chain protecting groups. Peptides 61, 62 were 
cleaved from solid support using TFA:H2O:TES (95:2.5:2.5) for 60 min. The crude peptides 61, 
62 were precipitated in ice-cold diethyl ether, dried, dissolved in water or aqueous acetonitrile 
and isolated by lyophilization. Analysis was performed by LC MS and reverse-phase HPLC. 
H-CYEIS-NH2 61 
Yield: 15mg (48.99% calculated on average loading) 
RP-HPLC (50 to 100% B): tR = 19.21 min. 
ESI-MS calc. for C26H40N6O9S m/z: 612.70 meas. 613.28 [M+H]+. 
H-ANKPG-NH2 62 
Yield: 13mg (53.66% calculated on average loading) 
RP-HPLC (normalized B): tR = 9.94 min. 
ESI-MS calc. for C20H36N8O9 m/z: 484.56 meas. 485.37 [M+H]+.  
Samples 61, 62 as well as Smoc-Asn-OH 7 were sent to C.A.T. GmbH & Co Chromatographie 
und Analysentechnik KG (Tübingen, Germany) for analysis of amino acid racemization. 
7.9.16. Synthesis of Pal-GHK-OH 63 
 
Figure 61: Structure of Pal-GHK-OH 63. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg preloaded H-Lys(Boc)-HMPB-ChemMatrix resin (0.30-0.60 mmol/g, 0.045 mmol; 
calculated on average loading) in a water ethanol mixture (80:20). Coupling was performed 
according to the general procedure for 30 min at ambient temperature, deprotection of the 
Smoc protecting group was performed with 1M NaOH(aq). Palmitoylation was performed with 
palmitic acid (3 eq.), EDC-HCl 37 (5.5 eq.), Oxyma 39 (3 eq.) and NaHCO3 (3 eq.) in ethanol 
water (70:30) at pH 7.2 for 45 min. Washing was performed twice with ethanol water (70:30) 
at pH 7.2 and twice with diethyl ether. Peptide 63 was cleaved from solid support using 95% 
TFA(aq) for 60 min, solvent was removed by lyophilisation.  
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Yield: 14.12 mg (54.23% calculated on average loading) 
RP-HPLC (10 to 60% B): tR = 20.34 min. 
ESI-MS calc. for C30H54N6O5 m/z: 578.80 meas. 579.57 [M+H]+. 
7.9.17. Synthesis of Pal-GQPR-OH 64 
 
Figure 62: Structure of Pal-GQPR-OH 64. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg preloaded H-Arg-HMPB-ChemMatrix resin (0.30-0.60 mmol/g, 0.045 mmol; 
calculated on average loading) in a water ethanol mixture (80:20). Coupling was performed 
according to the general procedure for 30 min at ambient temperature, deprotection of the 
Smoc protecting group was performed with 1M NaOH(aq). Smoc-Glutamine 10 was used without 
side-chain protecting group. Palmitoylation was performed with palmitic acid (3 eq.), EDC-HCl 
37 (5.5 eq.), Oxyma 39 (3 eq.) and NaHCO3 (3 eq.) in ethanol water (70:30) at pH 7.2 for 45 
min. Washing was performed twice with ethanol water (70:30) at pH 7.2 and twice with diethyl 
ether. Peptide 64 was cleaved from solid support using 95% TFA(aq) for 60 min, solvent was 
removed by lyophilisation. 
Yield: 18.68 mg (59.74% calculated on average loading) 
RP-HPLC (0 to 60% B): tR = 20.26 min. 
ESI-MS calc. for C34H62N8O7 m/z: 694.92 meas. 695.66 [M+H]+. 
7.9.18. Synthesis of H-GPRPA-NH2 Vialox (Pentapeptide-3) 65 
 
Figure 63: H-GPRPA-NH2 Vialox (Pentapeptide-3) 65. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg H-Rink amide-ChemMatrix (0.40-0.60 mmol/g, 0.05 mmol; calculated on maximal 
loading) in a water MeCN mixture (70:30). Preloading and coupling were performed according 
to the general procedure for 25 min at ambient temperature, deprotection of the Smoc 
protecting group was performed with 1M NaOH(aq). Peptide 65 was cleaved from solid support 
using TFA:H2O:TES (95:2.5:2.5) for 60 min. The crude peptide 65 was precipitated in ice-cold 
diethyl ether, dried, dissolved in water and isolated by lyophilization. Analysis was performed 
by LC MS and reverse-phase HPLC. 
Yield: 12 mg (48.43% calculated on average loading) 
RP-HPLC (normalized B): tR = 11.35 min. 
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ESI-MS calc. for C21H37N9O5 m/z: 495.59 meas. 496.37 [M+H]+, calc. 247.80 meas. 248.95 
[M+2H]2+. 
7.9.19. Synthesis of Oxytocin 66 
 
Figure 64: Oxytocin 66. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg H-Rink amide-ChemMatrix (0.40-0.60 mmol/g, 0.05 mmol; calculated on average 
loading) in a water MeCN mixture (70:30). Preloading and coupling were performed according 
to the general procedure for 25 min at ambient temperature as double coupling step, 
deprotection of the Smoc protecting group was performed with 1M NaOH(aq). Smoc-tyrosine 
28, Smoc-asparagine 7 and Smoc-glutamine 10 were used without side-chain protecting 
groups. Peptide 66 was cleaved from solid support using TFA:TES:H2O:DTT (90:2.5:2.5:5) for 
60 min. The crude peptide 66 was precipitated in ice-cold diethyl ether, dried, dissolved in 
water and isolated by lyophilization. The disulfide bond was closed in 0.1M NH4HCO3 buffer 
pH 8 in a concentration 1 mg/mL for 3 days at room temperature. Analysis was performed by 
LC MS and reverse-phase HPLC. 
Yield: 18 mg (35.75% calculated on average loading) 
RP-HPLC (10 to 100% B): tR = 11.82 min. 
ESI-MS calc. for C43H66N12O12S2 m/z: 1007.19 meas. 1007.67 [M+H]+, calc. 503.60 meas. 
504.55 [M+2H]2+. 
7.9.20. Synthesis of Vasopressin (peptide hormone) 67 
 
Figure 65: Vasopressin 67. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg H-Rink amide-ChemMatrix (0.40-0.60 mmol/g, 0.05 mmol; calculated on average 
loading) in a water MeCN mixture (70:30). Preloading and coupling were performed according 
to the general procedure for 25 min at ambient temperature as double coupling step, 
deprotection of the Smoc protecting group was performed with 1M NaOH(aq). Smoc-tyrosine 
28, Smoc-asparagine 7 and Smoc-glutamine 10 were used without side-chain protecting 
groups. Peptide 67 was cleaved from solid support using TFA:TES:H2O:DTT (90:2.5:2.5:5) for 
60 min. The crude peptide 67 was precipitated in ice-cold diethyl ether, dried, dissolved in 
water and isolated by lyophilization. The disulfide bond was closed in 0.1M NH4HCO3 buffer 
pH 8 in a concentration 1 mg/mL for 3 days at room temperature. Analysis was performed by 
LC MS and reverse-phase HPLC. 
Yield: 20 mg (39.71% calculated on average loading) 
RP-HPLC (10 to 100% B): tR = 10.47 min. 
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ESI-MS calc. for C46H65N15O12S2 m/z: 1084.24 meas. 1084.57 [M+H]+, calc. 542.12 meas. 
543.05 [M+2H]2+. 
7.9.21. Synthesis of heptaarginine cell-penetrating peptide 68 
 
Figure 66: Heptaarginine cell-penetrating peptide 68. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg H-Rink amide-ChemMatrix (0.40-0.60 mmol/g, 0.05 mmol; calculated on average 
loading) in a water MeCN mixture (70:30). Preloading and coupling were performed according 
to the general procedure for 45 min at ambient temperature, deprotection of the Smoc 
protecting group was performed with 1M NaOH(aq). Smoc-arginine 5 was used without side-
chain protecting groups. Peptide 68 was cleaved from solid support using TFA:H2O: (95:5) for 
60 min. The crude peptide 68 was precipitated in ice-cold diethyl ether, dried, dissolved in 
water or aqueous acetonitrile and isolated by lyophilization. Analysis was performed by LC MS 
and reverse-phase HPLC. 
Yield: 23 mg (41.43% calculated on average loading) 
RP-HPLC (normalized B): tR = 13.86 min. (Smoc-heptaarginine for easier detection) 
ESI-MS calc. for C42H87N29O7 m/z: 1110.35 meas. 1113.27 [M+H]+, calc. 555.18 meas. 557.15 
[M+2H]2+. 
7.9.22. Synthesis of H-Y(D-A)GFL-OH Leuphasyl 69  
 
Figure 67: Leuphasyl 69. 
Peptide synthesis was carried out according to the general procedure. Synthesis was carried out 
on 100 mg preloaded H-Leu-HMPB-ChemMatrix resin (0.30-0.60 mmol/g, 0.045 mmol; 
calculated on average loading) in a water MeCN mixture (80:20). Coupling was performed 
according to the general procedure for 45 min at ambient temperature, deprotection of the 
Smoc protecting group was performed with 1M NaOH(aq). Peptide 69 was cleaved from solid 
support using 1% TFA for 60 min. The crude peptide 69 was precipitated in ice-cold diethyl 
ether, dried, dissolved in water or aqueous acetonitrile and isolated by lyophilization. Analysis 
was performed by LC MS and reverse-phase HPLC. 
Yield: 17.3 mg (57.85% calculated on average loading) 
RP-HPLC (0 to 60% B): tR = 18.7 min. 
ESI-MS calc. for C29H39N5O7 m/z: 569.66 meas. 570.27 [M+H]+. 
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7.9.23. Studies on aspartimide formation  
For aspartimide formation, 4 classic model peptides derived from peptide scorpion toxin II 
(H-VKDGYI-NH2 70, H-VK(D-D)GYI-NH2 71, H-VKNGYI-NH2 72 and H-VK(β-D)GYI-NH2 73) 
were chosen. 
Figure 68: Model peptides for aspartimide formation H-VKDGYI-NH2 70, H-VKNGYI-NH2 72, H-VK(D-D)GYI-NH2 71 
and H-VK(β-D)GYI-NH2 73. 
Synthesis was performed on 200 mg ChemMatrix Rink amide resin (0.4-0.6 mmol/g, 0.23 
mmol; calculated on average loading) by manual standard Fmoc-based SPPS. Afterwards the 
peptide-resins 70-73 were split into 15 equal parts and incubated for 3h and 16h with the 
following bases: 1M NaOH(aq), 1M NaOH in EtOH, 5% piperazine in DMF, 5% piperazine(aq), 
20% piperidine in DMF and 10% ethanolamine(aq). As a reference, a non-incubated resin was 
subjected to global cleavage. After the respective incubation time, the samples were cleaved 
from the resin and analyzed by RP-HPLC and LC-MS. Aspartic acid was added as internal 
standard to all HPLC runs to achieve comparable HPLC retention times. 
Aspartimide tests with model peptides with organic synthesis and incubation with various bases 
for 3h and 16h: 
• Standard 
• 1M NaOH in H2O 
• 1M NaOH in EtOH 
• 5% piperazine in DMF 
• 5% piperazine in H2O 
• 20% piperidine in DMF 
• 10% ethanolamine in H2O 
7.10. Fluorescence monitoring of Nα-Smoc amino acids 
A 100 nM aqueous solutions of all Nα-Smoc amino acids were prepared and transferred to a 
Greiner Bio-One (Kremsmünster, Austria) UV-STAR®, flat-bottom, black 96 well plate for 
fluorescent measurements. Absorbance and fluorescent measurements were performed with a 
CLARIOstar (BMG LABTECH GmbH, Ortenberg, Germany), absorbance was measured in the 
range of 220-700 nm and fluorescence was measured in the range of 300-400nm. 
7.11. Fluorescence monitoring of resin loading and coupling status during ASPPS 
Smoc-Gly-OH 12 was loaded in two different concentrations onto a water-compatible 2-CTC 
resin with DMSO as solvent. The resin was washed thrice with water, suspended in water and 
split into three equal portions that were transferred to a Greiner Bio-One (Kremsmünster, 
Austria) UV-STAR®, flat-bottom, black 96 well plate for fluorescent measurements. The 
fluorescence was measured at the excitation maxima of 280 nm and emission maxima of 
340 nm. 
 
Figure 69: H-LVAIG-NH2 74. 
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H-LVAIG-NH2 74 was synthesized on a Rink amide PEGA resin in water according to the general 
procedure. After each respective coupling or deprotection step, the resin was washed thrice 
with water, suspended in water and split into three equal portions that were transferred to a 
Greiner Bio-One (Kremsmünster, Austria) UV-STAR®, flat-bottom, black 96 well plate for 
fluorescent measurements. After the measurements, the resin was reunited and the synthesis 
continued. 
7.12. Purification by affinity column chromatography 
 
7.12.1. Synthesis of H-GPQGPQ-OH Hexapeptide 9 49 in water  
 
Figure 70: H-GPQGPQ-OH (Hexapeptide-9) 49 for capping experiments. 
Peptide synthesis was carried out according to the general procedure. Synthesis was performed 
on 100 mg preloaded H-Gln-HMPB-ChemMatrix resin (0.30-0.70 mmol/g, 0.05 mmol; 
calculated on average loading) in water. Coupling was performed with 0.95 eq. of Nα-Smoc 
amino acid compared to prior coupling in order to maximize by-product formation, EDC-HCl 
37 (2 eq.), Oxyma 39 (1 eq.) and NaHCO3 (1 eq.) as base in 6 mL water for 25 min at ambient 
temperature. Resin was washed thrice with water followed by capping with sulfoacetic acid 76 
(50 eq.), EDC-HCl 37 (60 eq.), Oxyma 39 (50 eq.) and NaHCO3 (100 eq.) as base for 15 min 
(capping mixture was reused). Deprotection of the Smoc protecting group was performed with 
5% piperazine(aq). Smoc-glutamine 10 was used without sidechain protecting group. Peptide 49 
was cleaved from solid support using TFA:H2O (95:5) for 120 min. The crude mixture was 
analysed by analytical HPLC. Afterwards, the crude mixture was put on a DEAE Sephadex A-25 
ion-exchange column for purification. The column was washed twice with water and an 
additional HPLC of the purified peptide was monitored. 
7.12.2. Synthesis of H-YGGFMRRV-NH2 Adrenorphin 77 in DMF 
 
Figure 71: H-YGGFMRRV-NH2 Adrenorphin 77 for capping experiments in DMF. 
Synthesis was performed on 100 mg ChemMatrix rink amide resin (0.4-0.6 mmol/g, 0.05 mmol; 
calculated on average loading) by manual standard Fmoc-based SPPS in DMF. Coupling was 
performed with 0.95 eq. of Fmoc-amino acid compared to prior coupling in order to maximize 
by-product formation, HBTU (0.95 eq. to the amino acid) and DIPEA (2 eq. to the amino acid) 
as base in 6 mL DMF for 25 min at ambient temperature. Resin was washed thrice with DMF 
followed by capping with an organic 4-sulfobenzoic acid 75 salt in DMF (50 eq.), HBTU (49.8 
eq.) and DIPEA (100 eq.) as base for 15 min (capping mixture was reused). Deprotection of the 
Fmoc-protecting group was performed with 20% piperidine in DMF. Peptide 77 was cleaved 
from solid support using TFA:H2O (95:5) for 120 min. The crude mixture was analysed by 
analytical HPLC. Afterwards, the crude mixture was put on a DEAE Sephadex A-25 ion-
exchange column for purification. The column was washed twice with water and an additional 
HPLC of the purified peptide was monitored.
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8. Supporting information 
8.1. Analytical data of Smoc-Chloride 2 
 
Figure 72: HR-MS of Smoc-chloride 2 (M measured=416.95146 [M-H]-, M calc.=416.95111). 
 
Figure 73: 1H-NMR of Smoc-Cl 2. 
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Figure 74: 13C-NMR of Smoc-Cl 2. 
 
Figure 75: 1H-1H COSY-NMR of Smoc-Cl 2. 
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Figure 76: 1H-13C HSQC-NMR of Smoc-Cl 2. 
 
Figure 77: 1H-13C HMBC-NMR of Smoc-Cl 2. 
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8.2. Amino Acids 
 
8.2.1. Analytical data of Smoc-L-Ala-OH 3 
 
Figure 78: HPLC chromatogram of Smoc-L-Ala-OH 3 at λ=220 nm (0 to 40% MeCN). 
 
Figure 79: HPLC chromatogram of Smoc-L-Ala-OH 3 at λ=280 nm (0 to 40% MeCN). 
 
Figure 80: ESI-MS of Smoc-L-Ala-OH 3 (M measured=470.17[M-H]-, M calc.=471.45). 
 
Figure 81: HR-MS of Smoc-L-Ala-OH 3 (M measured=472.03698 [M+H]+, M calc.=472.03666) 
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Figure 82: Excitation and emission spectra of Smoc-L-Ala-OH 3, excitation and emission have been normalized 
between 0 and 1 for illustration.  
 
Figure 83: 1H-NMR of Smoc-L-Ala-OH 3. 
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Figure 84: 13C NMR of Smoc-L-Ala-OH 3. 
 
Figure 85: 1H-13C HSQC-NMR of Smoc-L-Ala-OH 3. 
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Figure 86: 1H-13C HMBC-NMR of Smoc-L-Ala-OH 3. 
 
8.2.2. Analytical data of Smoc-D-Ala-OH 4 
 
Figure 87: HPLC chromatogram of Smoc-D-Ala-OH 4 at λ=220 nm (0 to 40% MeCN). 
 
Figure 88: HPLC chromatogram of Smoc-D-Ala-OH 4 at λ=280 nm (0 to 40% MeCN). 
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Figure 89: ESI-MS of Smoc-D-Ala-OH 4 (M measured=470.05[M-H]-, M calc.=471.45). 
 
Figure 90: HR-MS of Smoc-D-Ala-OH 4 (M measured=470.02370 [M-H]-, M calc.=470.02211). 
 
Figure 91: Excitation and emission spectra of Smoc-D-Ala-OH 4, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 92: 1H-NMR of Smoc-D-Ala-OH 4. 
 
Figure 93: 13C-NMR of Smoc-D-Ala-OH 4. 
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Figure 94: 1H-13C HSQC-NMR of Smoc-D-Ala-OH 4. 
 
Figure 95: 1H-13C HMBC-NMR of Smoc-D-Ala-OH 4. 
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8.2.3. Analytical data of Smoc-L-Arg-OH 5 
 
Figure 96: HPLC chromatogram of Smoc-L-Arg-OH 5 at λ=220 nm (0 to 40% MeCN). 
 
Figure 97: HPLC chromatogram of Smoc-L-Arg-OH 5 at λ=280 nm (0 to 40% MeCN).
Figure 
98: ESI-MS of Smoc-L-Arg-OH 5 (M measured=555.40 [M-H]-, M calc.=556.56). 
 
Figure 99: HR-MS of Smoc-L-Arg-OH 5 (M measured=557.10069 [M+H]+, M calc.=557.010066). 
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Figure 100: Excitation and emission spectra of Smoc-L-Arg-OH 5, excitation and emission have been normalized 
between 0 and 1 for illustration.  
 
Figure 101: 1H-NMR of Smoc-L-Arg-OH 5. 
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Figure 102: 13C-NMR of Smoc-L-Arg-OH 5. 
 
Figure 103: 1H-13C HSQC-NMR of Smoc-L-Arg-OH 5. 
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Figure 104: 1H-13C HMBC-NMR of Smoc-L-Arg-OH 5. 
8.2.4. Analytical data of Smoc-L-Arg(Pbf)-OH 6 
 
Figure 105: HPLC chromatogram of Smoc-L-Arg(Pbf)-OH 6 at λ=220 nm (10 to 100% MeCN). 
 
Figure 106: HPLC chromatogram of Smoc-L-Arg(Pbf)-OH 6 at λ=280 nm (10 to 100% MeCN). 
 
Figure 107: ESI-MS of Smoc-L-Arg(Pbf)-OH 6 (M measured=807.19 [M-H]-, M calc.=808.89). 
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Figure 108: HR-MS of Smoc-L-Arg(Pbf)-OH 6 (M measured=809.18227 [M+H]+, M calc.=809.18268). 
 
Figure 109: Excitation and emission spectra of Smoc-L-Arg(Pbf)-OH 6, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 110: 1H-NMR of Smoc-L-Arg(Pbf)-OH 6. 
 
Figure 111: 13C-NMR of Smoc-L-Arg(Pbf)-OH 6. 
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Figure 112: 1H-13C HSQC-NMR of Smoc-L-Arg(Pbf)-OH 6. 
 
Figure 113: 1H-13C HMBC-NMR of Smoc-L-Arg(Pbf)-OH 6. 
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8.2.5. Analytical data of Smoc-L-Asn-OH 7 
 
Figure 114: HPLC chromatogram of Smoc-L-Asn-OH 7 at λ=220 nm (0 to 40% MeCN). 
 
Figure 115: HPLC chromatogram of Smoc-L-Asn-OH 7 at λ=280 nm (0 to 40% MeCN). 
Figure 116: ESI-MS of Smoc-L-Asn-OH 7 (M measured=513.20 [M-H]-, M calc.=514.48). 
Figure 117: HR-MS of Smoc-L-Asn-OH 7 (M measured=515.04298 [M+H]+, M calc.=515.04248). 
    
Page 140 Supporting information 
 
Figure 118: Excitation and emission spectra of Smoc-L-Asn-OH 7, excitation and emission have been normalized 
between 0 and 1 for illustration. 
 
Figure 119: 1H-NMR of Smoc-L-Asn-OH 7. 
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Figure 120: 13C-NMR of Smoc-L-Asn-OH 7. 
 
Figure 121: 1H-13C HSQC-NMR of Smoc-L-Asn-OH 7. 
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Figure 122: 1H-13C HMBC-NMR of Smoc-L-Asn-OH 7. 
8.2.6. Analytical data of Smoc-L-Asp(OtBu)-OH 8 
 
Figure 123: HPLC chromatogram of Smoc-L-Asp(OtBu)-OH 8 at λ=220 nm (0 to 60% MeCN). 
 
Figure 124: HPLC chromatogram of Smoc-L-Asp(OtBu)-OH 8 at λ=280 nm (0 to 60% MeCN). 
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Figure 125: ESI-MS of Smoc-L-Asp(OtBu)-OH 8 (M measured=570.08 [M-H]-, M calc.= 571.57).
Figure 126: HR-MS of Smoc-L-Asp(OtBu)-OH 8 (M measured=610.04568 [M+H]+, M calc.=610.04498). 
 
Figure 127: Excitation and emission spectra of Smoc-L-Asp(OtBu)-OH 8, excitation and emission have been 
normalized between 0 and 1 for illustration. 
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Figure 128: 1H-NMR of Smoc-L-Asp(OtBu)-OH 8. 
 
Figure 129: 13C-NMR of Smoc-L-Asp(OtBu)-OH 8. 
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Figure 130: 1H-13C HSQC-NMR of Smoc-L-Asp(OtBu)-OH 8. 
 
Figure 131: 1H-13C HMBC-NMR of Smoc-L-Asp(OtBu)-OH 8. 
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8.2.7. Analytical data of Smoc-L-Cys(Trt)-OH 9 
 
Figure 132: HPLC chromatogram of Smoc-L-Cys(Trt)-OH 9 at λ=220 nm (10 to 100% MeCN). 
 
Figure 133: HPLC chromatogram of Smoc-L- Cys(Trt)-OH 9 at λ=280 nm (10 to 100% MeCN). 
Figure 134: ESI-MS of Smoc-L- Cys(Trt)-OH 9 (M measured=744.18 [M-H]-, M calc.=745.83). 
 
Figure 135: HR-MS of Smoc-L-Cys(Trt)-OH 9 (M measured=744.10393 [M-H]-, M calc.=744.10373). 
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Figure 136: Excitation and emission spectra of Smoc-L-Cys(Trt)-OH 9, excitation and emission have been normalized 
between 0 and 1 for illustration. 
 
Figure 137: 1H-NMR of Smoc-L-Cys(Trt)-OH 9. 
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Figure 138: 13C-NMR of Smoc-L-Cys(Trt)-OH 9. 
 
Figure 139: 1H-13C HSQC-NMR of Smoc-L-Cys(Trt)-OH 9. 
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Figure 140: 1H-13C HMBC-NMR of Smoc-L-Cys(Trt)-OH 9. 
8.2.8. Analytical data of Smoc-L-Gln-OH 10 
 
Figure 141: HPLC chromatogram of Smoc-L-Gln-OH 10 at λ=220 nm (0 to 40% MeCN). 
 
Figure 142: HPLC chromatogram of Smoc-L- Gln-OH 10 at λ=280 nm (0 to 40% MeCN). 
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Figure 143: ESI-MS of Smoc-L- Gln-OH 10 (M measured=527.20 [M-H]-, M calc.=528.50). 
Figure 144: HR-MS of Smoc-L-Gln-OH 10 (M measured=529.05847 [M+H]+, M calc.=529.05813). 
 
Figure 145: Excitation and emission spectra of Smoc-L-Gln-OH 10, excitation and emission have been normalized 
between 0 and 1 for illustration. 
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Figure 146: 1H-NMR of Smoc-L- Gln-OH 10. 
 
Figure 147: 13C-NMR of Smoc-L- Gln-OH 10. 
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Figure 148: 1H-13C HSQC-NMR of Smoc-L- Gln-OH 10. 
 
Figure 149: 1H-13C HMBC-NMR of Smoc-L- Gln-OH 10. 
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8.2.9. Analytical data of Smoc-L-Glu(OtBu)-OH 11 
 
Figure 150: HPLC chromatogram of Smoc-L-Glu(OtBu)-OH 11 at λ=220 nm (0 to 60% MeCN). 
 
Figure 151: HPLC chromatogram of Smoc-L-Glu(OtBu)-OH 11 at λ=280 nm (0 to 60% MeCN). 
 
Figure 152: ESI-MS of Smoc-L-Glu(OtBu)-OH 11 (M measured=584.08 [M-H]-, M calc.=585.60). 
 
Figure 153: HR-MS of Smoc-L-Glu(OtBu)-OH 11 (M measured=608.08669 [M+H]+, M calc.=608.08709). 
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Figure 154: Excitation and emission spectra of Smoc-L-Glu(OtBu)-OH 11, excitation and emission have been 
normalized between 0 and 1 for illustration.  
 
Figure 155: 1H-NMR of Smoc-L-Glu(OtBu)-OH 11. 
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Figure 156: 13C-NMR of Smoc-L-Glu(OtBu)-OH 11. 
 
Figure 157: 1H-13C HSQC-NMR of Smoc-L-Glu(OtBu)-OH 11. 
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Figure 158: 1H-13C HMBC-NMR of Smoc-L-Glu(OtBu)-OH 11. 
8.2.10. Analytical data of Smoc-Gly-OH 12 
 
Figure 159: HPLC chromatogram of Smoc-Gly-OH 12 at λ=220 nm (0 to 40% MeCN). 
 
Figure 160: HPLC chromatogram of Smoc-Gly-OH 12 at λ=280 nm (0 to 40% MeCN). 
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Figure 161: ESI-MS of Smoc-Gly-OH 12 (M measured=456.17 [M-H]-, M calc.=457.42). 
 
Figure 162: HR-MS of Smoc-Gly-OH 12 (M measured=458.02086 [M+H]+, M calc.=458.02101). 
 
Figure 163: Excitation and emission spectra of Smoc-Gly-OH 12, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 164: 1H-NMR of Smoc-Gly-OH 12. 
 
Figure 165: 13C-NMR of Smoc-Gly-OH 12. 
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Figure 166: 1H-13C HSQC-NMR of Smoc-Gly-OH 12. 
 
Figure 167: 1H-13C HMBC-NMR of Smoc-Gly-OH 12. 
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8.2.11. Analytical data of Smoc-L-His-OH 13 
 
Figure 168: HPLC chromatogram of Smoc-L-His-OH 13 at λ=220 nm (0 to 40% MeCN). 
 
Figure 169: HPLC chromatogram of Smoc-L-His-OH 13 at λ=280 nm (0 to 40% MeCN). 
Figure 170: ESI-MS of Smoc-L-His-OH 13 (M measured=534.40 [M-H]-, M calc.=537.51). 
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Figure 171: HR-MS of Smoc-L-His-OH 13 (M measured=538.05888 [M+H]+, M calc.=538.05846). 
 
Figure 172: Excitation and emission spectra of Smoc-L-His-OH 13, excitation and emission have been normalized 
between 0 and 1 for illustration.  
 
Figure 173: 1H-NMR of Smoc-L-His-OH 13. 
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Figure 174: 13C-NMR of Smoc-L-His-OH 13. 
 
Figure 175: 1H-13C HSQC-NMR of Smoc-L-His-OH 13. 
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Figure 176: 1H-13C HMBC-NMR of Smoc-L-His-OH 13. 
8.2.12. Analytical data of Smoc-L-His(Trt)-OH 14 
 
Figure 177: HPLC chromatogram of Smoc-L-His(Trt)-OH 14 at λ=220 nm (10 to 100% MeCN). 
 
Figure 178: HPLC chromatogram of Smoc-L-His(Trt)-OH 14 at λ=280 nm (10 to 100% MeCN). 
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Figure 179: ESI-MS of Smoc-L-His(Trt)-OH 14 (M measured=778.19 [M-H]-, M calc.=779.84). 
 
Figure 180: HR-MS of Smoc-L-His(Trt)-OH 14 (M measured=780.16788 [M+H]+, M calc.=780.16801). 
 
Figure 181: Excitation and emission spectra of Smoc-L-His(Trt)-OH 14, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 182: 1H-NMR of Smoc-L-His(Trt)-OH 14. 
 
Figure 183: 13C-NMR of Smoc-L-His(Trt)-OH 14. 
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Figure 184: 1H-13C HSQC-NMR of Smoc-L-His(Trt)-OH 14. 
 
Figure 185: 1H-13C HMBC-NMR of Smoc-L-His(Trt)-OH 14. 
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8.2.13. Analytical data of Smoc-L-Ile-OH 15 
 
Figure 186: HPLC chromatogram of Smoc-L-Ile-OH 15 at λ=220 nm (0 to 40% MeCN). 
 
Figure 187: HPLC chromatogram of Smoc-L-Ile-OH 15 at λ=280 nm (0 to 40% MeCN). 
Figure 188: ESI-MS of Smoc-L-Ile-OH 15 (M measured=512.17 [M-H]-, M calc.=513.53).
 
Figure 189: HR-MS of Smoc-L-Ile-OH 15 (M measured=514.08407 [M+H]+, M calc.=514.08361). 
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Figure 190: Excitation and emission spectra of Smoc-L-Ile-OH 15, excitation and emission have been normalized 
between 0 and 1 for illustration.  
 
Figure 191: 1H-NMR of Smoc-L-Ile-OH 15. 
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Figure 192: 13C-NMR of Smoc-L-Ile-OH 15. 
 
Figure 193: 1H-13C HSQC-NMR of Smoc-L-Ile-OH 15. 
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Figure 194: 1H-13C HMBC-NMR of Smoc-L-Ile-OH 15. 
8.2.14. Analytical data of Smoc-L-Leu-OH 16 
 
Figure 195: HPLC chromatogram of Smoc-L-Leu-OH 16 at λ=220 nm (0 to 40% MeCN). 
 
Figure 196: HPLC chromatogram of Smoc-L-Leu-OH 16 at λ=280 nm (0 to 40% MeCN). 
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Figure 197: ESI-MS of Smoc-L-Leu-OH 16 (M measured=512.17 [M-H]-, M calc.=513.53). 
 
Figure 198: HR-MS of Smoc-L-Leu-OH 16 (M measured=514.08410 [M+H]+, M calc.=514.08361). 
 
Figure 199: Excitation and emission spectra of Smoc-L-Leu-OH 16, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 200: 1H-NMR of Smoc-L-Leu-OH 16. 
 
Figure 201: 13C-NMR of Smoc-L-Leu-OH 16. 
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Figure 202: 1H-13C HSQC-NMR of Smoc-L-Leu-OH 16. 
 
Figure 203: 1H-13C HMBC-NMR of Smoc-L-Leu-OH 16. 
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8.2.15. Analytical data of Smoc-D-Leu-OH 17 
 
Figure 204: HPLC chromatogram of Smoc-D-Leu-OH 17 at λ=220 nm (0 to 40% MeCN). 
 
Figure 205: HPLC chromatogram of Smoc-D-Leu-OH 17 at λ=280 nm (0 to 40% MeCN). 
Figure 206: ESI-MS of Smoc-D-Leu-OH 17 (M measured=512.07 [M-H]-, M calc.=513.53). 
 
Figure 207: HR-MS of Smoc-D-Leu-OH 17 (M measured=512.0739 [M+H]+, M calc.=512.0691). 
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Figure 208: Excitation and emission spectra of Smoc-D-Leu-OH 17, excitation and emission have been normalized 
between 0 and 1 for illustration.  
 
Figure 209: 1H-NMR of Smoc-D-Leu-OH 17. 
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Figure 210: 13C-NMR of Smoc-D-Leu-OH 17. 
 
Figure 211: 1H-13C HSQC-NMR of Smoc-D-Leu-OH 17. 
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Figure 212: 1H-13C HMBC-NMR of Smoc-D-Leu-OH 17. 
8.2.16. Analytical data of Smoc-L-Lys(Boc)-OH 18 
 
Figure 213: HPLC chromatogram of Smoc-L-Lys(Boc)-OH 18 at λ=220 nm (0 to 60% MeCN). 
 
Figure 214: HPLC chromatogram of Smoc-L-Lys(Boc)-OH 18 at λ=280 nm (0 to 60% MeCN). 
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Figure 
215: ESI-MS of Smoc-L-Lys(Boc)-OH 18 (M measured=627.09 [M-H]-, M calc.=628.66).
Figure 
216: HR-MS of Smoc-L-Lys(Boc)-OH 18 (M measured= 629.14704 [M+H]+, M calc.=629.14694). 
 
Figure 217: Excitation and emission spectra of Smoc-L-Lys(Boc)-OH 18, excitation and emission have been 
normalized between 0 and 1 for illustration.  
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Figure 218: 1H-NMR of Smoc-L-Lys(Boc)-OH 18. 
 
Figure 219: 13C-NMR of Smoc-L-Lys(Boc)-OH 18. 
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Figure 220: 1H-13C HSQC-NMR of Smoc-L-Lys(Boc)-OH 18. 
 
Figure 221: 1H-13C HMBC-NMR of Smoc-L-Lys(Boc)-OH 18. 
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8.2.17. Analytical data of Smoc-L-Met-OH 19 
 
Figure 222: HPLC chromatogram of Smoc-L-Met-OH 19 at λ=220 nm (0 to 40% MeCN). 
 
Figure 223: HPLC chromatogram of Smoc-L-Met-OH 19 at λ=280 nm (0 to 40% MeCN). 
Figure 224: ESI-MS of Smoc-L-Met-OH 19 (M measured=530.10 [M-H]-, M calc.=531.57). 
Figure 225: HR-MS of Smoc-L-Met-OH 19 (M measured=532.04046 [M+H]+, M calc.=532.04004). 
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Figure 226: Excitation and emission spectra of Smoc-L-Met-OH 19, excitation and emission have been normalized 
between 0 and 1 for illustration.  
 
Figure 227: 1H-NMR of Smoc-L-Met-OH 19. 
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Figure 228: 13C-NMR of Smoc-L-Met-OH 19. 
 
Figure 229: 1H-13C HSQC-NMR of Smoc-L-Met-OH 19. 
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Figure 230: 1H-13C HMBC-NMR of Smoc-L-Met-OH 19. 
8.2.18. Analytical data of Smoc-L-Phe-OH 20 
 
Figure 231: HPLC chromatogram of Smoc-L-Phe-OH 20 at λ=220 nm (0 to 40% MeCN). 
 
Figure 232: HPLC chromatogram of Smoc-L-Phe-OH 20 at λ=280 nm (0 to 40% MeCN). 
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Figure 233: ESI-MS of Smoc-L-Phe-OH 20 (M measured=546.20 [M-H]-, M calc.=547.55). 
 
Figure 234: HR-MS of Smoc-L-Phe-OH 20 (M measured=548.06857 [M+H]+, M calc.=548.006796). 
 
Figure 235: Excitation and emission spectra of Smoc-L-Phe-OH 20, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 236: 1H-NMR of Smoc-L-Phe-OH 20. 
 
Figure 237: 13C-NMR of Smoc-L-Phe-OH 20. 
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Figure 238: 1H-13C HSQC-NMR of Smoc-L-Phe-OH 20. 
 
Figure 239: 1H-13C HMBC-NMR of Smoc-L-Phe-OH 20. 
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8.2.19. Analytical data of Smoc-L-Pro-OH 21 
 
Figure 240: HPLC chromatogram of Smoc-L-Pro-OH 21 at λ=220 nm (0 to 40% MeCN). 
 
Figure 241: HPLC chromatogram of Smoc-L-Pro-OH 21 at λ=280 nm (0 to 40% MeCN). 
Figure 242: ESI-MS of Smoc-L-Pro-OH 21 (M measured=496.17 [M-H]-, M calc.=497.49). 
 
Figure 243: HR-MS of Smoc-L-Pro-OH 21 (M measured=498.05248 [M+H]+, M calc.=498.05231). 
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Figure 244: Excitation and emission spectra of Smoc-L-Pro-OH 21, excitation and emission have been normalized 
between 0 and 1 for illustration.  
 
Figure 245: 1H-NMR of Smoc-L-Pro-OH 21. 
    
Page 190 Supporting information 
 
Figure 246: 13C-NMR of Smoc-L-Pro-OH 21. 
 
Figure 247: 1H-13C HSQC-NMR of Smoc-L-Pro-OH 21. 
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Figure 248: 1H-13C HMBC-NMR of Smoc-L-Pro-OH 21. 
8.2.20. Analytical data of Smoc-L-Ser-OH 22 
 
Figure 249: HPLC chromatogram of Smoc-L-Ser-OH 22 at λ=220 nm (0 to 40% MeCN). 
 
Figure 250: HPLC chromatogram of Smoc-L-Ser-OH 22 at λ=280 nm (0 to 40% MeCN). 
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Figure 251: ESI-MS of Smoc-L-Ser-OH 22 (M measured=486.20 [M-H]-, M calc.=487.45).
Figure 252: HR-MS of Smoc-L-Ser-OH 22 (M measured=488.03176 [M+H]+, M calc.=488.03158). 
 
Figure 253: Excitation and emission spectra of Smoc-L-Ser-OH 22, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 254: 1H-NMR of Smoc-L-Ser-OH 22. 
 
Figure 255: 13C-NMR of Smoc-L-Ser-OH 22. 
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Figure 256: 1H-13C HSQC-NMR of Smoc-L-Ser-OH 22. 
 
Figure 257: 1H-13C HMBC-NMR of Smoc-L-Ser-OH 22. 
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8.2.21. Analytical data of Smoc-L-Ser(tBu)-OH 23 
 
Figure 258: HPLC chromatogram of Smoc-L-Ser(tBu)-OH 23 at λ=220 nm (0 to 60% MeCN). 
 
Figure 259: HPLC chromatogram of Smoc-L-Ser(tBu)-OH 23 at λ=280 nm (0 to 60% MeCN). 
Figure 260: ESI-MS of Smoc-L-Ser(tBu)-OH 23 (M measured=542.08 [M-H]-, M calc.=543.56). 
Figure 261: HR-MS of Smoc-L-Ser(tBu)-OH 23 (M measured=544.09431 [M+H]+, M calc.=544.09418). 
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Figure 262: Excitation and emission spectra of Smoc-L-Ser(tBu)-OH 23, excitation and emission have been 
normalized between 0 and 1 for illustration.  
 
Figure 263: 1H-NMR of Smoc-L-Ser(tBu)-OH 23. 
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Figure 264: 13C-NMR of Smoc-L-Ser(tBu)-OH 23. 
 
Figure 265: 1H-13C HSQC-NMR of Smoc-L-Ser(tBu)-OH 23. 
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Figure 266: 1H-13C HMBC-NMR of Smoc-L-Ser(tBu)-OH 23. 
8.2.22. Analytical data of Smoc-L-Thr-OH 24 
 
Figure 267: HPLC chromatogram of Smoc-L-Thr-OH 24 at λ=220 nm (0 to 40% MeCN). 
 
Figure 268: HPLC chromatogram of Smoc-L-Thr-OH 24 at λ=280 nm (0 to 40% MeCN). 
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Figure 269: ESI-MS of Smoc-L-Thr-OH 24 (M measured=500.07 [M-H]-, M calc.=501.48).
Figure 270: HR-MS of Smoc-L-Thr-OH 24 (M measured=502.04749 [M+H]+, M calc.=502.04723). 
 
Figure 271: Excitation and emission spectra of Smoc-L-Thr-OH 24, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 272: 1H-NMR of Smoc-L-Thr-OH 24. 
 
Figure 273: 13C-NMR of Smoc-L-Thr-OH 24. 
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Figure 274: 1H-13C HSQC-NMR of Smoc-L-Thr-OH 24. 
 
Figure 275: 1H-13C HMBC-NMR of Smoc-L-Thr-OH 24. 
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8.2.23. Analytical data of Smoc-L-Thr(tBu)-OH 25 
 
Figure 276: HPLC chromatogram of Smoc-L-Thr(tBu)-OH 25 at λ=220 nm (0 to 60% MeCN). 
 
Figure 277: HPLC chromatogram of Smoc-L-Thr(tBu)-OH 25 at λ=280 nm (0 to 60% MeCN). 
 
Figure 278: ESI-MS of Smoc-L-Thr(tBu)-OH 25 (M measured=556.08 [M-H]-, M calc.=557.59). 
 
Figure 279: HR-MS of Smoc-L-Thr(tBu)-OH 25 (M measured=580.09193 [M+Na]+, M calc.=580.09177; 
M measured=596.06589 [M+K]+, M calc.=596.06571 ). 
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Figure 280: Excitation and emission spectra of Smoc-L-Thr(tBu)-OH 25, excitation and emission have been 
normalized between 0 and 1 for illustration.  
 
Figure 281: 1H-NMR of Smoc-L-Thr(tBu)-OH 25. 
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Figure 282: 13C-NMR of Smoc-L-Thr(tBu)-OH 25. 
 
Figure 283: 1H-13C HSQC-NMR of Smoc-L-Thr(tBu)-OH 25. 
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Figure 284: 1H-13C HMBC-NMR of Smoc-L-Thr(tBu)-OH 25. 
8.2.24. Analytical data of Smoc-L-Trp-OH 26 
 
Figure 285: HPLC chromatogram of Smoc-L-Trp-OH 26 at λ=220 nm (0 to 40% MeCN). 
 
Figure 286: HPLC chromatogram of Smoc-L-Trp-OH 26 at λ=280 nm (0 to 40% MeCN). 
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Figure 287: ESI-MS of Smoc-L-Trp-OH 26 (M measured=585.20 [M-H]-, M calc.=586.59). 
Figure 288: HR-MS of Smoc-L-Trp-OH 26 (M measured=587.07914 [M+H]+, M calc.=587.07886). 
 
Figure 289: Excitation and emission spectra of Smoc-L-Trp-OH 26, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 290: 1H-NMR of Smoc-L-Trp-OH 26. 
 
Figure 291: 13C-NMR of Smoc-L-Trp-OH 26. 
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Figure 292: 1H-13C HSQC-NMR of Smoc-L-Trp-OH 26. 
 
Figure 293: 1H-13C HMBC-NMR of Smoc-L-Trp-OH 26. 
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8.2.25. Analytical data of Smoc-L-Trp(Boc)-OH 27 
 
Figure 294: HPLC chromatogram of Smoc-L-Trp(Boc)-OH 27 at λ=220 nm (0 to 100% MeCN). 
 
Figure 295: HPLC chromatogram of Smoc-L-Trp(Boc)-OH 27 at λ=280 nm ( 0to 100% MeCN). 
 
Figure 296: ESI-MS of Smoc-L-Trp(Boc)-OH 27 (M measured=685.08 [M-H]-, M calc.=686.70). 
 
Figure 297: HR-MS of Smoc-L-Trp(Boc)-OH 27 (M measured=685.11679 [M-H]-, M calc.=685.11674). 
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Figure 298: Excitation and emission spectra of Smoc-L-Trp(Boc)-OH 27, excitation and emission have been 
normalized between 0 and 1 for illustration.  
 
Figure 299: 1H-NMR of Smoc-L-Trp(Boc)-OH 27. 
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Figure 300: 13C-NMR of Smoc-L-Trp(Boc)-OH 27. 
 
Figure 301: 1H-13C HSQC-NMR of Smoc-L-Trp(Boc)-OH 27. 
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Figure 302: 1H-13C HMBC-NMR of Smoc-L-Trp(Boc)-OH 27. 
8.2.26. Analytical data of Smoc-L-Tyr-OH 28 
 
Figure 303: HPLC chromatogram of Smoc-L-Tyr-OH 28 at λ=220 nm (0 to 40% MeCN). 
 
Figure 304: HPLC chromatogram of Smoc-L-Tyr-OH 28 at λ=280 nm (0 to 40% MeCN). 
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Figure 305: ESI-MS of Smoc-L-Tyr-OH 28 (M measured=562.20 [M-H]-, M calc.=563.55). 
 
Figure 306: HR-MS of Smoc-L-Tyr-OH 28 (M measured=564.06314 [M+H]+, M calc.=564.06288). 
 
Figure 307: Excitation and emission spectra of Smoc-L-Tyr-OH 28, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 308: 1H-NMR of Smoc-L-Tyr-OH 28. 
 
Figure 309: 13C-NMR of Smoc-L-Tyr-OH 28. 
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Figure 310: 1H-13C HSQC-NMR of Smoc-L-Tyr-OH 28. 
 
Figure 311: 1H-13C HMBC-NMR of Smoc-L-Tyr-OH 28. 
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8.2.27. Analytical data of Smoc-L-Tyr(tBu)-OH 29 
 
Figure 312: HPLC chromatogram of Smoc-L-Tyr(tBu)-OH 29 at λ=220 nm (0 to 60% MeCN). 
 
Figure 313: HPLC chromatogram of Smoc-L-Tyr(tBu)-OH 29 at λ=280 nm (0 to 60% MeCN). 
 
Figure 314: ESI-MS of Smoc-L-Tyr(tBu)-OH 29 (M measured=618.09 [M-H]-, M calc.=619.66). 
 
Figure 315: HR-MS of Smoc-L-Tyr(tBu)-OH 29 (M measured=620.12539 [M+H]+, M calc.=620.12548). 
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Figure 316: Excitation and emission spectra of Smoc-L-Tyr(tBu)-OH 29, excitation and emission have been 
normalized between 0 and 1 for illustration.  
 
Figure 317: 1H-NMR of Smoc-L-Tyr(tBu)-OH 29. 
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Figure 318: 13C-NMR of Smoc-L-Tyr(tBu)-OH 29. 
 
Figure 319: 1H-13C HSQC-NMR of Smoc-L-Tyr(tBu)-OH 29. 
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Figure 320: 1H-13C HMBC-NMR of Smoc-L-Tyr(tBu)-OH 29. 
8.2.28. Analytical data of Smoc-L-Val-OH 30 
 
Figure 321: HPLC chromatogram of Smoc-L-Val-OH 30 at λ=220 nm (0 to 40% MeCN). 
 
Figure 322: HPLC chromatogram of Smoc-L-Val-OH 30 at λ=280 nm (0 to 40% MeCN). 
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Figure 323: ESI-MS of Smoc-L-Val-OH 30 (M measured=498.20 [M-H]-, M calc.=499.51). 
 
Figure 324: HR-MS of Smoc-L-Val-OH 30 (M measured=500.06823 [M+H]+, M calc.=500.06796). 
 
Figure 325: Excitation and emission spectra of Smoc-L-Val-OH 30, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 326: 1H-NMR of Smoc-L-Val-OH 30. 
 
Figure 327: 13C-NMR of Smoc-L-Val-OH 30. 
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Figure 328: 1H-13C HSQC-NMR of Smoc-L-Val-OH 30. 
 
Figure 329: 1H-13C HMBC-NMR of Smoc-L-Val-OH 30. 
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8.2.29. Analytical data of Smoc-β-Ala-OH 31 
 
Figure 330: HPLC chromatogram of Smoc-β-Ala-OH 31 at λ=220 nm (0 to 40% MeCN). 
 
Figure 331: HPLC chromatogram of Smoc-β-Ala-OH 31 at λ=280 nm (0 to 40% MeCN). 
 
Figure 332: ESI-MS of Smoc-β-Ala-OH 31 (M measured=470.20 [M-H]-, M calc.=471.45). 
 
Figure 333: HR-MS of Smoc-β-Ala-OH 31 (M measured=470.02236 [M-H]-, M calc.=470.02211). 
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Figure 334: Excitation and emission spectra of Smoc-β-Ala-OH 31, excitation and emission have been normalized 
between 0 and 1 for illustration.  
 
Figure 335: 1H-NMR of Smoc-β-Ala-OH 31. 
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Figure 336: 13C-NMR of Smoc-β-Ala-OH 31. 
 
Figure 337: 1H-13C HSQC-NMR of Smoc-β-Ala-OH 31. 
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Figure 338: 1H-13C HMBC-NMR of Smoc-β-Ala-OH 31. 
8.2.30. Analytical data of Smoc-Aib-OH 32 
 
Figure 339: HPLC chromatogram of Smoc-Aib-OH 32 at λ=220 nm (0 to 40% MeCN). 
 
Figure 340: HPLC chromatogram of Smoc-Aib-OH 32 at λ=280 nm (0 to 40% MeCN). 
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Figure 341: ESI-MS of Smoc-Aib-OH 32 (M measured=484.20 [M-H]-, M calc.=485.48). 
 
Figure 342: HR-MS of Smoc-Aib-OH 32 (M measured=484.03817 [M-H]-, M calc.=484.03776). 
 
Figure 343: Excitation and emission spectra of Smoc-Aib-OH 32, excitation and emission have been normalized 
between 0 and 1 for illustration.  
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Figure 344: 1H-NMR of Smoc-Aib-OH 32. 
 
Figure 345: 13C-NMR of Smoc-Aib-OH 32. 
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Figure 346: 1H-13C HSQC-NMR of Smoc-Aib-OH 32. 
 
Figure 347: 1H-13C HMBC-NMR of Smoc-Aib-OH 32. 
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8.3. Analytical data of deprotection studies 
 
8.3.1. Analytical data of Smoc-Arg-OH 5 deprotection 
 
Figure 348: HPLC chromatogram of Smoc-L-Arg-OH 5 Ref for deprotection at λ=220 nm (0 to 40% MeCN). 
 
Figure 349: HPLC chromatogram of Smoc-L-Arg-OH 5 deprotection with 20% piperidine in water after 5min at 
λ=220 nm (0 to 40% MeCN). 
 
Figure 350: HPLC chromatogram of Smoc-L-Arg-OH 5 deprotection with 10% ethanolamine in water after 5min at 
λ=220 nm (0 to 40% MeCN). 
 
Figure 351: HPLC chromatogram of Smoc-L-Arg-OH 5 deprotection with 10% ethanolamine in Ethanol after 5min at 
λ=220 nm (0 to 40% MeCN). 
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Figure 352: HPLC chromatogram of Smoc-L-Arg-OH 5 deprotection with 1M NaOH in water after 5min at λ=220 nm 
(0 to 40% MeCN). 
 
Figure 353: HPLC chromatogram of Smoc-L-Arg-OH 5 deprotection with 1M NaOH in ethanol after 5min at λ=220 
nm (0 to 40% MeCN). 
 
Figure 354: HPLC chromatogram of Smoc-L-Arg-OH 5 deprotection with 0.2M NaOH in water after 5min at λ=220 
nm (0 to 40% MeCN). 
 
Figure 355: HPLC chromatogram of Smoc-L-Arg-OH 5 deprotection with 5% piperazine in water after 5min at λ=220 
nm (0 to 40% MeCN). 
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Figure 356: HPLC chromatogram of Smoc-L-Arg-OH 5 deprotection with 10% ammonia in water after 5min at λ=220 
nm (0 to 40% MeCN). 
8.3.2. Analytical data of Smoc-Leu-OH 16 deprotection 
 
Figure 357: HPLC chromatogram of Smoc-L-Leu-OH 16 Ref for deprotection at λ=220 nm (0 to 40% MeCN). 
 
Figure 358: HPLC chromatogram of Smoc-L-Leu-OH 16 deprotection with 20% piperidine in water after 5min at 
λ=220 nm (0 to 40% MeCN). 
 
Figure 359: HPLC chromatogram of Smoc-L-Leu-OH 16 deprotection with 10% ethanolamine in water after 5min at 
λ=220 nm (0 to 40% MeCN). 
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Figure 360: HPLC chromatogram of Smoc-L-Leu-OH 16 deprotection with 10% ethanolamine in Ethanol after 5min 
at λ=220 nm (0 to 40% MeCN). 
 
Figure 361: HPLC chromatogram of Smoc-L-Leu-OH 16 deprotection with 1M NaOH in water after 5min at λ=220 
nm (0 to 40% MeCN). 
 
Figure 362: HPLC chromatogram of Smoc-L-Leu-OH 16 deprotection with 1M NaOH in ethanol after 5min at λ=220 
nm (0 to 40% MeCN). 
 
Figure 363: HPLC chromatogram of Smoc-L-Leu-OH 16 deprotection with 0.2M NaOH in water after 5min at λ=220 
nm (0 to 40% MeCN). 
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Figure 364: HPLC chromatogram of Smoc-L-Leu-OH 16 deprotection with 5% piperazine in water after 5min at 
λ=220 nm (0 to 40% MeCN). 
 
Figure 365: HPLC chromatogram of Smoc-L-Leu-OH 16 deprotection with 10% ammonia in water after 5min at 
λ=220 nm (0 to 40% MeCN). 
8.3.3. Analytical data of Smoc-Tyr-OH 28 deprotection 
 
Figure 366: HPLC chromatogram of Smoc-L-Tyr-OH 28 Ref for deprotection at λ=220 nm (0 to 40% MeCN). 
 
Figure 367: HPLC chromatogram of Smoc-L-Tyr-OH 28 deprotection with 20% piperidine in water after 5min at 
λ=220 nm (0 to 40% MeCN). 
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Figure 368: HPLC chromatogram of Smoc-L-Tyr-OH 28 deprotection with 10% ethanolamine in water after 5min at 
λ=220 nm (0 to 40% MeCN). 
 
Figure 369: HPLC chromatogram of Smoc-L-Tyr-OH 28 deprotection with 10% ethanolamine in Ethanol after 5min 
at λ=220 nm (0 to 40% MeCN). 
 
Figure 370: HPLC chromatogram of Smoc-L-Tyr-OH 28 deprotection with 1M NaOH in water after 5min at λ=220 nm 
(0 to 40% MeCN). 
 
Figure 371: HPLC chromatogram of Smoc-L-Tyr-OH 28 deprotection with 1M NaOH in ethanol after 5min at λ=220 
nm (0 to 40% MeCN). 
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Figure 372: HPLC chromatogram of Smoc-L-Tyr-OH 28 deprotection with 0.2M NaOH in water after 5min at λ=220 
nm (0 to 40% MeCN). 
 
Figure 373: HPLC chromatogram of Smoc-L-Tyr-OH 28 deprotection with 5% piperazine in water after 5min at 
λ=220 nm (0 to 40% MeCN). 
 
Figure 374: HPLC chromatogram of Smoc-L-Tyr-OH 28 deprotection with 10% ammonia in water after 5min at 
λ=220 nm (0 to 40% MeCN).  
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8.4. Analytical data of stability studies of Smoc-protected amino acids 
 
8.4.1. Analytical data of Smoc-Arg-OH 5 stability studies 
 
Figure 375: HPLC chromatogram of Smoc-L-Arg-OH 5 under reaction conditions reference at λ=220 nm (0 to 40% 
MeCN). 
 
Figure 376: HPLC chromatogram of Smoc-L-Arg-OH 5 under reaction conditions after 7 days at λ=220 nm (0 to 40% 
MeCN). 
 
Figure 377: HPLC chromatogram of Smoc-L-Arg-OH 5 under reaction conditions after 14 days at λ=220-nm (0 to 
40% MeCN). 
 
Figure 378: HPLC chromatogram of Smoc-L-Arg-OH 5 under reaction conditions after 21 days at λ=220-nm (0 to 
40% MeCN). 
    
Page 238 Supporting information 
8.4.2. Analytical data of Smoc-Ile-OH 15 stability studies 
 
Figure 379: HPLC chromatogram of Smoc-L-Ile-OH 15 under reaction conditions reference at λ=220 nm (0 to 40% 
MeCN). 
 
Figure 380: HPLC chromatogram of Smoc-L-Ile-OH 15 under reaction conditions after 7 days at λ=220 nm (0 to 40% 
MeCN). 
 
Figure 381: HPLC chromatogram of Smoc-L-Ile-OH 15 under reaction conditions after 14 days at λ=220-nm (0 to 
40% MeCN). 
 
Figure 382: HPLC chromatogram of Smoc-L-Ile-OH 15 under reaction conditions after 21 days at λ=220-nm (0 to 
40% MeCN). 
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8.4.3. Analytical data of Smoc-Phe-OH 20 stability studies 
 
Figure 383: HPLC chromatogram of Smoc-L-Phe-OH 20 under reaction conditions reference at λ=220 nm (0 to 40% 
MeCN). 
 
Figure 384: HPLC chromatogram of Smoc-L-Phe-OH 20 under reaction conditions after 7 days at λ=220 nm (0 to 
40% MeCN). 
 
Figure 385: HPLC chromatogram of Smoc-L-Phe-OH 20 under reaction conditions after 14 days at λ=220-nm (0 to 
40% MeCN). 
 
Figure 386: HPLC chromatogram of Smoc-L-Phe-OH 20 under reaction conditions after 21 days at λ=220-nm (0 to 
40% MeCN). 
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8.4.4. Analytical data of Smoc-Pro-OH 21 stability studies 
 
Figure 387: HPLC chromatogram of Smoc-L-Pro-OH 21 under reaction conditions reference at λ=220 nm (0 to 40% 
MeCN). 
 
Figure 388: HPLC chromatogram of Smoc-L-Pro-OH 21 under reaction conditions after 7 days at λ=220 nm (0 to 40% 
MeCN). 
 
Figure 389: HPLC chromatogram of Smoc-L-Pro-OH 21 under reaction conditions after 14 days at λ=220-nm (0 to 
40% MeCN). 
 
Figure 390: HPLC chromatogram of Smoc-L-Pro-OH 21 under reaction conditions after 21 days at λ=220-nm (0 to 
40% MeCN). 
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8.4.5. Analytical data of Smoc-Ser-OH 22 stability studies 
 
Figure 391: HPLC chromatogram of Smoc-L-Ser-OH 22 under reaction conditions reference at λ=220 nm (0 to 40% 
MeCN). 
 
Figure 392: HPLC chromatogram of Smoc-L-Ser-OH 22 under reaction conditions after 7 days at λ=220 nm (0 to 40% 
MeCN). 
 
Figure 393: HPLC chromatogram of Smoc-L-Ser-OH 22 under reaction conditions after 14 days at λ=220-nm (0 to 
40% MeCN). 
 
Figure 394: HPLC chromatogram of Smoc-L-Ser-OH 22 under reaction conditions after 21 days at λ=220-nm (0 to 
40% MeCN). 
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8.5. Analytical data of coupling efficiency and solvent influence 
 
8.5.1. Analytical Reference data 
 
Figure 395: HPLC chromatogram of Smoc-L-Pro-L-Tyr-OMe 36 Reference at λ=220 nm (0 to 40% MeCN). 
 
Figure 396: HPLC chromatogram of Smoc-L-Pro-OH 21 Reference at λ=220 nm (0 to 40% MeCN). 
 
Figure 397: HPLC chromatogram of L-Tyr-OMe 35 Reference at λ=220 nm (0 to 40% MeCN). 
 
Figure 398: HPLC chromatogram of Oxyma 39 Reference at λ=220 nm (0 to 40% MeCN). 
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Figure 399: HPLC chromatogram of HOPO 40 Reference at λ=220 nm (0 to 40% MeCN). 
 
Figure 400: HPLC chromatogram of HONB 41 Reference at λ=220 nm (0 to 40% MeCN). 
 
Figure 401: HPLC chromatogram of EEDQ 42 Reference at λ=220 nm (0 to 40% MeCN). 
 
Figure 402: HPLC chromatogram of DMT-MM 43 Reference at λ=220 nm (0 to 40% MeCN). 
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Figure 403: HPLC chromatogram of COMU 44 Reference at λ=220 nm (0 to 40% MeCN). 
8.5.2. ESI-MS data of isolated side products 
 
Figure 404: ESI-MS of isolated Smoc-Pro-NHS 45 (M measured=593.07 [M-H]-, M calc.=592.54) at 15.5min. 
 
Figure 405: ESI-MS of isolated Smoc-Pro-HONB 46 (M measured=656.99 [M-H]-, M calc.=656.63) at 20.55min. 
8.5.3. Analytical data of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 in water 
 
Figure 406: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.3min) with EDC-HCl 37/Oxyma 39 
in water after 25min at λ=220 nm (0 to 40% MeCN). 
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Figure 407: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.3min) with EDC-HCl 37/HOPO 40 
in water after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 408: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.3min) with EDC-HCl 37/NHS 38 in 
water after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 409: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.3min) with EDC-HCl 37/HONB 41 
in water after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 410: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.5min) with EEDQ 42 in water after 
25min at λ=220 nm (0 to 40% MeCN). 
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Figure 411: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.3min) with DMT-MM 43 in water 
after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 412: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with COMU 44 in water 
after 25min at λ=220 nm (0 to 40% MeCN). 
8.5.4. Analytical data of the synthesis of Smoc-Pro-Tyr-OMe 36 in 30% aq. MeCN 
 
Figure 413: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.4min) with EDC-HCl 37/Oxyma 39 
in 30% aq. MeCN after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 414: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.4min) with EDC-HCl 37/HOPO 40 
in 30% aq. MeCN after 25min at λ=220 nm (0 to 40% MeCN). 
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Figure 415: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.4min) EDC-HCl 37/NHS 38 in 30% 
aq. MeCN after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 416: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) EDC-HCl 37/HONB 41 in 
30% aq. MeCN after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 417: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with EEDQ 42 in 30% aq. 
MeCN after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 418: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with DMT-MM 43 in 30% 
aq. MeCN after 25min at λ=220 nm (0 to 40% MeCN). 
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Figure 419: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with COMU 44 in 30% aq. 
MeCN after 25min at λ=220 nm (0 to 40% MeCN). 
8.5.5. Analytical data of the synthesis Smoc-Pro-Tyr-OMe 36 in 30% EtOAc water 
mixture (biphasic) 
 
Figure 420: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17min) with EDC-HCl 37/Oxyma 39 in 
30% EtOAc water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 421: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17min) with EDC-HCl 37/HOPO 40 in 
30% EtOAc water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
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Figure 422: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.1min) with EDC-HCl 37/NHS 38 in 
30% EtOAc water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 423: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with EDC-HCl 37/HONB 41 
in 30% EtOAc water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 424: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with EEDQ 42 in 30% EtOAc 
water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 425: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with DMT-MM 43 in 30% 
EtOAc water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
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Figure 426: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36(17.2min) with COMU 44 in 30% 
EtOAc water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
8.5.6. Analytical data of the synthesis Smoc-Pro-Tyr-OMe 36 in 30% aq. ethanol 
 
Figure 427: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.5min) with EDC-HCl 37/Oxyma 39 
in 30% aq. ethanol after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 428: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.5min) with EDC-HCl 37/HOPO 40 
in 30% aq. ethanol after 25min at λ=220 nm (0 to 40% MeCN). 
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Figure 429: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.6min) with EDC-HCl 37/NHS 38 in 
30% aq. ethanol after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 430: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.5min) with EDC-HCl 37/HONB 41 
in 30% aq. ethanol after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 431: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.5min) with EEDQ 42 in 30% aq. 
ethanol after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 432: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.5min) with DMT-MM 43 in 30% 
aq. ethanol after 25min at λ=220 nm (0 to 40% MeCN). 
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Figure 433: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.5min) with COMU 44 in 30% aq. 
ethanol after 25min at λ=220 nm (0 to 40% MeCN). 
8.5.7. Analytical data of the synthesis Smoc-Pro-Tyr-OMe 36 in 30% aq. isopropanol 
 
Figure 434: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with EDC-HCl 37/Oxyma 39 
in 30% aq. isopropanol after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 435: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with EDC-HCl 37/HOPO 40 
in 30% aq. isopropanol after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 436: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with EDC-HCl 37/NHS 38 in 
30% aq. isopropanol after 25min at λ=220 nm (0 to 40% MeCN). 
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Figure 437: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with EDC-HCl 37/HONB 41 
in 30% aq. isopropanol after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 438: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with EEDQ 42 in 30% aq. 
isopropanol after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 439: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with DMT-MM 43 in 30% 
aq. isopropanol after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 440: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.2min) with COMU 44 in 30% aq. 
isopropanol after 25min at λ=220 nm (0 to 40% MeCN). 
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8.5.8. Analytical data of the synthesis Smoc-Pro-Tyr-OMe 36 in 30% MeTHF water 
mixture (biphasic) 
 
Figure 441: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.3min) with EDC-HCl 37/Oxyma 39 
in 30% Me-THF water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 442: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.3min) with EDC-HCl 37/HOPO 40 
in 30% Me-THF water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 443: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.4min) with EDC-HCl 37/NHS 38 in 
30% Me-THF water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
  
Supporting information   Page 255 
 
Figure 444: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.4min) EDC-HCl 37/HONB 41 in 
30% Me-THF water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 445: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.4min) with EEDQ 42 in 30% Me-
THF water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 446: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.4min) with DMT-MM 43 in 30% 
Me-THF water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 447: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.4min) with COMU 44 in 30% Me-
THF water mixture (biphasic) after 25min at λ=220 nm (0 to 40% MeCN). 
    
Page 256 Supporting information 
8.5.9. Analytical data of the synthesis Smoc-Pro-Tyr-OMe 36 in 10% aq. Me-THF 
 
Figure 448: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.3min) with EDC-HCl 37/Oxyma 39 
in 10% aq. Me-THF after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 449: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.3min) with EDC-HCl 37/HOPO 40 
in 10% aq. Me-THF after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 450: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.3min) with EDC-HCl 37/NHS 38 in 
10% aq. Me-THF after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 451: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.3min) with EDC-HCl 37/HONB 41 
in 10% aq. Me-THF after 25min at λ=220 nm (0 to 40% MeCN). 
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Figure 452: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.4min) with EEDQ 42 in 10% aq. 
Me-THF after 25min at λ=220 nm (0 to 40% MeCN). 
 
Figure 453: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.4min) with DMT-MM 43 in 10% 
aq. Me-THF after 25min at λ=220 nm (0 to 40% MeCN). 
 
 
Figure 454: HPLC chromatogram of the synthesis of Smoc-L-Pro-L-Tyr-OMe 36 (17.4min) with COMU 44 in 10% aq. 
Me-THF after 25min at λ=220 nm (0 to 40% MeCN). 
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8.6. Analytical data of SPPS coupling efficiency test with Oxyma 39 and HOPO 40 
 
Figure 455: HPLC chromatogram of the synthesis of Smoc-LAGV-NH2 47 with EDC-HCl 37 and Oxyma 39 in water at 
λ=220 nm (0 to 60% MeCN). 
 
Figure 456: ESI-MS HPLC of the synthesis of Smoc-LAGV-NH2 47 with EDC-HCl 37 and Oxyma 39 in water 
(M measured=738.18 [M-2H]-, M calc.=740.80). 
 
Figure 457: HPLC chromatogram of the synthesis of Smoc-LAGV-NH2 47 with EDC-HCl 37 and Oxyma 39 in 30% aq. 
MeCN at λ=220 nm (0 to 60% MeCN). 
 
Figure 458: ESI-MS HPLC of the synthesis of Smoc-LAGV-NH2 47 with EDC-HCl 37 and Oxyma 39 in 30% aq. MeCN 
(M measured=738.18 [M-H]-, M calc.=740.80). 
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Figure 459: HPLC chromatogram of the synthesis of Smoc-LAGV-NH2 47 with EDC-HCl 37 and HOPO 40 in water at 
λ=220 nm (0 to 60% MeCN). 
 
Figure 460: ESI-MS HPLC of the synthesis of Smoc-LAGV-NH2 47 with EDC-HCl 37 and HOPO 40 in water 
(M measured=738.18 [M-H]-, M calc.=740.80). 
 
Figure 461: HPLC chromatogram of the synthesis of Smoc-LAGV-NH2 47 with EDC-HCl 37 and HOPO 40 in 30% aq. 
MeCN at λ=220 nm (0 to 60% MeCN). 
 
Figure 462: ESI-MS HPLC of the synthesis of Smoc-LAGV-NH2 47 with EDC-HCl 37 and HOPO 40 in 30% aq. MeCN 
(M measured=738.18 [M-H]-, M calc.=740.80). 
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8.7. Peptides 
 
8.7.1. Analytical data of H-AGELS-NH2 (Pentapeptide-31) 48 
 
Figure 463: HPLC chromatogram of H-AGELS-NH2 (Pentapeptide-31) 48 at λ=220 nm (0 to 60% MeCN). 
 
Figure 464: HPLC chromatogram of H-AGELS-NH2 (Pentapeptide-31) 48 at λ=280 nm (0 to 60% MeCN). 
 
Figure 465: ESI-MS of H-AGELS-NH2 (Pentapeptide-31) 48 (M measured=475.37 [M+H]+, M calc.=474.52). 
8.7.2. Analytical data of H-GPQGPQ-OH (Hexapeptide-9) 49 
 
Figure 466: HPLC chromatogram of H-GPQGPQ-OH (Hexapeptide-9) 49 at λ=220 nm (0 to 60% MeCN). 
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Figure 467: ESI-MS of H-GPQGPQ-OH (Hexapeptide-9) 49 (M measured=581.37 [M-H]-, M calc.=581.37). 
8.7.3. Analytical data of H-EEMQRR-NH2 (Hexapeptide 3) 50 
 
Figure 468: HPLC chromatogram of H-EEMQRR-NH2 (Hexapeptide 3) 50 at λ=220 nm (0 to 60% MeCN). 
 
Figure 469: ESI-MS of H-EEMQRR-NH2 (Hexapeptide 3) 50 (M measured=847.60 [M+H]+, M calc.=846.96). 
8.7.4. Analytical data of Ac-EEMQRR-NH2 (Acetyl-Hexapeptide 3) 51 
 
Figure 470: HPLC chromatogram of Ac-EEMQRR-NH2 51 at λ=220 nm (0 to 60% MeCN). 
 
Figure 471: ESI-MS of Ac-EEMQRR-NH2 51 (M measured=889.70 [M+H]+, M calc.=889.00). 
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8.7.5. Analytical data of Synthesis of Leu-Enkephalin amide 52 
 
Figure 472: HPLC chromatogram of Synthesis of Leu-Enkephalin amide 52 at λ=220 nm (0 to 60% MeCN). 
 
Figure 473: ESI-MS of Synthesis of Leu-Enkephalin amide 52 (M measured=554.65 [M+H]+, M calc.=554.65). 
8.7.6. Analytical data of Synthesis of Met-Enkephalin 53 
 
Figure 474: HPLC chromatogram of Synthesis of Met-Enkephalin 53 at λ=220 nm (0 to 60% MeCN). 
 
Figure 475: ESI-MS of Synthesis of Met-Enkephalin 53 (M measured=574.18 [M+H]+, M calc.=573.67). 
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8.7.7. Analytical data of Synthesis of Leu-Enkephalin 54 
 
Figure 476: HPLC chromatogram of Synthesis of Leu-Enkephalin 54 at λ=220 nm (0 to 60% MeCN). 
 
Figure 477: ESI-MS of Synthesis of Leu-Enkephalin 54 (M measured=556.37 [M+H]+, M calc.=555.63). 
8.7.8. Analytical data of Synthesis of H-VQAAIDYING-OH 55 
 
Figure 478: HPLC chromatogram of Synthesis of H-VQAAIDYING-OH 55 at λ=220 nm (10 to 100% MeCN). 
 
Figure 479: ESI-MS of Synthesis of H-VQAAIDYING-OH 55 (M measured=1063.67 [M+H]+, M calc.=1062.19). 
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8.7.9. Analytical data of Synthesis of H-VQAAIDYING-NH2 56 
 
Figure 480: HPLC chromatogram of Synthesis of H-VQAAIDYING-NH2 56 at λ=220 nm (10 to 100% MeCN). 
 
Figure 481: ESI-MS of Synthesis of H-VQAAIDYING-NH2 56 (M measured=1062.67 [M+H]+, M calc.=1063.18). 
8.7.10. Analytical data of Synthesis of H-GPRP-OH 57 
 
Figure 482: HPLC chromatogram of Synthesis of H-GPRP-OH 57 at λ=220 nm (0 to 40% MeCN). 
 
Figure 483: ESI-MS of Synthesis of H-GPRP-OH 57 (M measured=426.40 [M+H]+, M calc.=425.49). 
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8.7.11. Analytical data of Synthesis of Smoc-VIAA-NH2 58 
 
Figure 484: HPLC chromatogram of Synthesis of Smoc-VIAA-NH2 58 at λ=220 nm (0 to 40% MeCN). 
 
Figure 485: ESI-MS of Synthesis of Smoc-VIAA-NH2 58 (M measured=780.40 [M+H]+, M calc.=781.89). 
8.7.12. Analytical data of Synthesis of Smoc-DIIW-OH 59 
 
Figure 486: HPLC chromatogram of Synthesis of Smoc-DIIW-OH 59 at λ=220 nm (0 to 40% MeCN). 
 
Figure 487: ESI-MS of Synthesis of Smoc-DIIW-OH 59 (M measured=928.40 [M+H]+, M calc.=927.99). 
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8.7.13. Analytical data of Smoc-E(OtBu)K(Boc)R(Pbf)S(tBu)C(Trt)-OH 60 
 
Figure 488: HPLC chromatogram of Smoc-E(OtBu)K(Boc)R(Pbf)S(tBu)C(Trt)-OH 60 at λ=220 nm (50 to 100% 
MeCN). 
 
Figure 489: ESI-MS of Smoc-E(OtBu)K(Boc)R(Pbf)S(tBu)C(Trt)-OH 60 (M measured=854.30 [M-2H]2-, M calc.= 
855.53). 
8.7.14. Analytical data of H-CYEIS-NH2 61 
 
Figure 490: HPLC chromatogram of H-CYEIS-NH2 61 at λ=220 nm (0 to 40% MeCN). 
 
Figure 491: ESI-MS of H-CYEIS-NH2 61 (M measured=613.28 [M+H]+, M calc.=612.70 ). 
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8.7.15. Analytical data of amino acid racemization of H-CYEIS-NH2 61 by C.A.T. GmbH 
& Co Chromatographie und Analysentechnik KG (Tübingen, Germany) 
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8.7.16. Analytical data of H-ANKPG-NH2 62 
 
Figure 492: HPLC chromatogram of H-ANKPG-NH2 62 at λ=220 nm (0 to 40% MeCN). 
 
Figure 493: ESI-MS of H-ANKPG-NH2 62 (M measured=485.37 [M+H]+, M calc.= 484.56). 
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8.7.17. Analytical data of amino acid racemization of H-ANKPG-NH2 62 by C.A.T. 
GmbH & Co Chromatographie und Analysentechnik KG (Tübingen, Germany) 
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8.7.18. Analytical data of amino acid racemization of Smoc-Asn-OH 7 by C.A.T. GmbH 
& Co Chromatographie und Analysentechnik KG (Tübingen, Germany) 
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8.7.19. Analytical data of Pal-GHK-OH 63 
 
Figure 494: HPLC chromatogram of Pal-GHK-OH 63 at λ=220 nm (10 to 60% MeCN). 
 
Figure 495: ESI-MS of Pal-GHK-OH 63 (M measured=579.57 [M+H]+, M calc.= 578.80). 
8.7.20. Analytical data of Pal-GQPR-OH 64 
 
Figure 496: HPLC chromatogram of Pal-GQPR-OH 64 at λ=220 nm (0 to 60% MeCN). 
 
Figure 497: ESI-MS of Pal-GQPR-OH 64 (M measured=695.66 [M+H]+, M calc.=695.66). 
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8.7.21. Analytical data of H-GPRPA-NH2 Vialox (Pentapeptide-3) 65 
 
Figure 498: HPLC chromatogram of H-GPRPA-NH2 65 at λ=220 nm (0 to 60% MeCN). 
 
Figure 499: ESI-MS of H-GPRPA-NH2 65 (M measured=496.37 [M+H]+, M calc.=495.59). 
 
8.7.22. Analytical data of Oxytocin 66 
 
Figure 500: HPLC chromatogram of Oxytocin 66 at λ=220 nm (10 to 100% MeCN). 
 
Figure 501: ESI-MS of Oxytocin 66 (M measured=1007.67 [M+H]+, M calc.=1007.19). 
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8.7.23. Analytical data of Vasopressin 67 (peptide hormone) 
 
Figure 502: HPLC chromatogram of Vasopressin 67 at λ=220 nm (10 to 100% MeCN). 
 
Figure 503: ESI-MS of Vasopressin 67 (M measured=1084.57 [M+H]+, M calc.=1084.57). 
8.7.24. Analytical data of heptaarginine 68 
 
Figure 504: HPLC chromatogram of Smoc-heptaarginine 68 at λ=220 nm (10 to 100% MeCN). 
 
Figure 505: ESI-MS of heptaarginine 68 (M measured=1113.27 [M+H]+, M calc.=1110.35). 
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8.7.25. Analytical data of H-YDAGFL-OH Leuphasyl 69 
 
Figure 506: HPLC chromatogram of H-YDAGFL-OH 69 at λ=220 nm (0 to 60% MeCN). 
 
Figure 507: ESI-MS of H-YDAGFL-OH 69 (M measured=570.27 [M+H]+, M calc.=569.66). 
8.8. Analytical data of Aspartimide formation 
 
8.8.1. Reference HPLC data of peptides 70-73 
  
Figure 508: HPLC chromatogram of H-VKDGYI-NH2 70 as reference at λ=220 nm (0 to 60% MeCN) with ascorbic 
acid as standard at ≈3.95 min. 
 
Figure 509: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 as reference at λ=220 nm (0 to 60% MeCN) with ascorbic 
acid as standard at ≈3.95 min. 
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Figure 510: HPLC chromatogram of H-VKNGYI-NH2 72 as reference at λ=220 nm (0 to 60% MeCN) with ascorbic 
acid as standard at ≈3.95 min. 
 
Figure 511: HPLC chromatogram of H-VK(β-D)GYI-NH273 as reference at λ=220 nm (0 to 60% MeCN) with ascorbic 
acid as standard at ≈3.95 min. 
 
Figure 512: ESI-MS of H-VKDGYI-NH2 70 (M measured=693.58 [M+H]+, M calc.=692.82). 
 
Figure 513: ESI-MS of H-VK(D-D)GYI-NH2 71 (M measured=693.58 [M+H]+, M calc.=692.82). 
 
Figure 514: ESI-MS of H-VK(β-D)GYI-NH2 73 (M measured=693.58 [M+H]+, M calc.=692.82). 
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Figure 515: ESI-MS of H-VKNGYI-NH2 72 (M measured=692.48 [M+H]+, M calc.=691.83). 
8.8.2. HPLC data of H-VKDGYI-OH 70 after 3h incubation with different bases 
 
Figure 516: HPLC chromatogram of H-VKDGYI-NH2 70 after 3h with 5% piperazine in DMF at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
 
Figure 517: HPLC chromatogram of H-VKDGYI-NH2 70 after 3h with 5% piperazine in water at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 518: HPLC chromatogram of H-VKDGYI-NH2 70 after 3h with 10% ethanolamine in water at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
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Figure 519: HPLC chromatogram of H-VKDGYI-NH2 70 after 3h with 20% piperidine in DMF at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 520: HPLC chromatogram of H-VKDGYI-NH2 70 after 3h with 1M NaOH in water at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 521: HPLC chromatogram of H-VKDGYI-NH2 70 after 3h with 1M NaOH in ethanol at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
8.8.3. HPLC data of H-VKDGYI-OH 70 after 16h incubation with different bases 
 
Figure 522: HPLC chromatogram of H-VKDGYI-NH2 70 after 16h with 5% piperazine in DMF at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
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Figure 523: HPLC chromatogram of H-VKDGYI-NH2 70 after 16h with 5% piperazine in water at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 524: HPLC chromatogram of H-VKDGYI-NH2 70 after 16h with 10% ethanolamine in water at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 525: HPLC chromatogram of H-VKDGYI-NH2 70 after 16h with 20% piperidine in DMF at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 526: HPLC chromatogram of H-VKDGYI-NH2 70 after 16h with 1M NaOH in water at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
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Figure 527: HPLC chromatogram of H-VKDGYI-NH2 70 after 16h with 1M NaOH in ethanol at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
8.8.4. HPLC data of H-VK(D-D)GYI-NH2 71 after 3h incubation with different bases 
 
Figure 528: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 after 3h with 5% piperazine in DMF at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 529: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 after 3h with 5% piperazine in water at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 530: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 after 3h with 10% ethanolamine in water at λ=220 nm (0 
to 60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
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Figure 531: HPLC chromatogram of H H-VK(D-D)GYI-NH2 71 after 3h with 20% piperidine in DMF at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 532: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 after 3h with 1M NaOH in water at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 533: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 after 3h with 1M NaOH in ethanol at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
8.8.5. HPLC data of H-VK(D-D)GYI-NH2 71 after 16h incubation with different bases 
 
Figure 534: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 after 16h with 5% piperazine in DMF at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
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Figure 535: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 after 16h with 5% piperazine in water at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 536: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 after 16h with 10% ethanolamine in water at λ=220 nm 
(0 to 60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 537: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 after 16h with 20% piperidine in DMF at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 538: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 after 16h with 1M NaOH in water at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
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Figure 539: HPLC chromatogram of H-VK(D-D)GYI-NH2 71 after 16h with 1M NaOH in ethanol at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
8.8.6. HPLC data of H-VKNGYI-NH2 72 after 3h incubation with different bases 
 
Figure 540: HPLC chromatogram of H-VKNGYI-NH2 72 after 3h with 5% piperazine in DMF at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 541: HPLC chromatogram of H-VKNGYI-NH2 72 after 3h with 5% piperazine in water at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 542: HPLC chromatogram of H-VKNGYI-NH2 72 after 3h with 10% ethanolamine in water at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
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Figure 543: HPLC chromatogram of H H-VKNGYI-NH2 72 after 3h with 20% piperidine in DMF at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 544: HPLC chromatogram of H-VKNGYI-NH2 72 after 3h with 1M NaOH in water at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 545: HPLC chromatogram of H-VKNGYI-NH2 72 after 3h with 1M NaOH in ethanol at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
8.8.7. HPLC data of H-VKNGYI-NH2 72 after 16h incubation with different bases 
 
Figure 546: HPLC chromatogram of H-VKNGYI-NH2 72 after 16h with 5% piperazine in DMF at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
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Figure 547: HPLC chromatogram of H-VKNGYI-NH2 72 after 16h with 5% piperazine in water at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 548: HPLC chromatogram of H-VKNGYI-NH2 72 after 16h with 10% ethanolamine in water at λ=220 nm (0 to 
60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 549: HPLC chromatogram of H-VKNGYI-NH2 72 after 16h with 20% piperidine in DMF at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 550: HPLC chromatogram of H-VKNGYI-NH2 72 after 16h with 1M NaOH in water at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
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Figure 551: ESI-MS of H-VKNGYI-NH2 72 after 16h with 1M NaOH showing unidentified side product at 16.45min. 
 
Figure 552: HPLC chromatogram of H-VKNGYI-NH2 72 after 16h with 1M NaOH in ethanol at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
8.8.8. Temperature dependent formation of H-VK(β-D)GYI-NH2 73 in water 
 
Figure 553: HPLC chromatogram of H-VK(β-D)GYI-NH2 73 formation at ambient temperature (26°C) in water at 
λ=220 nm (0 to 60% MeCN) with ascorbic acid as standard at ≈3.95 min. 
 
Figure 554: HPLC chromatogram of H-VK(β-D)GYI-NH2 73 formation at 40°C in water at λ=220 nm (0 to 60% 
MeCN) with ascorbic acid as standard at ≈3.95 min. 
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Figure 555: HPLC chromatogram of H-VK(β-D)GYI-NH2 73 formation at 4°C in water at λ=220 nm (0 to 60% MeCN) 
with ascorbic acid as standard at ≈3.95 min. 
8.9. HPLC data of the capping experiments 
 
Figure 556: HPLC chromatogram of crude H-GPQGPQ-OH Hexapeptide 9 49 in water using 0.95 eq. of Nα-Smoc amino 
acid compared to prior coupling in order to maximize by-product formation, capping was performed with sulfoacetic 
acid 76 at λ=220 nm (0 to 40% MeCN). 
 
Figure 557: HPLC chromatogram of H-GPQGPQ-OH Hexapeptide 9 49 after purification with IEC and the removal of 
all labelled side products at λ=220 nm (0 to 40% MeCN). 
 
Figure 558: HPLC chromatogram of crude H-YGGFMRRV-NH2 77 in DMF using 0.95 eq. of Nα-Fmoc amino acid 
compared to prior coupling in order to maximize by-product formation, capping was performed with 4-sulfobenzoic 
acid 75 at λ=220 nm (10 to 60% MeCN). 
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Figure 559: HPLC chromatogram of H-YGGFMRRV-NH2 77 after purification with IEC and the removal of all labelled 
side products at λ=220 nm (10 to 60% MeCN). 
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Abbreviations 
2-Cl-Z  2-chlorobenzyloxycarbonyl 
2-CTC  2-chlorotrityl chloride 
2‐MeTHF  2‐methyl tetrahydrofuran 
2-PhiPr  2-phenylisopropyl 
aa  amino acids 
Acm  acetamidomethyl 
AiB  2-aminoisobutyric acid 
Al  allyl 
Alloc  allyloxycarbonyl 
Arg  arginine 
Asn  asparagine 
Asp  aspartic acid 
ASPPS  aqueous solid-phase peptide synthesis 
BAL  backbone amide linker 
Boc  tert-butyloxycarbonyl 
Bom  Benzyloxymethyl 
Bum  tert-butoxymethyl 
Bzl  benzyl 
CBz  carboxybenzoxy 
CMR  carcinogenic, mutagenic, or toxic for reproduction 
COMBU  4 ((1,3-dimethyl-2,4,6-trioxotetrahydro-pyrimidin-5(6H)ylidene-
aminooxy)(dimethylamino)methylene) morpholin-4-ium hexafluorophosphate 
COMU  (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium 
hexafluorophosphate 
COSS  cube‐octameric silsesquioxanes 
Cys  cysteine 
DCC  N,N'-dicyclohexylcarbodiimide, N,N’-dicyclohexylcarbodiimide 
DCM  dichloromethane 
DIC  N,N’-diisopropylcarbodiimide 
DIPEA  N,N-diisopropylethylamine 
DMF  N,N-dimethylformamide 
DNP  dinitrophenyl 
DVB  divinylbenzene 
EDC  1-ethyl-3-(3-dimethylaminopropyl)carbodiimid 
EDC-HCl  1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
EEDQ  N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline 
Esc  ethanesulfonylethoxycarbonyl 
Fmoc  9-fluorenylmethoxycarbonyl 
Fmoc-Cl  9-fluorenylmethoxycarbonyl chloride 
Fmoc-NHS  9-fluorenylmethyl N-succinimidyl carbonate 
For  formyl 
Gln  glutamine 
Glu  glutamic acid 
GVL  γ-valerolactone 
    
Page 304   Abbreviations 
HATU  1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid 
hexafluorophosphate 
HBr  hydrogen bromide 
HBTU  2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HCl  hydrogen chloride 
HCTU  O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HF  hydrogen fluoride 
His  histidine 
Hmb  2-hydroxyl-4-methoxybenzyl 
HMBA  4-hydroxymethylbenzoic acid 
HMPB  4-(4-hydroxymethyl-3-methoxyphenoxy)-butyric acid 
HOAt  1-hydroxy-7-azabenzotriazole 
HOBt  1-hydroxy-1H-benzotriazole 
Hoc  cyclohexyloxycarbonyl 
HONB  N-hydoxybicyclo[2.2.1]hept-5-ene-2,3-dicarboximide 
HOPO  1-hydroxy-2-pyridone 
HPLC  high performance liquid chromatography 
IE column  ion-exchange column 
IEC  ion-exchange chromatography 
Lys  lysine 
MBHA  4-methylbenzhydrylamine 
MBom  4-methoxybenzyloxymethyl 
MCC  multicolumn chromatography 
MeOBzl  4 methoxybenzyl 
Me-THF  2-Methyltetrahydrofuran 
MMT  monomethoxytrityl 
Mtr  4-methoxy-2,3,6-trimethyl-benzenesulphonyl 
Mts  mesitylen-2-sulfonyl 
Mtt  4-methyltrityl 
NFM  N-formylmorpholine 
NHS  N-hydroxysuccinimide 
NMP  N-methylpyrrolidone 
Nsmoc  1,1-dioxonaptho[1,2-b]thiophene-2-methyloxy-carbonyl 
Oxyma  ethyl-2‐cyano‐2‐(hydroxyimino)acetate 
PA  polyamide 
Pbf  2,2,4,6,7-pentamethyl-dihydro-benzofuran-5-sulfony 
PC  propylene carbonate 
PEG  polyethylene glycol 
Pmc  2,2,5,7,8-pentamethyl-chroman-6-sulfonyl 
Pms  2 [phenyl(methyl)sulfonio]ethyloxycarbonyl 
PS  polystyrenes 
PyBOP  benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphat 
RP-HPLC  reversed phase high-performance liquid chromatography 
RT  room temperature 
SASRIN  super acid-sensitive resin 
Ser  serine 
Smoc  2,7-disulfo-9-fluorenylmethoxycarbonyl chloride 
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SPFC  solid phase fragment condensation 
SPPS  solid-phase peptide synthesis 
Sps  2-(4-sulfophenylsulfonyl)ethoxy-carbonyl 
StBu  tert‐butylsulfenyl 
Tbdms  tert-butyldimethylsilyl 
tBu  tert-butyl 
TFA  trifluoroacetic acid 
TFFH  tetramethylfluoroformamidinium hexafluorophosphate 
TFMSA  trifluoromethanesulfonic acid 
Thr  threonine 
Tmob  2,4,6-trimethoxybenzyl 
TOMBU  N-((1,3-dimethyl-2,4,6-trioxotetra-hydropyrimidin-5(6H)-
ylideneaminooxy)(dimethylamino)methylene)-N-methylmethanaminiumhexa-fluoro-
phosphate 
TOS  toluolsulfonyl 
Trp  tryptophan 
Trt  trityl 
Tyr  tyrosine 
Xan  9-xanthenyl 
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